---
document_datetime: 2023-09-21 21:17:32
document_pages: 109
document_pathfilename: www.ema.europa.eu/en/documents/assessment-report/vegzelma-epar-public-assessment-report_en.pdf
document_name: vegzelma-epar-public-assessment-report_en.pdf
version: success
processing_time: 120.6182723
conversion_datetime: 2025-12-20 08:39:13.165056
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

23 June 2022 EMA/CHMP/636045/2022 Committee for Medicinal Products for Human Use (CHMP)

## Assessment report

## Vegzelma

International non-proprietary name: bevacizumab

Procedure No. EMEA/H/C/005534/0000

## Note

Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Administrative information

| Name of the medicinal product:                  | Vegzelma                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|-------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Applicant:                                      | Celltrion Healthcare Hungary Kft. Westend Office Building B Torony Vaci Ut 1-3 1062 Budapest HUNGARY                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Active substance:                               | Bevacizumab                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| International Non-proprietary Name/Common Name: | bevacizumab                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Pharmaco-therapeutic group (ATC Code):          | other antineoplastic agents, (L01FG01)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Therapeutic indication(s):                      | Vegzelma in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. Vegzelma in combination with paclitaxel is indicated for first-line treatment of adult patients with metastatic breast cancer. For further information as to human epidermal growth factor receptor 2 (HER2) status, please refer to section 5.1. Vegzelma in combination with capecitabine is indicated for first-line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. Patients who have received taxane and anthracycline-containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with Vegzelma in combination with capecitabine. For further information as to HER2 status, please refer to section 5.1. Vegzelma, in addition to platinum-based chemotherapy, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer (NSCLC) other than predominantly |

<div style=\"page-break-after: always\"></div>

| squamous cell histology. Vegzelma, in combination with erlotinib, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent NSCLC with Epidermal Growth Factor Receptor (EGFR) activating mutations (see section 5.1). Vegzelma, in combination with interferon alfa-2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. Vegzelma, in combination with carboplatin and paclitaxel is indicated for the front-line treatment of adult patients with advanced (International Federation of Gynecology and Obstetrics (FIGO) stages III B, III C and IV) epithelial ovarian, fallopian tube, or primary peritoneal cancer (see section 5.1). Vegzelma, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vascular endothelial growth factor (VEGF) inhibitors or VEGF receptor-targeted agents. Vegzelma in combination with paclitaxel, topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor-targeted agents (see section 5.1). Vegzelma, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix (see section 5.1).   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

Pharmaceutical form(s):

Concentrate for solution for infusion

Strength(s):

25 mg/ml

Route(s) of administration:

Intravenous use

Packaging:

vial (glass)

Package size(s):

1 vial and 10 vials

<div style=\"page-break-after: always\"></div>

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure                                                                                  | ............................................10                                                           |
|-----------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------|
| 1.1. Submission of the dossier....................................................................................10        |                                                                                                          |
| 1.2. Legal basis and dossier content............................................................................11          |                                                                                                          |
| 1.3. Information on Paediatric requirements.................................................................11              |                                                                                                          |
| 1.4. Information relating to orphan market exclusivity...................................................12                 |                                                                                                          |
| 1.4.1. Similarity........................................................................................................12 |                                                                                                          |
| 1.5. Scientific advice                                                                                                      | .................................................................................................12      |
| 1.6. Steps taken for the assessment of the product.......................................................12                 |                                                                                                          |
| 2. Scientific discussion                                                                                                    | ..............................................................................14                         |
| 2.1. Problem statement                                                                                                      | .............................................................................................14          |
| 2.2. Quality aspects                                                                                                        | ..................................................................................................14     |
| 2.2.1. Introduction....................................................................................................14   |                                                                                                          |
| 2.2.2. Active Substance.............................................................................................14      |                                                                                                          |
| 2.2.3. Finished Medicinal Product                                                                                           | ................................................................................16                       |
| 2.2.4. Discussion on chemical, pharmaceutical and biological aspects..............................23                        |                                                                                                          |
| 2.2.5. Conclusions on the chemical, pharmaceutical and biological aspects                                                   | ......................24                                                                                 |
| 2.2.6. Recommendations for future quality development................................................24                     |                                                                                                          |
| 2.3. Non-clinical aspects                                                                                                   | ............................................................................................24           |
| 2.3.1. Introduction....................................................................................................24   |                                                                                                          |
| 2.3.2. Pharmacology                                                                                                         | .................................................................................................25      |
| 2.3.3. Pharmacokinetics.............................................................................................25      |                                                                                                          |
| 2.3.4. Toxicology                                                                                                           | ......................................................................................................26 |
| 2.3.5. Ecotoxicity/environmental risk assessment                                                                            | .........................................................28                                              |
| 2.3.6. Discussion on non-clinical aspects......................................................................28           |                                                                                                          |
| 2.3.7. Conclusion on the non-clinical aspects................................................................28             |                                                                                                          |
| 2.4. Clinical aspects                                                                                                       | ..................................................................................................29     |
| 2.4.1. Introduction....................................................................................................29   |                                                                                                          |
| 2.4.2. Clinical pharmacology                                                                                                | ......................................................................................30                 |
| 2.4.3. Discussion on clinical pharmacology...................................................................36             |                                                                                                          |
| 2.4.4. Conclusions on clinical pharmacology.................................................................39              |                                                                                                          |
| 2.4.5. Clinical efficacy                                                                                                    | ...............................................................................................39        |
| 2.4.6. Discussion on clinical efficacy............................................................................72        |                                                                                                          |
| 2.4.7. Conclusions on the clinical efficacy.....................................................................76          |                                                                                                          |
| 2.4.8. Clinical safety..................................................................................................76  |                                                                                                          |
| 2.4.9. Discussion on clinical safety                                                                                        | ..............................................................................97                         |
| 2.4.10. Conclusions on the clinical safety...................................................................               | 101                                                                                                      |
| 2.5. Risk Management Plan ......................................................................................            | 101                                                                                                      |
| 2.5.1. Safety concerns.............................................................................................         | 101                                                                                                      |
| 2.5.2. Pharmacovigilance plan ..................................................................................            | 101                                                                                                      |
| 2.5.3. Risk minimisation measures............................................................................               | 101                                                                                                      |
| 2.5.4. Conclusion....................................................................................................       | 101                                                                                                      |
| 2.6. Pharmacovigilance............................................................................................          | 101                                                                                                      |
| 2.6.1. Pharmacovigilance system..............................................................................               | 101                                                                                                      |

<div style=\"page-break-after: always\"></div>

| 2.6.2. Periodic Safety Update Reports submission requirements                                                       | ................................... 101                                                             |
|---------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------|
| 2.7. Product information .......................................................................................... | 102                                                                                                 |
| 2.7.1. User consultation........................................................................................... | 102                                                                                                 |
| 2.7.2. Additional monitoring.....................................................................................   | 102                                                                                                 |
| 3. Biosimilarity assessment.....................................................................102                 | 3. Biosimilarity assessment.....................................................................102 |
| 3.1. Comparability exercise and indications claimed ....................................................            | 102                                                                                                 |
| 3.2. Results supporting biosimilarity..........................................................................     | 104                                                                                                 |
| 3.3. Uncertainties and limitations about biosimilarity...................................................           | 106                                                                                                 |
| 3.4. Discussion on biosimilarity.................................................................................   | 107                                                                                                 |
| 3.5. Extrapolation of safety and efficacy ....................................................................      | 108                                                                                                 |
| 3.6. Additional considerations...................................................................................   | 108                                                                                                 |
| 3.7. Conclusions on biosimilarity and benefit risk balance ............................................             | 108                                                                                                 |
| 4. Recommendations...............................................................................108                |                                                                                                     |

<div style=\"page-break-after: always\"></div>

## List of abbreviations

ADA

antidrug antibody

ADCC

antibody-dependent cell-mediated cytotoxicity

ADL

activities of daily living

ADR

adverse drug reaction

AE

adverse event

AESI

adverse event of special interest

ALK

anaplastic lymphoma kinase

ASAT

aspartate aminotransferase

ATE

arterial thromboembolism

AUC

area under the curve

AUC0-72

area under the concentration time curve from 0 hour to 72 hours

BLA

biologics license application

BOR

best overall response

BSA

body surface area

C1q

complement component 1, Q subcomponent

CDC

complement-dependent cytotoxicity

CELISA

cellular enzyme-linked immunosorbent assay

CE-SDS

capillary electrophoresis sodium dodecyl sulfate

CHF

congestive heart failure

CI

confidence interval

Cmax

maximum serum concentration

CMC

Chemistry, Manufacturing and Control

CNS

central nervous system

COVID

Coronavirus disease

CPK

creatine phosphokinase

CR

complete response

CrCl

creatinine clearance

CSR

clinical study report

CT

computerised tomography

CTCAE

common terminology criteria for adverse events

CTD

common technical document

Ctrough

trough serum concentration

CV

coefficient of variation

DKMA

Danish medicines agency

DP

drug product

DRM

data review meeting

DSMB

data safety monitoring board

ECG

electrocardiogram

ECOG

Eastern Cooperative Oncology Group

eCRF

electronic case report form

EGFR

epidermal growth factor receptor

ELISA

enzyme-linked immunosorbent assay

EMA

European medicines agency

EMEA

Europe, Middle East, and Africa

EORTC QLQ

European Organisation for Research and Treatment of Cancer Quality of Life

EOT

end of treatment

EU

European Union

Fc

fragment crystallizable

FcRn

neonatal Fc receptor

FcγRI

Fc-gamma receptor I

FcγRIIa

Fc-gamma receptor II a

FcγRIIb

Fc-gamma receptor II b

FcγRIIIa

Fc-gamma receptor III a

Fc γ RIIIa-F

Fc-gamma receptor III a-F

Fc γ RIIIa-V

Fc-gamma receptor III a-V

FcγRIIIb

Fc-gamma receptor III b

FDA

Food and Drug Administration

FTIR

Fourier transformed Infrared spectroscopy

GCP

Good Clinical Practice

GLP

Good Laboratory Practice

HBcAb

hepatitis B core antibody

HBsAb

hepatitis B surface antibody

HBsAg

hepatitis B surface antigen

HBV

hepatitis B virus

HCP

host cell proteins

HIV

human immunodeficiency virus

HMW

high molecular weight

HPLC

high performance liquid chromatography

HUVEC

human umbilical vein endothelial cells

IB

investigator's brochure

ICF

informed consent form

ICH

International Council for Harmonisation

IEC

independent ethics committee

IEC-HPLC

ion exchange HPLC

IPC

in-process control

IRB

institutional review board

IRR

infusion-related reaction

ITT

intent-to-treat

IV

intravenous

IWRS

interactive web response system

KDR

kinase insert domain receptor

kg

kilogram(s)

LLOQ

lower limit of quantification

LMW

low molecular weight

MAA

marketing authorisation application

MCB

Master Cell Bank

mCRC

metastatic carcinoma of the colon or rectum

MedDRA

Medical Dictionary for Regulatory Activities

mg

milligram(s)

MNAR

missing not at random

MoA

mechanism of action

MPA

medical products agency (Sweden)

MRI

magnetic resonance imaging

NAb

neutralising antibody

NCI

National Cancer Institute

NE

inevaluable

NSCLC

non-small cell lung cancer

nsNSCLC

non-squamous non-small cell lung cancer

<div style=\"page-break-after: always\"></div>

OECD

Organisation for Economic Co-operation and Development

ORR

objective response rate

OS

overall survival

PD

progressive disease

PD

pharmacodynamic(s)

PFS

progression-free survival

PK

pharmacokinetic(s)

PlGF

placental growth factor

PP

per protocol

PR

partial response

PRES

posterior reversible encephalopathy syndrome

PT

preferred term

PVG

pharmacovigilance

QLQ-C30

Quality of Life Questionnaire Core 30

QLQ-LC13

Quality of Life Questionnaire Lung Cancer-specific module

QoL

quality of life

QTPP

quality target product profile

RECIST

Response Evaluation Criteria in Solid Tumors

RH

relative humidity

RTK

receptor tyrosine kinase

SAE

serious adverse event

SAP

statistical analysis plan

SD

stable disease

SEC-HPLC

size exclusion HPLC

SmPC

summary of product characteristics

SOC

system organ class

SPR

surface plasmon resonance

TEAE

treatment-emergent adverse event

TEAESI

treatment-emergent adverse event of special interest

TESAE

treatment-emergent serious adverse event

TK

toxicokinetic(s)

TSE

Transmissible Spongiform Encephalopathy

TTP

time to progression

ULN

upper limit of normal

US

United States

VEGF

vascular endothelial growth factor

VEGFR

vascular endothelial growth factor receptor

VTE

venous thromboembolism

WCB

Working Cell Bank

<div style=\"page-break-after: always\"></div>

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Submission of the dossier

The applicant Celltrion Healthcare Hungary Kft. submitted on 8 October 2021 an application for marketing authorisation to the European Medicines Agency (EMA) for Vegzelma, through the centralised procedure falling within the Article 3(1) and point 1 of Annex of Regulation (EC) No 726/2004.

The applicant applied for the following indication:

Vegzelma in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum.

Vegzelma in combination with paclitaxel is indicated for first-line treatment of adult patients with metastatic breast cancer. For further information as to human epidermal growth factor receptor 2 (HER2) status, please refer to section 5.1.

Vegzelma in combination with capecitabine is indicated for first-line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. Patients who have received taxane and anthracycline-containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with Vegzelma in combination with capecitabine. For further information as to HER2 status, please refer to section 5.1.

Vegzelma, in addition to platinum-based chemotherapy, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer (NSCLC) other than predominantly squamous cell histology.

Vegzelma, in combination with erlotinib, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent NSCLC with Epidermal Growth Factor Receptor (EGFR) activating mutations (see section 5.1).

Vegzelma, in combination with interferon alfa-2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer.

Vegzelma, in combination with carboplatin and paclitaxel is indicated for the front-line treatment of adult patients with advanced (International Federation of Gynecology and Obstetrics (FIGO) stages III B, III C and IV) epithelial ovarian, fallopian tube, or primary peritoneal cancer (see section 5.1).

Vegzelma, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vascular endothelial growth factor (VEGF) inhibitors or VEGF receptor-targeted agents.

Vegzelma in combination with paclitaxel, topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor-targeted agents (see section 5.1).

Vegzelma, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with

<div style=\"page-break-after: always\"></div>

persistent, recurrent, or metastatic carcinoma of the cervix (see section 5.1).

## 1.2. Legal basis and dossier content

## The legal basis for this application refers to:

Article 10(4) of Directive 2001/83/EC - relating to applications for a biosimilar medicinal products

The application submitted is composed of administrative information, complete quality data, appropriate non-clinical and clinical data for a similar biological medicinal product.

The chosen reference product is:

Medicinal product which is or has been authorised in accordance with Union provisions in force for not less than 10 years in the EEA:

- Product name, strength, pharmaceutical form: Avastin, 100 mg and 400 mg, Concentrate for solution for infusion
- Marketing authorisation holder: Roche Registration GmbH
- Date of authorisation: 12-01-2005
- Marketing authorisation granted by:
- -Union
- Marketing authorisation number: EU/1/04/300/001, EU/1/04/300/002

Medicinal product authorised in the Union/Members State where the application is made or European reference medicinal product:

- Product name, strength, pharmaceutical form: Avastin, 100 mg and 400 mg, Concentrate for solution for infusion
- Marketing authorisation holder: Roche Registration GmbH
- Date of authorisation: 12-01-2005
- Marketing authorisation granted by:
- -Union
- Marketing authorisation number: EU/1/04/300/001, EU/1/04/300/002

Medicinal product which is or has been authorised in accordance with Union provisions in force and to which bioequivalence has been demonstrated by appropriate bioavailability studies:

- Product name, strength, pharmaceutical form: Avastin, 100 mg and 400 mg, Concentrate for solution for infusion
- Marketing authorisation holder: Roche Registration GmbH
- Date of authorisation: 12-01-2005
- Marketing authorisation granted by:
- -Union
- Marketing authorisation number: EU/1/04/300/001, EU/1/04/300/002

## 1.3. Information on Paediatric requirements

Not applicable

<div style=\"page-break-after: always\"></div>

## 1.4. Information relating to orphan market exclusivity

## 1.4.1. Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the applicant did submit a critical report addressing the possible similarity with authorised orphan medicinal products.

## 1.5. Scientific advice

The applicant received the following Scientific advice on the development relevant for the indication subject to the present application:

| Date         | Reference                 | SAWP co-ordinators                         |
|--------------|---------------------------|--------------------------------------------|
| 21 July 2016 | EMA/CHMP/SAWP/476333/2016 | Ira Palminger Hallen; Kirstine Moll Harboe |

The Scientific advice pertained to the following quality, non-clinical, and clinical aspects:

- Physico-chemical and biological testing approach to demonstrate comparability of CT-P16 to the reference product Avastin.
- Release specifications of CT-P16 active substance and drug product.
- Assessment of potency of CT-P16 active substance and drug product by vascular endothelial growth factor (VEGF) blockade assay using kinase insert domain receptor (KDR) HEK293 cell line.
- Adequacy of CT-P16 non-clinical development to support clinical development programme.
- Design of an in vivo xenograft study in mice to compare the inhibition of tumour growth between CT-P16 and the reference product.
- Design of Phase 1, randomised, double-blind, three-arm, parallel group, single-dose study in healthy male subjects to compare CT-P16 to EU- and US-approved Avastin including study population, dose, primary PK endpoints, sampling duration, sample size, equivalence margin, necessity of VEGF-A evaluation.
- Design of Phase 3, randomised, double-blind clinical study to compare efficacy, safety, and immunogenicity of CT-P16 and Avastin in patients with not squamous non-small cell lung cancer and metastatic colorectal cancer including study population, primary, secondary, and tertiary endpoints, statistical plan, sample size, statistical power.
- Extrapolation of clinical study results to all indication of the reference product.
- Size of safety and immunogenicity database.

## 1.6. Steps taken for the assessment of the product

The Rapporteur and Co-Rapporteur appointed by the CHMP were:

Rapporteur: Outi Mäki-Ikola Co-Rapporteur:  Andrea Laslop

<div style=\"page-break-after: always\"></div>

| The application was received by the EMA on                                                                                                                                               | 8 October 2021   |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------|
| The procedure started on                                                                                                                                                                 | 28 October 2021  |
| The CHMP Rapporteur's first Assessment Report was circulated to all CHMP and PRAC members on                                                                                             | 17 January 2022  |
| The PRAC Rapporteur's first Assessment Report was circulated to all PRAC and CHMP members on                                                                                             | 1 February 2022  |
| The CHMP agreed on the consolidated List of Questions to be sent to the applicant during the meeting on                                                                                  | 24 February 2022 |
| The applicant submitted the responses to the CHMP consolidated List of Questions on                                                                                                      | 18 March 2022    |
| The CHMP Rapporteurs circulated the CHMP and PRAC Rapporteurs Joint Assessment Report on the responses to the List of Questions to all CHMP and PRAC members on                          | 25 April 2022    |
| The CHMP agreed on a list of outstanding issues in writing to be sent to the applicant on                                                                                                | 19 May 2022      |
| The applicant submitted the responses to the CHMP List of Outstanding Issues on                                                                                                          | 25 May 2022      |
| The CHMP Rapporteurs circulated the CHMP and PRAC Rapporteurs Joint Assessment Report on the responses to the List of Outstanding Issues to all CHMP and PRAC members on                 | 8 June 2022      |
| The CHMP, in the light of the overall data submitted and the scientific discussion within the Committee, issued a positive opinion for granting a marketing authorisation to Vegzelma on | 23 June 2022     |
| The CHMP adopted a report on similarity of Vegzelma with Zejula on                                                                                                                       | 23 June 2022     |

<div style=\"page-break-after: always\"></div>

## 2. Scientific discussion

## 2.1. Problem statement

## About the product

Vegzelma has been developed as a biosimilar to the reference  product  Avastin  (bevacizumab).  The applicant is claiming all of the approved indications for Avastin.

The  active  substance  (bevacizumab)  is  a  recombinant  humanised  monoclonal  IgG1  antibody.  The mechanisms of action (MoA) of bevacizumab is known as Fab-mediated neutralizing activity. The Fab region of CT-P16 has the ability to bind and neutralise VEGF to block its binding to VEGF receptors (VEGFR1 and VEGFR2) thereby inhibiting the process of angiogenesis in tumours.

The applicant is seeking marketing authorisation for CT-P16 in accordance with Article 10(4) of Directive 2001/83/EC, as amended. The reference biological medicinal product Avastin was originally approved in the US in February 2004 and in the EU in January 2005 (EMEA/H/C/000582).

## 2.2. Quality aspects

## 2.2.1. Introduction

Vegzelma has been developed as biosimilar to the reference medicinal product Avastin. The finished product is presented as concentrate for solution for infusion containing 25 mg/mL of bevacizumab as active  substance.  The  finished  product  is  supplied  in  two  presentations,  i.e.  100 mg /4 mL  and  400 mg/16 mL in single-use vials and are the same as approved for the reference product.

Other ingredients are: trehalose dihydrate, sodium phosphate, polysorbate 20 and water for injections.

The finished product is available in Type I glass a vial with a chlorobutyl rubber stopper and aluminum flip-off seal.

## 2.2.2. Active Substance

## 2.2.2.1. General information

The  active  substance  (AS)  is  bevacizumab,  a  recombinant  humanised  monoclonal  IgG1  antibody (referred by the applicant as CT-P16). Like other IgG of IgG1 subclass, CT-P16 is a glycoprotein with one N-linked glycosylation site in the CH2 domain of each heavy chain. The detected oligosaccharides consist mostly of G0F and G1F structures. The molecular weight is 146,306 g/mol and formulae for the light and heavy chains are C1034H1595N273O338S6 and C2229H3409N583O677S16, respectively. Each heavy chain consists of 453 amino acids with 11 cysteine residues, and each light chain consists of 214 amino acids with 5 cysteine residues. Each heavy chain contains an N-linked oligosaccharide at glycosylation site at N303. All cysteines in the heavy and light chain are involved in either intra- chain or inter-chain disulfide bonding.

<div style=\"page-break-after: always\"></div>

The mechanisms of action (MoA) of bevacizumab is known as Fab-mediated neutralizing activity. The Fab region of CT-P16 has the ability to bind and neutralise VEGF to block its binding to VEGF receptors (VEGFR1 and VEGFR2) thereby inhibiting the process of angiogenesis in tumours.

## 2.2.2.2. Manufacture, process controls and characterisation

CT-P16 is  produced  and  release  tested  at  Celltrion  Plant  II  Korea.  The  process  setup  is  a  standard monoclonal technology. Upstream process consists of several cell expansion steps, harvest, clarification and  finally  filtration.  In  the  downstream  process  the  clarified  harvest  is  purified  using  a  series  of purification  steps.  Purification  includes  virus  inactivation  and  removal  steps  (low-pH  hold  and nanofiltration) and final filtration.

Information on the source of the cell substrate and analysis of the expression construct used to develop the Master Cell Bank is described in satisfactory detail. Chinese hamster cells were used to generate the transfected cell line. Selection process of production cell line is described adequately. A common twotiered cell banking system consisting of a Master Cell Bank (MCB) and Working Cell Bank (WCB), is used. Overall, the cell banking system, including characterisation and testing is adequately described.

Critical parameters include AS-related attributes, process/material-related impurities, general requirements and formulation-related attributes. Relevant process parameters are set to control the manufacturing process. Process characterisation and validation studies support the established process parameters.

Process validation studies were performed at commercial scale. Overall, there were no batch failure during validation, and all AS results met acceptance criteria. Some deviations were observed during the process  validation  studies.  In  general,  observed  deviations  are  adequately  discussed  and  relevant adjustments were applied.

Characterisation studies were performed using several batches of AS manufactured using the current process and several lots of finished product (FP) manufactured using AS from the current process. The characterisation studies include determination of primary and higher order structure, charge variants, N-linked  glycans,  purity,  and  biological  activity.  Overall,  the  performed  characterisation  studies  are considered relevant and cover a wide variety of physicochemical and biological characterisation studies. Justification of the identification and classification of the product-related impurities can be agreed.

The development of the manufacturing process and the comparability studies conducted were adequately described. Generally, comparability assessment covers all necessary tests to conclude the similarity of the  AS  before  and  after  the  manufacturing  changes  between  earlier  processes  and  current  one. Description of changes and reasons for changes (justification) with respect to the impact on quality was provided and is acceptable.

## 2.2.2.3. Specification

The release specification includes tests for general attributes, microbial, identity, glycosylation, purity and impurities, content, and potency.

Overall, the proposed test parameters are considered relevant and cover variety of physicochemical test methods and one parameter for biological activity. The proposed acceptance criteria are agreeable.

The stability  specification  test  items  are  identical  to  that  employed  at  release  with  the  exception  of parameters, for which no change is expected; this is acceptable.

<div style=\"page-break-after: always\"></div>

Analytical methods were sufficiently described including system suitability testing and assay acceptance criteria of the methods and listing of key materials and equipment. Qualification of used standards and antigen for HCP and residual host cell DNA was described in section S.5. Representative chromatograms were provided for relevant methods. The Validation for the used analytical methods has been adequately performed.

The reference standards used during the product development and for routine batch release use, have been adequately described. A two-tiered reference standard system is used for commercial manufacturing including primary reference standard (PRS) and working reference standards (WRS). The WRS is used for routine  lot  release  and  stability  testing,  as  well  as  other  quality  activities  such  as investigations and method transfers/validation.

The active  substance  is  filled  into  pre-sterilised,  pyrogen  free  polycarbonate  bottles.  Representative certificates of analysis provided by the vendor are provided. The CHMP made a recommendation (REC) to the applicant to submit the final report for the leachables studies for the active substance container closure in H1/2026. In summary, the container closure system is considered suitable.

## 2.2.2.4. Stability

Stability data at long-term (-40 ± 5°C), intermediate (5 ± 3ºC) and at accelerated (25 ± 2ºC / 60 ± 5% RH) stability conditions was provided. All stability batches were manufactured at CELLTRION Plant II (CLT2)  at  commercial  batch  scale.  Batches  manufactured  by  the  previous  process  were  used  to manufacture product for clinical studies. For these batches, real-time stability data is completed and available  for  60  months  at  long-term  conditions,  12  months  at  intermediate  conditions  and  for accelerated  conditions  for  6  months.  Stability  data  for  batches  manufactured  with  the  commercial process  is  available  for  12  months  at  long-term  conditions.  For  studies  under  intermediate  and accelerated conditions (study completed), 12 months and 6 months data is available, respectively. In addition, photostability study results for one batch (commercial process) were provided. Shelf-life of 60 months at -40±5°C is being proposed.

Long-term stability results demonstrate that all quality attributes studied were within the acceptance criteria through 60 months for all clinical lots with minor exception; all long-term results available for the current process batches (i.e. up to 12 months) comply as well. Intermediate stability study results comply  with  specifications  and  are  completed  for  batches  manufactured  with  the  current  process. Accelerated stability study results revealed a downward trend and OOS results in some parameters and an upward trend others.

The applicant has conducted photostability studies and concluded, that the AS should be protected from light as changes in some quality attributes were observed in the AS when stored without light protection.

Overall, the provided stability data support the proposed shelf-life for the AS packaged in the proposed container closure (polycarbonate bottles) and stored at the recommended storage condition.

## 2.2.3. Finished Medicinal Product

## 2.2.3.1. Description of the product and pharmaceutical development

The finished product is a sterile liquid solution containing 400 mg or 100 mg of bevacizumab active substance. Each vial is designed to deliver a single dose of 400 mg or 100 mg active ingredient in 16 mL or 4 mL of solution at a nominal concentration of 25.0 mg/mL. The finished product contains the active

<div style=\"page-break-after: always\"></div>

substance (bevacizumab), di-sodium hydrogen phosphate, anhydrous, sodium dihydrogen phosphate monohydrate, α , α - trehalose, dihydrate, polysorbate 20, and water for injection.

The development strategy of Vegzelma focused on developing a similar biological medicinal product comparable to EU-approved reference product Avastin. To this end, the CT-P16 formulation used in nonclinical,  clinical  development  and  commercial  supply  are  identical  to  that  of  Avastin  with  respect  to pharmaceutical form, concentration and composition.

Since the CT-P16 formulation is identical to the reference product, the applicant performed only limited qualitative  and  quantitative  formulation  studies,  the  purpose  of  which  was  to  demonstrate  that  the formulation is robust in terms of product stability and quality, and comparable with the reference product. Five formulation parameters were varied as part of this study. The two presentations are comparable and representative of one another in that the AS and formulated bulk product used to make the finished product is identical for the two presentations.

An extensive characterisation of CT-P16 was conducted including physicochemical and biological analysis. The  results  show  that  CT-P16  AS  and  FP  have  the  expected  primary,  secondary  and  higher  order structure of bevacizumab, acceptable levels of protein content and purity, and the biological activities expected  of  bevacizumab.  The  physicochemical  and  biological  comparability  program  undertaken indicate that CT-P16 AS and FP are comparable with respect to primary structure and post-translational modifications; charge variants; glycation / glycosylation; purity; higher-order structure; content and biological activities as confirmed using a number of orthogonal techniques.

Based on the results of EU approved (and US-licensed) reference product Avastin 100 mg, an overfill is applied during filling of the 100 mg presentation into vials to ensure similarity in protein content and extractable volume. Similarly, based on the results of the 400 mg Avastin, an overfill is applied during filling of the 400 mg presentation into vials to ensure similarity of protein content and extractable volume.

## Manufacturing process development

The manufacturing process development has been described in sufficient detail. The production scale, manufacturing  site  and  details  of  the  material  usage  from  each  facility  were  adequately  presented. Changes  were  introduced  to  the  manufacturing  process  for  process  validation  of  the  commercial manufacture of both 400 mg and 100 mg presentations with modification of in-process controls. To demonstrate that the change in scale of manufacture of CT-P16  finished product has not adversely impacted product quality, an extensive comparability study has been performed between processes. In addition, during CT-P16 development, changes to the FP manufacturing process for CT-P16 100 mg and CT-P16 400 mg presentations were introduced. A summary of the comparability studies undertaken was provided and sufficiently demonstrated the comparability of each product presentation manufactured with the previous and current process.

## Container closure system

The primary container closure system for CT-P16 finished product is composed of a type I borosilicate glass vial, a rubber stopper and a cap. Each CT-P16 finished product vial is packed individually in an outer carton box to prevent exposure to UV light and to protect the vial from any potential physical damage during handling, shipping, and storage.

The  glass  vials  and  rubber  stoppers  comply  with  the  appropriate  Ph.  Eur.  monographs  for  primary containers and closures.

Results of the leachable studies for vial and stopper indicate that no leachables of toxicological concern are present, which is compatible with vial and stopper. The leachable study will be continued. The vials used for CT-P16 400 mg and 100 mg presentations are manufactured with same type glass vial and the stoppers used are identical.

<div style=\"page-break-after: always\"></div>

The CHMP recommended that the leachables study should be continued up to the end of shelf-life. The final study report of the leachables study should be submitted by July of 2026. Furthermore, the Agency should be informed in the event that any compound of toxicological concern is identified in the study at 5 ± 3°C prior to 48 months (REC).

## 2.2.3.2. Manufacture of the product and process controls

Finished product manufacture is performed at CELLTRION, Inc., Plant II (CLT2), 20 Academy-ro 51 beongil, Yeonsu-gu, Incheon, 22014, Republic of Korea.

Three sites are responsible for the physical importation and batch release of the FP to Europe: Millmount Healthcare Ltd., Block 7, City North Business Campus, Stamullen, Co. Meath K32 YD60, Ireland; Nuvisan GmbH, Wegenerstraße 13, 89231 Neu Ulm, Germany and Nuvisan France SARL, 2400, Route des Colles 06410, Sophia Antipolis, France.

The  applicant  has  provided  a  brief  description  and  a  flow  chart  of  the  manufacturing  process.  The 400 mg/16 mL and 100 mg/4 mL (both 25 mg/mL) presentations are manufactured using the same process steps and controls. The only differences between the presentations are the fill volume. All other manufacturing steps and process parameters are the same. The manufacturing process is described with sufficient details.

Appropriate critical process steps and IPCs are described in the dossier. The commercial manufacturing process  has  been  validated.  Validation  of  the  finished  product  manufacturing  process  included consecutive performance qualifications lots; covering both presentations. The validation lots met the proposed release specifications. Sufficient information is provided on media fills, filter validation and shipping validation

The data gathered during the FP process validation show that the manufacturing process of CT-P16 meets the predetermined quality characteristics and the process validation is acceptable. Moreover, the defined set of process parameters have been shown to be suitable for monitoring the manufacturing process. In addition, ranges and values chosen for the processing parameters are acceptable to support the commercial manufacture of the product.

## 2.2.3.3. Product specification

The specification for the finished product, include tests for general attributes, microbial safety, identity, purity and impurities, SEC, content, potency.

The methodology for preparation of the specification was in compliance with ICH Q6B. the specification includes the critical quality attributes (CQA) of the product that can affect the safety and efficacy of the finished product and defines the acceptable range of the physicochemical and biological characteristics of the FP. The specification was established based on development data, a reasonable range of expected analytical  and  manufacturing  variability,  and  reference  information  including  literature,  regulatory guidelines,  and  pharmacopoeial  limits.  The  initially  proposed  acceptance  criteria  groups  of  charge variants  and  total  aggregates  have  been  revised  in  line  with  those  proposed  for  the  AS.  Shelf-life specifications  have  been  adapted  accordingly.  In  addition,  as  a  proposed  biosimilar  product  to  EUapproved Avastin, the acceptance criteria also consider the quality range of reference product where appropriate. Overall the specifications limits have been appropriately justified and are acceptable.

The potential presence of elemental impurities in the finished product has been assessed on a risk-based approach in line with the ICH Q3D Guideline for Elemental Impurities. Based on the risk assessment and elemental analysis results of three batches, it is confirmed that elemental impurities are within the limits

<div style=\"page-break-after: always\"></div>

set out in ICH Q3D and that testing for elemental impurities does not need to be included in the finished product specification. The information on the control of elemental impurities is satisfactory.

A risk evaluation concerning the presence of nitrosamine impurities in the finished product has been performed  (as  requested)  in  line  with  the  'Questions  and  answers  for  marketing  authorisation holders/applicants on the CHMP Opinion for the Article 5(3) of Regulation (EC) No 726/2004 referral on nitrosamine impurities in human medicinal products' (EMA/409815/2020) and the 'Assessment reportProcedure under Article 5(3) of Regulation EC (No) 726/2004- Nitrosamine impurities in human medicinal products'  (EMA/369136/2020).  Based  on  the  information  provided  it  is  accepted  that  no  risk  was identified  on  the  possible  presence  of  nitrosamine  impurities  in  the  active  substance  or  the  related finished product. Therefore, no additional control measures are deemed necessary.

The analytical methods chosen to monitor the CT-P16 FP's identity, purity, potency and quantity have been demonstrated to be suitable for their intended purpose. Both compendial and non-compendial methods have been adequately validated. Detailed information on the current and previous reference standard lots has been provided and discussed previously in the respective AS section in this report.

The batch analysis data presented derived from several lots of CT-P16 400 mg and several lots of CTP16 100 mg manufactured throughout development. Data was obtained from testing according to the development specifications in place at the time of batch release. The changes made to analytical methods and acceptance criteria during development of CT-P16 FP were described in the dossier.

Batch analysis data also included commercial scale batches used for process validation, characterisation studies,  comparability  studies,  stability  studies,  similarity  studies,  justification  of  specification.  All batches met the acceptance criteria in place at the time of release. The results demonstrate consistency of the manufacturing process capabilities.

## 2.2.3.4. Stability of the product

Stability studies have been conducted on both presentations 400 mg and 100 mg. The studies were conducted in accordance with the guidance provided in ICH Q5C Quality of Biotechnological Products: Stability Testing of Biotechnological/Biological Products and ICH Q1A (R2) Stability Testing of New Drug Substances and Products. The proposed storage condition for Vegzelma is 5 ± 3°C.

Long-term stability data at 5 ± 3°C has been presented for batches for each presentation manufactured with either the previous or the current process for up to 48 months for the 400 mg and up to 24 months for the 100 mg presentation.

The panel of stability indicating methods applied provides assurance that potential changes in the purity, content and potency will be detected. No trends were observed and all the batches met the acceptance criteria at all timepoints at the long-term storage condition. Assignment of the shelf life is based on real time stability data (400 mg/16 mL 48 months, 100 mg/4 mL 24 months).

In addition, the same 400 mg batches were subjected to accelerated stability study (25 ± 2°C / 60 ± 5% RH), and stress stability study (40 ± 2°C / 75 ± 5% RH). Dilution for infusion stability study (5 ± 3°C and 30 ± 2°C / 75 ± 5% RH),  and confirmatory photostability study (1,200,000 Lux hr Vis. and 200 Whr/m2 UV) were performed for each presentations; positioning study was conducted on 400 mg batch.

The proposed shelf-life for diluted product in 100 mL polyolefin (PP and PE) bag containing 0.9% sodium chloride  is  60  days  at  5 ± 3ºC  and  subsequently  for  7  days  at  30  ±  2°C  /  75  ±  5%  RH,  which  is acceptable. The finished product is light sensitive, but sufficiently protected by the outer packaging.

<div style=\"page-break-after: always\"></div>

Finally, a forced degradation study was performed to characterise and understand the processes and pathways associated with degradation. This study was also conducted to evaluate the similarity of the degradation pathways of Vegzelma and EU-approved Avastin. Comparative stability testing was also performed with several US-licensed Avastin and several EU-approved Avastin under accelerated and stress conditions.

The post-approval stability protocol and the stability commitment has been provided and are considered acceptable.

Taken  together,  the  presented  stability  data  sufficiently  support  the  proposed  shelf-life  of  2 years (100 mg / 4 mL) and 4 years (400 mg / 16 mL) for the unopened vial at the intended storage conditions (i.e. 2-8°C, protected from light) as per SmPC sections 6.3 and 6.4.

## 2.2.3.5. Biosimilarity

A comprehensive similarity exercise following the general principles outlined in the guideline on similar biological  medicinal  products  containing  biotechnology-derived  proteins  as  active  substance;  Quality issues (EMA/CHMP/BWP/247713/2012) has been performed. Several independent CT-P16 FP batches representative of the commercial scale and several EU-approved Avastin batches were included in the similarity study. The batches reflected a range of expiration dates and product ages. The FP material used in the analytical biosimilarity studies is considered representative of the material used in clinical trials.

The  similarity  ranges  were  established  for  quantitative  key  quality  parameters  using  data  from EU-approved Avastin batches. For key biological quality attributes, a ±3*SD quality range was set by analysis of EU-approved Avastin batches. Results of physicochemical analyses were presented without statistical analysis; instead the mean and SD as well as the spread of the underlying distribution from quantitative analyses have been compared and differences have been highlighted and discussed. Since tabular and graphical presentation allows for a clear comparison of CT-P16 to the RMP, this is considered acceptable.  In  addition,  generally  sufficient  raw  data  has  been  provided  to  allow  assessment  of biosimilarity independently of statistical approach chosen. The overall approaches used for establishment of the biosimilarity assessment criteria are considered acceptable.

The  comparative  testing  included  analysis  of  primary  structure  and  post-translational  modifications, biological activity, glycation and glycosylation, charge heterogeneity, purity/impurity, disulfide bonds, higher  order  structures,  content,  and  comparative  forced  degradation  studies  of  CT-P16  and EU-approved Avastin. Appropriate analytical methods have been utilised to ensure an understanding of the EU-approved Avastin product profile and the CT-P16 product developed.

A summary of the results including a critical evaluation of biosimilarity is presented in Table 1.

Table 1. Summary of biosimilarity assessment between Vegzelma and EU-Avastin

| Molecular parameter   | Attribute                         | Methods                | Key findings, conclusions                                                                                                                                                                                                                                                                   |
|-----------------------|-----------------------------------|------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Primary structure     | Intact Mass                       | LC-MS (reduced)        | The mass of LC and HC were similar for the 2 products. Amino acid sequence coverage was confirmed to be 100 %, and the amino acid sequence of CT-P16 was confirmed to be identical to the sequence of EU-approved Avastin. Both products have the same N-terminal and C-terminal sequences. |
| Primary structure     | Amino acid sequence               | Peptide mapping LC- MS | The mass of LC and HC were similar for the 2 products. Amino acid sequence coverage was confirmed to be 100 %, and the amino acid sequence of CT-P16 was confirmed to be identical to the sequence of EU-approved Avastin. Both products have the same N-terminal and C-terminal sequences. |
| Primary structure     | Post- translational modifications |                        | The mass of LC and HC were similar for the 2 products. Amino acid sequence coverage was confirmed to be 100 %, and the amino acid sequence of CT-P16 was confirmed to be identical to the sequence of EU-approved Avastin. Both products have the same N-terminal and C-terminal sequences. |

<div style=\"page-break-after: always\"></div>

|                             | N/C-terminal integrity                                                                       | Peptide mapping MS- MS                                                                                                                                                                                                                                                                                   | CT-P16 and EU-approved Avastin contain the same post-translational modifications but with minor quantitative differences. The observed differences are small and adequate justification based on scientific literature was included for the lack of potential clinical relevance / impact. Overall, similarity in terms of primary structure was demonstrated.                                                                                                                                               |
|-----------------------------|----------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Higher order structure      | Secondary and tertiary structure                                                             | Far/Near UV CD, DSC, FTIR                                                                                                                                                                                                                                                                                | Secondary and tertiary structure appear comparable.                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Higher order structure      | Disulphide bonds                                                                             | Native / reduced peptide mapping LC-MS                                                                                                                                                                                                                                                                   | The same disulphide bond linkages in CT-P16 and EU-approved Avastin has been demonstrated. Minor differences were noted in the level of free thiol groups as compared to EU-approved Avastin.                                                                                                                                                                                                                                                                                                                |
| Higher order structure      | Free thiols                                                                                  | Ellman's assay                                                                                                                                                                                                                                                                                           | The same disulphide bond linkages in CT-P16 and EU-approved Avastin has been demonstrated. Minor differences were noted in the level of free thiol groups as compared to EU-approved Avastin.                                                                                                                                                                                                                                                                                                                |
| Content                     | Protein content                                                                              | OD280                                                                                                                                                                                                                                                                                                    | CT-P16 and EU-approved Avastin are similar in their protein concentration.                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Content                     | Extinction coefficient                                                                       | Amino acid analysis                                                                                                                                                                                                                                                                                      | CT-P16 and EU-approved Avastin are similar in their protein concentration.                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Charged variants            | Basic species, acidic species and main variants                                              | icIEF IEC-HPLC                                                                                                                                                                                                                                                                                           | The icIEF electropherograms show a similar pattern in all samples. Any detected difference are considered unlikely to be clinically significant. Minor differences between CT-P16 and EU- approved Avastin were noted in the relative proportion of the charge variants. However, based on the characterisation results presented, it can be concluded that the slight differences observed in charge variant profiles are clinically insignificant. All variants are biologically active. The applicant has |
| Charged variants            | Basic species, acidic species and main variants                                              | Isolated fractions were further characterised via Peptide mapping (LC-MS), SEC-HPLC, CE-SDS (reduced/non- reduced), Intact mass analysis (reduced / non-reduced), VEGF- A165 Binding (ELISA), anti-proliferation assay using HUVECs, FcγRIIIa (V -type) binding affinity and FcRn binding affinity (SPR) | appropriately discussed and justified the differences detected in CT-P16 and EU-approved Avastin to support the similarity.                                                                                                                                                                                                                                                                                                                                                                                  |
| Glycation and glycosylation | Glycation                                                                                    | LC/MS                                                                                                                                                                                                                                                                                                    | CT-P16 was shown to have minor differences in glycation level and oligosaccharide profiles compared to EU-approved Avastin, but it has been sufficiently justified that these differences are highly unlikely to be of clinical relevance.                                                                                                                                                                                                                                                                   |
| Glycation and glycosylation | N-linked glycans                                                                             | Peptide mapping (LC/MS)                                                                                                                                                                                                                                                                                  | CT-P16 was shown to have minor differences in glycation level and oligosaccharide profiles compared to EU-approved Avastin, but it has been sufficiently justified that these differences are highly unlikely to be of clinical relevance.                                                                                                                                                                                                                                                                   |
| Glycation and glycosylation | Oligosaccharide profile (afucosylation, high mannose variants, galactosylation, sialylation) | HILIC-UPLC-FLD                                                                                                                                                                                                                                                                                           | CT-P16 was shown to have minor differences in glycation level and oligosaccharide profiles compared to EU-approved Avastin, but it has been sufficiently justified that these differences are highly unlikely to be of clinical relevance.                                                                                                                                                                                                                                                                   |
|                             |                                                                                              | SEC-HPLC (diluted, non-diluted)                                                                                                                                                                                                                                                                          | CT-P16 and EU-approved Avastin are primarily monomers and similar in their size heterogeneity.                                                                                                                                                                                                                                                                                                                                                                                                               |

<div style=\"page-break-after: always\"></div>

| Aggregates, fragmentation, aglycosylation   | Monomers, dimers, HMW, purity/impurity                                                  | SEC-MALS                                                                                                                                                                                                                                                                  | SEC-MALLS analysis indicated that the molecular                                                                                                                                                                                                            | SEC-MALLS analysis indicated that the molecular                                                                                                                                                                                                            |
|---------------------------------------------|-----------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Aggregates, fragmentation, aglycosylation   | Monomers, dimers, HMW, purity/impurity                                                  | AUC                                                                                                                                                                                                                                                                       | weights of the monomer and HMW forms in CT-P16 and EU-approved                                                                                                                                                                                             | that the                                                                                                                                                                                                                                                   |
| Aggregates, fragmentation, aglycosylation   | Monomers, dimers, HMW, purity/impurity                                                  | CE-SDS (non- reduced/reduced)                                                                                                                                                                                                                                             | HMW forms of both products consist predominantly of dimers.                                                                                                                                                                                                | HMW forms of both products consist predominantly of dimers.                                                                                                                                                                                                |
| Aggregates, fragmentation, aglycosylation   | Monomers, dimers, HMW, purity/impurity                                                  | Impact of non- glycosylation on Fc and Fab functionality was assessed via binding affinities to FcγRIIIa -V, FcRn, VEGF-A165 binding (ELISA) and anti-proliferation assay using HUVEC                                                                                     | Non-glycosylated HC in CT-P16 and EU-approved Avastin had a similar impact on biological activity. Any observed differences are not considered clinically relevant.This conclusion is also supported by similar biological activities of the two products. | Non-glycosylated HC in CT-P16 and EU-approved Avastin had a similar impact on biological activity. Any observed differences are not considered clinically relevant.This conclusion is also supported by similar biological activities of the two products. |
| Biological activity                         | Potency                                                                                 | Anti-proliferation assay using HUVEC                                                                                                                                                                                                                                      | CT-P16 and EU-approved Avastin are highly similar in their inhibition of cell proliferation and binding to                                                                                                                                                 | CT-P16 and EU-approved Avastin are highly similar in their inhibition of cell proliferation and binding to                                                                                                                                                 |
| Biological activity                         | VEGF-A binding                                                                          | Binding to VEGF-A165 and VEGF-A121 (ELISA)                                                                                                                                                                                                                                | VEGF-A. The descriptions and qualification data that have been provided for the analytical methods used for the analytical comparability exercise are considered sufficient.                                                                               | VEGF-A. The descriptions and qualification data that have been provided for the analytical methods used for the analytical comparability exercise are considered sufficient.                                                                               |
| Biological activity                         | VEGF-A binding                                                                          | Binding to VEGF-A145, VEGF-A189, VEGF- A206, VEGF-B, VEGF- C, VEGF-D, VEGF-E, PlGF-2, PlGF-2 (ELISA)                                                                                                                                                                      | Any observed differences are unlikely to be clinically meaningful. The lack of effector functions was demonstrated in CT-P16 and EU-approved Avastin batches. In                                                                                           | Any observed differences are unlikely to be clinically meaningful. The lack of effector functions was demonstrated in CT-P16 and EU-approved Avastin batches. In                                                                                           |
| Biological activity                         | VEGFR2 RTK auto- phosphorylation                                                        | HUVEC (ELISA)                                                                                                                                                                                                                                                             | addition, CT-P16 and EU-approved Avastin were demonstrated to inhibit VEGFR2 RTK autophosphorylation and to be unable to bind a range of VEGF-A isoforms and VEGF family.                                                                                  | addition, CT-P16 and EU-approved Avastin were demonstrated to inhibit VEGFR2 RTK autophosphorylation and to be unable to bind a range of VEGF-A isoforms and VEGF family.                                                                                  |
| Biological activity                         | Binding to C1q                                                                          | ELISA                                                                                                                                                                                                                                                                     | on the biological activity similarity                                                                                                                                                                                                                      | on the biological activity similarity                                                                                                                                                                                                                      |
| Biological activity                         | Binding to FcγRIIIa (158F and V158), FcγRIIIb, FcγRIIa, FcγRIIb, FcRn, FcγRI            | SPR                                                                                                                                                                                                                                                                       | Based assessment, CT-P16 is similar to EU-approved Avastin.                                                                                                                                                                                                | Based assessment, CT-P16 is similar to EU-approved Avastin.                                                                                                                                                                                                |
| Biological activity                         | Effector functions                                                                      | ADCC using SKOV- 3/PBMC                                                                                                                                                                                                                                                   |                                                                                                                                                                                                                                                            |                                                                                                                                                                                                                                                            |
| Biological activity                         | Effector functions                                                                      | CDC assay                                                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                            |                                                                                                                                                                                                                                                            |
| Degradation profile                         | Degradation due to high temperature, oxidative stress, UV-light, low and high pH stress | Protein concentration, IEC-HPLC, Peptide mapping (LC/MS), SEC-HPLC (diluted/undiluted), CE-SDS (non- reduced/reduced), Oligosaccharide profile (HILIC-UPLC_FLD), Anti-proliferation assay using HUVEC, VEGF- A165 binding (ELISA), FcRn and FcγRIIIa (V158) binding (SPR) | Similarity in demonstrated.                                                                                                                                                                                                                                | was                                                                                                                                                                                                                                                        |

Similarity between CT-P16 and EU-approved Avastin has been demonstrated for the following physicochemical and biological properties:

- -Primary and higher order structure
- -Content
- -Charge heterogeneity
- -Glycan profile

<div style=\"page-break-after: always\"></div>

- -Size heterogeneity and purity/impurity profile
- -Antiproliferation activity, and binding to VEGF-A165 and VEGF-A121
- -Binding to FcγRIIIa (F -type, Vtype), FcγRIIa, FcγRIIb, FcγRI, FcRn, C1q
- -ADCC and CDC activity
- -Inhibition of VEGFR2 RTK autophosphorylation
- -Binding to VEGF-A isoforms (VEGF-A145, VEGF-A189, VEGF-A206) and VEGF family (VEGF-B, -C, -D, and -E; PlGF-1 and -2)
- -Stability under forced degradation

Minor differences in the levels of post-translational modifications, free thiol groups, relative proportion of the charge variants, individual fucosylated glycan species, levels of glycation, and levels of monomer, HMW, LMW, HC+LC and NGHC were sufficiently justified to have no clinical impact.

In conclusion, analytical similarity between Vegzelma and EU-approved Avastin has been demonstrated satisfactorily.

## 2.2.3.6. Post approval change management protocol(s)

N/A

## 2.2.3.7. Adventitious agents

The approach for adventitious agents testing was described. The MCB and WCB testing is reviewed as part of the AS control, as well as the control of raw materials. The results of viral testing performed as part  of  cell  line  qualification  demonstrate  that  CT-P16.  MCB  and  WCB  are  free  of  adventitious  and endogenous viral agents. These results also indicate that no viral contamination occurred during cell line development and cell banking MCB and WCB testing is reviewed as part of the AS control, as well as the control of raw materials.

Viral clearance studies were performed with a suitable panel of model viruses on qualified small-scale models.  Overall,  the  virus  clearance  studies  are  adequate.  The  original  study  reports  of  the  virus clearance studies have been provided. The virus assays are sufficiently described in the original reports. A brief description of the qPCR assay for quantitation of MVM has been provided by the applicant. The safety margin over the estimated retroviral burden per Retrovirus-like particles in unprocessed bulk is considered satisfactory.

The TSE risk associated with the raw materials used during the development of the production cell line has been presented in the dossier. No materials of animal origin are used during manufacture of the FP. On the basis of presented information, it can be concluded that there is minimal risk of contamination by TSE in the final product.

## 2.2.4. Discussion on chemical, pharmaceutical and biological aspects

Information on development, manufacture and control of the active substance and finished product has been presented in a satisfactory manner. The data provided support biosimilarity versus the EU reference medicinal product (Avastin) at the quality level. No major objections have been raised concerning the AS and FP. The available quality data support biosimilarity versus EU-approved Avastin. The risk for adventitious agents is adequately controlled. The results of tests carried out indicate consistency and uniformity of important product quality characteristics, and these in turn lead to the conclusion that the product should have a satisfactory and uniform performance in clinical use.

<div style=\"page-break-after: always\"></div>

At the time of the CHMP opinion, there were two minor unresolved quality issues having no impact on the Benefit/Risk ratio of the product, which pertain to the below aspect and are put forward and agreed as recommendations for future quality development:

-updated  leachable  studies  data  should  be  provided  and  the  final  study  results  submitted  upon completion of the studies for the both the AS and the FP.

## 2.2.5. Conclusions on the chemical, pharmaceutical and biological aspects

The quality of this product is considered to be acceptable when used in accordance with the conditions defined in the SmPC. Physicochemical and biological aspects relevant to the uniform clinical performance of the product have been investigated and are controlled in a satisfactory way. Data has been presented to give reassurance on viral/TSE safety.

## 2.2.6. Recommendations for future quality development

In the context of the obligation of the MAHs to take due account of technical and scientific progress, the CHMP recommends the following points for investigation:

| Area    |   Number | Description                                                                                                                                                                                                                                                                                                                                                                                                                                   | Classification*   | Due date   |
|---------|----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------|------------|
| Quality |        1 | to submit in H1/2026 the final report for the leachables studies for the active substance container closure.                                                                                                                                                                                                                                                                                                                                  | REC               | June 2026  |
| Quality |        2 | to continue the leachables study to evaluate the compatibility of the CT-P16 finished product with the vial and stopper up to the end of shelf- life (i.e. 48 month time point at 5 ± 3°C). The final study report of the leachables study should be submitted by July of 2026. Furthermore, the Agency should be informed in the event that any compound of toxicological concern is identified in the study at 5 ± 3 °C prior to 48 months. | REC               | July 2026  |

## 2.3. Non-clinical aspects

## 2.3.1. Introduction

The submitted nonclinical program is adequate for a biosimilar, and includes a battery of comparative in vitro primary  pharmacodynamic  (PD)  studies  (same  as  included  under  the  biosimilarity  studies)  of CT-P16 and the Reference Medicinal Product EU-Avastin, and a repeat-dose toxicity study in cynomolgus monkeys including toxicokinetic (TK) and immunogenicity assessment.

The data from a 2-way similarity assessments from a battery of state of the art receptor-binding studies and cell-based assays, and the analytical methods employed were included. Therefore, in order to avoid redundancy, thorough discussions of functional biosimilarity and adequacy of the methods employed are included under Quality/biosimilarity section, and are only shortly summarised under nonclinical aspects.

<div style=\"page-break-after: always\"></div>

In vitro studies were conducted using the drug product (DP) manufactured with the proposed commercial manufacturing process. The toxicology study in cynomolgus monkeys was conducted with CT-P16 DP lot 16P12B01 manufactured from Process A drug substance (DS). The comparability studies for both the DS (Process A) and the PD from commercial manufacturing process demonstrated that process changes have not had an adverse impact on the product quality.

## 2.3.2. Pharmacology

## 2.3.2.1. Primary pharmacodynamic studies

The in vitro functional assays covered all the relevant modes of action claimed in the indications for bevacizumab. Comparisons included lots used in the clinical studies. Ten lots of CT-P16 and EU-Avastin including  lots  used  in  the  comparative  clinical  studies  were  analysed  in  main  biological  similarity assessments. Statistical analysis using a quality range approach set based on the variation of the RMP values, expressed as ± 3*SD, was conducted. The data was considered similar where ≥ 90% of data points were within the quality range of EU-Avastin.

CT-P16 and EU-Avastin had similar binding activity to the main target VEGF-A165, and to VEGF-A121, VEGF-A145,  VEGF-A189  and  VEGF-A206  isoforms  and  had  similar  biological  activity  in  inhibition  of proliferation of human  umbilical vein endothelial cells and VEGFR2  receptor tyrosine kinase autophosphorylation.  CT-P16  was  similar  to  EUAvastin  in  binding  to  FcRn  C1q,  FcγRIIIa  (V  and  F variants), FcγRIIIb, FcγRIIa and FcγRIIb. Binding to FcγRI differed (50% of CT -P16 samples were within the quality range of EU-Avastin). Lack of triggering ADCC in PBMNCs and CDC in SKOV-3 cells was demonstrated for CT-P16 and EU-Avastin. No binding was observed to VEGF-B, VEGF-C, VEGF-D, VEGFE, PlGF-1 and PlGF-2.

## 2.3.2.2. Secondary pharmacodynamic studies

No secondary pharmacology studies were performed and are not required.

## 2.3.2.3. Safety pharmacology programme

No separate safety pharmacology studies were performed and are not required.

## 2.3.2.4. Pharmacodynamic drug interactions

No pharmacology drug interaction studies were performed and are not required.

## 2.3.3. Pharmacokinetics

The comparative toxicokinetic analysis were performed as part of repeat-dose toxicity study for CT-P16 and EU-Avastin in cynomolgus monkeys using two doses of 10 and 50 mg/kg. Analytical methods were adequately  validated  for  quantification  of  CT-P16  and  EU-Avastin  and  anti-CT-P16  and  anti-Avastin antibodies in cynomolgus monkey serum, and for formulation analysis of CT-P16 and EU-Avastin.

<div style=\"page-break-after: always\"></div>

## 2.3.4. Toxicology

## 2.3.4.1. Single dose toxicity

No single dose toxicity studies were conducted and are not required.

## 2.3.4.2. Repeat dose toxicity

A  GLP-compliant  4-week  repeat-dose  toxicity  study  (no  8342524)  in  cynomolgus  monkeys  with toxicokinetic assessment was conducted with CT-P16 (lot 16P12B01) and EU-Avastin. Doses of 10 mg/kg and 50 mg/kg were administered via intravenous (IV) bolus twice a week (in total of eight doses) to provide sufficient systemic exposure as determined based on exposure information in previous studies with the EU-Avastin.

The experimental setup of this study is summarised in the table below:

Table 2. Study design for 4-week Repeat-Dose Toxicity Study in Cynomolgus Monkeys

| Study Design   | Study Design    | Study Design      | Study Design      | Study Design   | Study Design               |
|----------------|-----------------|-------------------|-------------------|----------------|----------------------------|
| Group          |                 | Number of Animals | Number of Animals | Dose Level     | Dose Concentration (mg/ml) |
|                | Treatment       | Male              | Female            | (mg/kg/dose)   |                            |
| 1              | Vehicle Control | 3                 | 3                 | 0              | 0                          |
| 2              | Low-CT-P16      | 3                 | 3                 | 10             | 5                          |
| 3              | Low-EU-Avastin  | 3                 | 3                 | 10             | 5                          |
| 4              | High-CT-P16     | 3                 | 3                 | 50             | 25                         |
| 5              | High-EU-Avastin | 3                 | 3                 | 50             | 251                        |

Note: Nominal concentration. EU-Avastin was dosed as supplied (actual concentration was 25.1 mg/mL as listed in the Certificate of Analysis)

Abbreviations: kg. kilogram; mg, milligram; ml, milliliter

No  test-article-related  mortality  or  effects  on  vital  signs,  ophthalmic  parameters,  blood  pressure, immunophenotyping, organ weight, growth plate evaluation and anatomic pathology were noted.  CTP16 and Avastin were well tolerated in cynomolgus monkeys up to 50 mg/kg/d when administered for 4 weeks.

Only minor test-article related effects were noted, e.g. an increased incidence of fecal abnormalities and differences in ECG values. Statistically significant, but not dose-related, higher mean PR intervals were noted in males administered CT-P16 or EU-Avastin compared with control males. These changes were considered incidental, and did not differ significantly between CT-P16 administered cynomolgus monkeys compared  to  EU-Avastin.  Overall,  no  significant  changes  attributed  to  CT-P16  or  EU-Avastin  was observed in PR interval, QRS duration, QT interval, QTc interval, RR interval or heart rate.

Also  some  differences  between  monkeys  that  were  administered  CT-P16  and  EU-Avastin  were recognised: the significance of conduction delay abnormalities (incomplete right bundle branch block) exclusively noted in two monkeys of the highest CT-P16 group is unknown, but considered a background finding, and is thus not thought to raise a toxicological concern. At 50 mg/kg/bw, neutrophils and white blood cell counts were frequently increased in monkeys that were administered CT-P16, whereas this was  not  the  case  with  monkeys  from  EU-Avastin  groups.  The  observed  increases  were  frequently

<div style=\"page-break-after: always\"></div>

statistically significant. However, this was only observed after the 2nd day of dosing, later on this was not observed any more. Therefore, this observation is considered a chance finding.

## 2.3.4.3. Genotoxicity

No genotoxicity or mutagenicity studies were performed, and are not required.

## 2.3.4.4. Carcinogenicity

No carcinogenicity studies were performed, and are not required.

## 2.3.4.5. Reproductive and developmental toxicity

No reproductive and developmental studies were performed, and are not required.

## 2.3.4.6. Toxicokinetic data

Blood samples were taken pre-dose, and at approximately 0.5, 1, 2, 6, 12, 24, 48 (Day 26 only), 72, and 96 (Day 1 only) hours post-dose. For immunogenicity analysis of anti-CT-P16 and anti-EU-Avastin antibodies, blood samples were taken once during the pre-dose phase, approximately 96 hours post the Day 1 dose (prior to dosing on day 5), and approximately 72 hour post the Day 26 dose (prior to necropsy). The amount of CT-P16 or EU-Avastin and anti-drug antibodies in serum were quantified with validated analytical methods. The LLoQ for the serum concentration of CT-P16 and EU-Avastin was 10 ng/mL.

Exposure to bevacizumab increased with the increase in CT-P16 and EU-Avastin dose levels from 10 to 50 mg/kg/day. The increases in mean bevacizumab Cmax and AUC0-72h values for both CT-P16 and EUAvastin were generally dose proportional. Sex differences in concentrations were less than 2-fold.

The relative values (CT-P16/EU-Avastin) for Cmax and AUC0-72h for 10 mg/kg/day dose were 104% and 106% on Day 1, respectively, and 110% and 105% on Day 26, respectively. For dose 50 mg/kg/day, the  relative  values  were  101%  and  102%  on  Day  1,  respectively,  and  98%  and  110%  on  Day  26, respectively. Bevacizumab exposures were similar for CT-P16 and EU-Avastin.

The mean time to maximum serum concentration (Tmax) value of CT-P16 was 0.83 hours on Day 1 and 2.67 hours on Day 26 for both 10 mg/kg/day and 50 mg/kg/day, and of EU-Avastin was 0.92 hours and 3.58 hours for 10 mg/kg/day and 50 mg/kg/day, respectively, on Day 1 and 3.42 hours and 1.17 hours for 10 mg/kg/day and 50 mg/kg/day, respectively, on Day 26.

No anti-drug antibodies were detected in blood samples collected.

## 2.3.4.7. Local Tolerance

Macroscopic observation and histopathological assessments of local (injection site) tolerance were performed in the repeat-dose toxicity studies. There were no toxicologically significant differences in injection site findings between control animals and the animals administered CT-P16 or EU-Avastin.

## 2.3.4.8. Other toxicity studies

No other toxicity studies were conducted, and are not required.

<div style=\"page-break-after: always\"></div>

## 2.3.5. Ecotoxicity/environmental risk assessment

An ERA was submitted that included justification omitting the specific ERA studies ( CT-P16 belongs to proteins  (is  a  monoclonal  antibody),  which  do  not  require  specific  ERA  studies ).  The  use  of  CT-P16 (bevacizumab) is not considered to produce risk to the environment.

## 2.3.6. Discussion on non-clinical aspects

The submitted nonclinical program is adequate for the development of a CT-P16 biosimilar, and includes a battery of comparative in vitro functional studies of CT-P16 and EU-Avastin, and a repeat-dose toxicity study in cynomolgus monkeys including toxicokinetic and immunogenicity assessment.

The in vitro functional studies demonstrated that CT-P16 and EU-Avastin were similar in their biological activity, i.e. in binding activity to the main target VEGF-A165, and to other soluble or membrane-bound VEGF-A isoforms, in inhibition of proliferation of endothelial cells and VEGFR2 autophosphorylation, and binding to Fcγ -receptors, FcRn and C1q. Of all the biological activity analyses conducted, the binding to FcγRI differed (50% of CT-P16 samples being within the quality range of EU-Avastin). Nevertheless, it was justified that although FcγRI is known to trigger weak ADCC or ADCP, the therapeutic effect of bevacizumab  is  not  mediated  by  Fc-functions.  Therefore,  this  finding  is  unlikely  to  be  clinically meaningful. This justification is accepted. Moreover, the lack of triggering ADCC in PBMNCs and CDC in SKOV-3 cells was demonstrated for both, for CT-P16 and EU-Avastin. CT-P16 had similar specificity with EU-Avastin in lack of binding to other VEGF isoforms than VEGF-A or PlGF.

In conclusion, the 2-way similarity assessment data from the receptor-binding and cell-based assays demonstrate the similar functional activity of CT-P16 and EU-Avastin.

CT-P16 and EU-Avastin were well tolerated at dose levels up to maximum dose used, 50 mg/kg/day in cynomolgus monkeys. No treatment-related findings were noted with exception of minor changes (in increased incidence, fecal abnormalities and in ECG measurements, and increases of neutrophil and white  blood  cell  counts).  There  were  no  toxicologically  significant  differences  between  CT-P16  or EU-Avastin group animals, including the injection site findings. The results of the study in cynomolgus monkeys  did  not  reveal  notable  differences  in  effects  between  the  CT-P16  and  Avastin  in  their toxicological profiles.

Exposures (Cmax and AUC0-72h) to CT-P16 and EU-Avastin increased dose-proportionally, and were similar for CT-P16 and EU-Avastin. Sex differences in concentrations were less than 2-fold. The relative values (CT-P16/EU-Avastin) for Cmax and AUC0-72h for 10 mg/kg/day dose were 104% and 106% on Day 1, respectively, and 110% and 105% on Day 26, respectively. For the dose of 50 mg/kg/day, the relative values were 101% and 102% on Day 1, respectively, and 98% and 110% on Day 26, respectively.

CT-P16 or EU-Avastin did not trigger formation of anti-drug antibodies.

The  active  substance  is  a  natural  substance,  the  use  of  which  will  not  alter  the  concentration  or distribution of the substance in the environment. Therefore, CT-P16 (bevacizumab) is not expected to pose a risk to the environment.

## 2.3.7. Conclusion on the non-clinical aspects

The 2-way similarity assessment data from the receptor-binding and cell-based assays support the similar functional activity of CT-P16 and EU-Avastin. Based on the functional activity analysis, CT-P16 and EU-Avastin can be expected to have the same efficacy in vitro, PK profile, and similar lack of Fc receptor mediated effector functions (ADCC, CDC).

<div style=\"page-break-after: always\"></div>

The results from small-scale study in cynomolgus monkeys did not reveal notable differences in effects between the CT-P16 and Avastin in their toxicological or toxicokinetic profiles.

SmPC section 5.3. for CT-P16 and EU-Avastin is identical.

## 2.4. Clinical aspects

## 2.4.1. Introduction

## GCP aspects

The Clinical trials were performed in accordance with GCP as claimed by the applicant.

The applicant has provided a statement to the effect that clinical trials conducted outside the Community were carried out in accordance with the ethical standards of Directive 2001/20/EC.

- Tabular overview of clinical studies

<div style=\"page-break-after: always\"></div>

Table 3. Overview of clinical studies

| Type of Study                | Study ID   | Study Design and Iype of Control                                                                                                  | Test Product(s); Route of Administration;DosageRegimen                                                                                                                                                                                                                                                                               | Objective(s) ofthe Study                                                                                                                                                                                                                                                                                      | Study Population                                        | Duration of Treatment                                               | Healthy Subjects or Diagnosis of Patients                    | Study Status; Type of Report                                                                                                                                                |
|------------------------------|------------|-----------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------|---------------------------------------------------------------------|--------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Pivotal PK Study             | CT-P16 1.1 | Phase 1, randomized, double-blind, three-arm, parallel group, single-dose study in healthy male subjects                          | CT-Pi6,US-AvastinorEU-Avastin: 5 mg/kg, a single IV infusion for 90 mins                                                                                                                                                                                                                                                             | Prinary: Todemonstratethesimilarityof PKintermsofAUCo-inf,AUCo. It, Cmsx of CT-P16, US-Avastin and EU-Avastin Secondary: -To assess the additional PK parameters To evaluatesafety and immunogenicity of CT-P16, US-Avastin andEU-Avastin                                                                     | Randomized= 144 CT-P16: 47 EU-Avastin: 49 US-Avastin:48 | Up to Day 99                                                        | Healthy male subjects                                        | Completed CSR CT-P16 1.1                                                                                                                                                    |
| Supportive Japanese PK Study | CT-16 1.2  | Phase 1, randomized, parallel group, double-blind, single-dose study to compare thePKand safety in healthy Japanese male subjects | CT-P16,EU-Avastin: 5 mg/kg, a single IV infusion for 90 mins                                                                                                                                                                                                                                                                         | Primary: To demonstrate thesimilarity of Ist, Cmsx of CT-P16 and EU- PK in terms of AUCo-nt, AUCo. Avastin Secondary: -To assess the additional PK parameters Toevaluate safety and immunogenicity ofCT-P16 and EU-Avastin                                                                                    | Randomized=46 EU-Avastin: 24 CT-P16: 22                 | Up to Day 99                                                        | Healthy male subjects                                        | Completed 1.2 CSRCT-P16                                                                                                                                                     |
| Therapeutic Similarity Study | CT-P16 3.1 | Phase 3, randomized, double-blind, active- parallel group controlled, study in patients with metastatic orrecurrent nsNSCLC       | [InductionStudyPeriod] CT-P16 or EU-Avastin: 15 mg/kg IVonDay1 ofeach cycle,tobe repeated every 3 weeks up to 6 paclitaxel and carboplatin (at least cycles co-administered with for 4 cycles) [MaintenanceStudyPeriod] CT-P16 or EU-Avastin: monotherapy every 3 weeks until progressive disease or intolerable toxicity occurrence | Primary: To demonstrate CT-P16is similar to EU-Avastin in terms ofefficacy asdetermined by ORR during the Induction Study Period Secondary: -Toevaluate additional efficacy parameters To evaluate thePK profile (Ctough) -To evaluate the safety profile including immunogenicity -Toevaluatequality of life | Randomized= 689 CT-P16:342 EU-Avastin: 347              | Approximately 3 years from the day of enrolment of the last patient | Male or female patients with metastatic or nsNSCLC recurrent | Ongoing 1\"CSR CT-P16 3.1(data cut-off date: 22 April 2021) 2ndCSR CT-P16 3.1 (data cut-off date: 21 September 2021) Estimated final CSR (up to 3 years) completion: 2Q/2024 |

Abbreviations:AUC，area undertheconcentration-time curve;AUCo-infareaundertheconcentration-time curvefromtimeOtoinfinity;AUCo-lst,areaunder the concentration-time curvefrom time O to the last quantifiable concentration; Cmax.maximum serum concentration; CSR. clinical study report; Ctough, trough serum concentration; EU-Avastin,European Union-approved Avastin; IV, intravenous, nsNSCLC, Non-squamous non-small celllung cancer; ORR, objective response rate; PK, pharmacokinetics; US-Avastin, United States-licensed Avastin

## 2.4.2. Clinical pharmacology

## 2.4.2.1. Pharmacokinetics

CT-P16 (international non-proprietary name bevacizumab; the proposed name Vegzelma) is developed as a proposed biosimilar medicinal product to Avastin ® .

The pharmacokinetic (PK) similarity of CT-P16 has been investigated in the following three studies:

-  Study CT-P16 1.1 (pivotal PK study): A phase 1, randomized, double-blind, 3-arm, parallel group, single-dose study to compare the PK and safety of three formulations of bevacizumab (CT-P16, EU-Avastin and US-Avastin) in healthy male subjects. This study provides pivotal PK outcomes to demonstrate bioequivalence between CT-P16, EU-Avastin, and US-Avastin .
-  Study CT-P16 1.2 (supportive  Japanese  PK  study):  A phase 1, randomized,  double-blind, parallel group, single-dose study to compare the PK and safety of CT-P16 and EU-Avastin in healthy Japanese male subjects. This study was conducted to support approval of CT-P16 in Japan.

<div style=\"page-break-after: always\"></div>

-  Study  CT-P16  3.1 (comparative  efficacy  and  safety  study):  A  phase  3,  double-blind, randomized, active-controlled, parallel group study to compare efficacy and safety of CT-P16 and EU-Avastin as first-line treatment for metastatic or recurrent nsNSCLC. This study provides comparative PK data (trough serum concentrations [Ctrough] following repeated IV infusion) and long-term immunogenicity.

## Analytical methods

## Quantification of CT-P16 and bevacizumab in human serum

A MSD-ECL based method was used in the pharmacokinetics studies to quantify CT-P16 and bevacizumab (EU-Avastin and US-Avastin) concentrations in healthy human serum (clinical study CT-P16 1.2) and in human serum samples from the patients with nsNSCLC (clinical study CT-P16 3.1). An ELISA based method  was  used  for  the  quantification  of  CT-P16  and  bevacizumab  (EU-Avastin  and  US-Avastin) concentrations in healthy human serum samples collected in the clinical study CT-P16 1.1. Both methods were, in principle, validated according to ICH M10 Bioanalytical method validation guideline.

## Detection of ADA and NAb in human serum

A three-tiered approach comprising of screening, confirmation and titer was used for detection of antidrug antibodies. Two ECL based methods (validated either by PPD laboratory or BDS) were utilised for the detection of ADAs against CT-P16 and bevacizumab (EU-Avastin and US-Avastin) and two ECL based methods (validated either by PPD laboratory or BDS) were utilised for the detection of NAbs against CT-P16  and  bevacizumab  (EU-Avastin  and  US-Avastin)  in  healthy  and  diseased  human  serum.  In general, the method validation followed current guidance.

## Clinical pivotal PK study in healthy Asian male subjects (study Ct-P16 1.1)

The study was conducted at three centres in Republic of Korea between 01 st  Aug 2017 and 17 th  Jan 2018. The bioanalytical analyses were performed at Biologics Development Services, LLC US between 9 th  Oct 2017 and 28 th  Mar 2018.

The study was a phase I, randomised (the number of subjec ts with body weight &lt; 70 kg and ≥ 70 kg was balanced among the 3 treatment groups), double-blind, 3-arm, parallel group, single-dose study in adult  healthy  Asian  male  subjects.  Subjects  received  single  dose  (i.e.  5  mg  /kg)  of  either  CT-P16, EU-Avastin or US-Avastin by IV infusion for 90 minutes (± 5 minutes) on Day 1. Blood samples were collected for measurement of serum concentrations of bevacizumab from all subjects at the following time points: pre-dose, immediately end-of-infusion (EOI), 1 h after EOI, 4 h after start of infusion (SOI), 8 h after SOI and 12 h after SOI, days 2, 3, 4, 8, 15, 29, 43, 57, 71, 85 and 99.

## PK results:

The PK population consisted of 141 subjects (n = 46 in CT-P16 group, n =47 in the EU-Avastin group and n = 48 in the US-Avastin group).

Mean serum concentrations were similar between CT-P16, EU-Avastin and US-Avastin treatment groups (see Figure 1 below).

<div style=\"page-break-after: always\"></div>

Figure 1. Mean (± SD) serum concentrations of CT-P16, EU-Avastin and US-Avastin versus time in study CT-P16 1.1 (PK population)

Linear Scale

<!-- image -->

Abbreviations: EU = European Union; SD = standard deviation; US = United States.

Overall, the primary PK parameters were similar among 3 treatment groups (see Table 4).

<div style=\"page-break-after: always\"></div>

Table 4. Summary of primary serum PK parameters for bevacizumab in study CT-P16 1.1 (PK population)

| PK Parameter (unit)   | Statistic        | CT-P16 N= 46                                                    | EU-approved Avastin N=47                                                           | US-licensed Avastin N= 48                      |
|-----------------------|------------------|-----------------------------------------------------------------|------------------------------------------------------------------------------------|------------------------------------------------|
| AUCo-inf (h·μg/mL)    | 1n1 Mean ± SD CV | 45 42034.90 ± 6070.668 14.44 41608.53 41281.82 30241.1, 54111.9 | 46 40413.44±5012.778 12.40 40095.88 40294.19 27362.5.50941.1 47 39411.98± 4649.319 | 46 43017.95 ± 5782.951 13.44 42621.36 42898.41 |
| AUCo-inf (h·μg/mL)    | GM               |                                                                 |                                                                                    |                                                |
| AUCo-inf (h·μg/mL)    | Median           |                                                                 |                                                                                    |                                                |
| AUCo-inf (h·μg/mL)    | Min, Max         |                                                                 |                                                                                    | 28786.0, 54525.9                               |
| AUCo-last (h·μg/mL)   | n                | 45                                                              |                                                                                    | 44                                             |
| AUCo-last (h·μg/mL)   | Mean ± SD        | 41142.81 ± 5694.184                                             |                                                                                    | 41804.05 ± 5463.814                            |
| AUCo-last (h·μg/mL)   | CV               | 13.84                                                           | 11.80                                                                              | 13.07                                          |
| AUCo-last (h·μg/mL)   | GM               | 40757.85                                                        | 39133.03                                                                           | 41440.57                                       |
| AUCo-last (h·μg/mL)   | Median           | 40795.51                                                        | 39445.89                                                                           | 41781.24                                       |
| AUCo-last (h·μg/mL)   | Min, Max         | 30123.7, 52541.9                                                | 27156.6, 49635.7                                                                   | 27938.7,53737.3                                |
| Cmax (μg/mL)          | 1n1              | 46                                                              | 47                                                                                 | 48                                             |
| Cmax (μg/mL)          | Mean ± SD        | 117.22 ± 17.756                                                 | 114.06 ± 15.391                                                                    | 113.09 ± 17.402                                |
| Cmax (μg/mL)          | CV               | 15.15                                                           | 13.49                                                                              | 15.39                                          |
| Cmax (μg/mL)          | GM               | 115.96                                                          | 113.05                                                                             | 111.77                                         |
| Cmax (μg/mL)          | Median           | 116.00                                                          | 111.00                                                                             | 112.00                                         |
| Cmax (μg/mL)          | Min, Max         | 83.6, 173.0                                                     | 83.2, 148.0                                                                        | 72.6, 155.0                                    |

Abbreviations: AUCo-inf = area under the concentration-time curve from time zero to infinity; AUCo-last = area under the concentration-time curve from time zero to the last quantifiable concentration; Cmax =maximum serum concentration; CV = coefficient of variation; EMA = European Medicines Agency; EU = European Union; GM = geometric mean; Λz = Terminal elimination rate constant; Max = maximum; Min = minimum; PK = pharmacokinetic; SD = standard deviation; US = United States.

The 90% CIs for the geometric mean ratios of AUC0-inf, AUC0-last and Cmax were entirely contained within the predefined bioequivalence margin of 80% to 125%, indicating bioequivalence between CT-P16 and EU-Avastin, CT-P16 and US-Avastin, and EU-Avastin and US-Avastin (see Table 5).

<div style=\"page-break-after: always\"></div>

## Table 5. Statistical analysis of serum PK parameters for bevacizumab (ANCOVA) study CT-P16 1.1 (PK population)

|                     | GeometricLSMeans   | GeometricLSMeans   | GeometricLSMeans         | GeometricLSMeans         | GeometricLSMeans         | GeometricLSMeans         |                            |                            |                            |                            |                                        |                                        |
|---------------------|--------------------|--------------------|--------------------------|--------------------------|--------------------------|--------------------------|----------------------------|----------------------------|----------------------------|----------------------------|----------------------------------------|----------------------------------------|
| PKParameter's       | CT-P16 N=46        | CT-P16 N=46        | EU-approved Avastin N=47 | EU-approved Avastin N=47 | US-licensed Avastin N=48 | US-licensed Avastin N=48 | CT-P16 /EU-approvedAvastin | CT-P16 /EU-approvedAvastin | CT-P16 /US-licensedAvastin | CT-P16 /US-licensedAvastin | EU-approvedAvastin /US-licensedAvastin | EU-approvedAvastin /US-licensedAvastin |
| (unit)              | n                  | Results            | n                        | Results                  |                          | Results                  | Ratio                      | I0 %06                     | Ratio                      | ID%06                      | Ratio                                  | I0%06                                  |
| AUCo-inf (h·μg/mL)  | 45                 | 41608.92           | 46                       | 40054.33                 | 46                       | 42593.20                 | 103.88                     | [99.04,108.96]             | 97.69                      | [93.14,102.46]             | 94.04                                  | [89.68, 98.61]                         |
| AUCo-last (h·μg/mL) | 45                 | 40746.44           | 47                       | 39058.63                 | 44                       | 41400.01                 | 104.32                     | [99.70,109.15]             | 98.42                      | [93.99,103.06]             | 94.34                                  | [90.14, 98.74]                         |
| Cmax (μg/mL)        | 46                 | 116.01             | 47                       | 112.65                   | 48                       | 111.53                   | 102.98                     | [98.22,107.97]             | 104.02                     | [99.24,109.03]             | 101.01                                 | [96.39,105.85]                         |

Abbreviations: ANCOVA = analysis of covariance; AUCo-inf = area under the concentration-time curve from time zero to infinity, AUCo-last = area under the concentration-time curve from time zero to the last quantifiable concentration; CI = confidence interval; Cmax = maximum serum concentration; EMA = European Medicines Agency; EU = European Union; z =Terminal elimination rate constant;LS=leastsquares;PK=pharmacokinetic;US=United States.

Note: Ratio of geometric means was calculated by backed transforming difference of LS means calculated using an ANCOVA model with treatment as a fixed effect and body weight (&lt;70kgversus≥70kg)assessed on Day-1 and study site as covariates.

Overall,  the  secondary  PK  endpoints  (Tmax,  Vz, λ z,  t½,  CL  and  %AUCext)  were  similar  among  the 3 treatment groups.

## Supportive PK study in Japanese subjects (study CT-P16 1.2)

This study was conducted at one centre Anaheim Clinical Trials, LLC USA between 31 st  Jul and 22 nd  Dec 2020. Bioanalytical analyses were performed at PPD ®  Bioanalytical Lab USA between 29 th  Oct 2020 and 28 th  Jan 2021.

This study was a phase I, a single-centre, randomised, double-blind, parallel group, prospective singledose study. Subjects received a single IV infusion (5 mg/kg; 90 minutes ±5 minutes) of CT-P16 or EU-Avastin according to the randomly assigned treatment groups on Day 1. Blood samples were collected for measurement of serum concentrations of bevacizumab from all subjects at the following time points: pre-dose, immediately end-of-infusion (EOI), 1 h after EOI, 4 h after start of infusion (SOI), 8 h after SOI and 12 h after SOI, days 2, 3, 4, 8, 15, 29, 43, 57, 71, 85 and 99.

## PK results

The PK population consisted of 45 subjects (n = 22 subjects in the CT-P16 group and n = 23 subjects in the EU-Avastin group).

The 90% CIs of ratios of geometric LS means of Cmax, AUC0-last, and AUC0-inf were entirely contained within the predefined equivalence margin of 80% to 125% which indicated that bevacizumab exposures from CT-P16 were similar to those from EU-Avastin (see Table 6).

<div style=\"page-break-after: always\"></div>

Table 6. Statistical analysis of primary PK parameters (ANCOVA) in study CT-P16 1.2 (PK population)

|                     |                    | Geometric LS Means(a)   | Geometric LS Means(a)   | Geometric LS Means(a)   | Geometric LS Means(a)   |                     |                  |
|---------------------|--------------------|-------------------------|-------------------------|-------------------------|-------------------------|---------------------|------------------|
|                     | PK Parameter       | Test (N=22)             | Test (N=22)             | Reference (N=23)        | Reference (N=23)        | %Ratio              |                  |
| Comparison          | (unit)             | n                       | Result                  | n                       | Result                  | (Test/Reference)(a) | 90% CI(a)        |
| CT-P16 (Test) vs    | AUCo-inf (h-μg/mL) | 22                      | 37120.07                | 23                      | 37810.47                | 98.17               | (90.74, 106.22)  |
| EU-approved         | AUCo-last (hμg/mL) | 22                      | 36404.72                | 23                      | 36820.05                | 98.87               | (91.65, 106.67)  |
| Avastin (Reference) | Cmas (μg/mL)       | 22                      | 112.03                  | 23                      | 100.86                  | 111.08              | (100.37, 122.93) |

Abbreviations: AUCo-inf, area under the concentration versus time curve from time zero extrapolated to infinity; AUCo-last, area under the concentration-time curve from time zero to the time of the last quantifiable concentration; CI, confidence interval; Cmax, maximum serum concentration; EU, European Union; LS, least squares; PK, pharmacokinetic.

An analysis of covariance was performed with the natural log-transformed PK parameters as the dependent variable, treatment as a fixed effect and body weight (&lt; 70 kg vs ≥70 kg) assessed on Day 1 as a covariate.

(a) The adjusted mean differences and 90% CIs for the differences were exponentiated to provide estimates of the ratio of adjusted geometric means (Test/Reference) and 90% CIs for the ratios.

A statistical outlier was identified using the IQR method and robust regression method, which resulted in the detection of an unusual Cmax value in one subject in the EU-Avastin group. Therefore, a sensitivity analysis was performed on the primary PK endpoints with data excluding the observed outlier. It should also be noted that the subject  had an unusual profile shape that resembled more like subcutaneous administration and not an IV administration which aligns with the outlier analysis results.

Statistical analysis excluding the Cmax outlier value of the subject was performed and the 90% CIs of the %ratio of geometric LS mean were within the equivalence interval (80% to 125%) supporting the same outcome as in previous Table 11; i.e., no notable differences in Cmax between CT-P16 and EU-Avastin.

## Comparative efficacy and safety study in nsNSCLC patients (study CT-P16 3.1)

The secondary objective of this study was to evaluate the PK of CT-P16 compared with EU-Avastin in terms of Ctrough. Patients received 15 mg/kg study drug dose every 3 weeks.

PK samples were collected on Day 1 of each cycle (prior to the beginning of the study drug administration [-3 days as window were allowed]) in the induction study period, on Day 1 (-3 days as window were allowed) of cycle 1, and every 3 cycles (end of Cycle 3, Cycle 6, and Cycle 9, etc.) in the maintenance study period and EOT visit. In patients whose dose was delayed from the planned schedule, serum samples were obtained on Day 22 of the last cycle (-3 days as window were allowed).

PK and immunogenicity testing site: PPD Bioanalytical Laboratory, US

## PK results

A total of 650 patients (327 patients and 323 patients in the CT-P16 and EU-Avastin treatment groups, respectively) were included in the PK population. Thirty-seven patients who did not have post-treatment PK results were excluded from PK population and 2 patients who received the incorrect treatment during the induction study period were excluded from the PK population.

The mean (standard deviation) Ctrough at each cycle in the induction period was generally similar for the CT-P16 and EU-Avastin treatment groups in the PK population (see Table 7).

<div style=\"page-break-after: always\"></div>

Table 7. Mean (SD) trough serum concentrations of bevacizumab (µg/L) in study CT-P16 3.1 (PK population)

| Visit             |       | CT-P16 (N=327)      | EU-approved Avastin (N=323)   | EU-approved Avastin (N=323)   |
|-------------------|-------|---------------------|-------------------------------|-------------------------------|
| Induction Cycle 1 | n=318 | 50426.3 (39847.34)  | n=316                         | 52515.7 (32356.13)            |
| Induction Cycle 2 | n=302 | 73127.7 (35883.59)  | n=287                         | 81533.7 (52567.34)            |
| Induction Cycle 3 | n=283 | 93100.6 (50495.29)  | n=269                         | 95878.8 (53977.69)            |
| Induction Cycle 4 | n=268 | 96445.2 (45597.95)  | n=254                         | 101583.1 (46275.62)           |
| Induction Cycle 5 | n=252 | 108957.3 (55135.16) | n=238                         | 108512.5 (49823.61)           |
| Induction Cycle 6 | n=246 | 116188.2 (58735.47) | n=228                         | 114849.6 (56309.70)           |

Abbreviation: PK, pharmacokinetic.

## 2.4.2.2. Pharmacodynamics

## Mechanism of action

Bevacizumab binds and neutralises the biologic activity of human Vascular Endothelial Growth Factor (VEGF). The mechanism of action (MoA) for Avastin and CT-P16 across indications is binding to soluble VEGF and preventing the interaction of VEGF to its receptors, Flt-1 (VEGFR-1) and KDR (VEGFR-2), on the surface of endothelial cells. Neutralising the biological activity of VEGF results in the regression of tumour vascularisation, normalisation of remaining tumour vasculature, and inhibition of the formation of new tumour vasculature, thereby inhibiting tumour growth. In each approved indication, the MoA of bevacizumab  is  to  inhibit  VEGF-induced  angiogenesis  and  vascular  permeability.  According  to  the applicant, based on an extensive analysis of the role of VEGF and VEGF inhibition in each one of the indications for which licensure is sought, there is no evidence to support claims of a unique MoA in specific indications.

## Primary and Secondary pharmacology

Primary  pharmacology  was  not  separately  addressed  in  the  clinical  studies.  In  terms  of  secondary pharmacology, the clinical studies conducted as part of the CT-P16 development programme included standard safety assessments such as safety laboratories and ECG recordings. These are discussed within section 2.4.8 on clinical safety.

## 2.4.3. Discussion on clinical pharmacology

Three clinical studies were performed in which the PK of CT-P16 was compared to that of EU-Avastin and in one study (pivotal clinical PK study CT-P16 1.1) also US-Avastin was used as a comparator product. In the clinical phase I studies (i.e. CT-P16 1.1 in healthy Asian male subjects and CT-P16 1.2 in healthy Japanese male subjects), bevacizumab was administered as a single-dose of 5 mg/kg by an IV infusion. In the clinical phase III study (i.e. CT-P16 3.1) in nsNSCLC patients, bevacizumab was administered as 15 mg/kg every 3 weeks.

## Analytical methods

In general, the bioanalytical methods used in the clinical studies for CT-P16 have been appropriately described and validated according to the relevant guidelines.

<div style=\"page-break-after: always\"></div>

## Quantification of CT-P16 and bevacizumab concentration in human serum

Two analytical methods including ELISA (used in clinical study CT-P16 1.1) and MSD-ECL (used in clinical studies CT-P16 1.2 and CT-P16 3.1) were validated according to ICH M10 Bioanalytical method validation guideline. In both methods CT-P16, EU-Avastin and US-Avastin seemed to perform analytical similarity in terms of selectivity, precision and accuracy.

MSD-ECL based method was used in the analysis of healthy and nsNSCLC patient human serum samples. The usage of same analytical method for healthy and nsNSCLC samples was acceptable since the method demonstrated selectivity for both healthy and nsNSCLC serum. The analysis of clinical samples was reliable within the given accuracy and precision ranges.

## Determination of ADA by MSD-ECL

Two ECL based methods were used for the detection of ADAs in the healthy and nsNSCLC serum samples by utilizing three-tiered approach. The first ADA-assay validated by PPD Laboratory was utilised in the analysis of serum samples from clinical studies CT-P16 1.2 and 3.1. Screening, confirmatory and tier cut points were determined both in healthy and NSCLC serum in acceptable manner. The intra- and interassay precisions for screening and confirmation met the acceptance criteria. No matrix interference in healthy  nor  nsNSCLC  serum  was  observed  and  drug  tolerance  was  acceptable.  According  to  drug equivalence studies the originator drug (EU-Avastin) was comparable to CT-P16.

The second ADA-assay was used in the analysis of serum samples from clinical study CT-P16 1.1 and was validated by BDS. The method validation was acceptable and no further concerns are pursued for this method.

## Determination of NAb by using MSD-ECL

Two ECL based methods were used for the detection of NAbs in the healthy and nsNSCLC serum samples. The first NAb-assay validated by PPD Laboratory was utilised in the analysis of serum samples from clinical studies CT-P16 3.1. In general, an appropriate method validation following the current guidance was provided. Screening cut points and sensitivity were evaluated both in healthy and nsNSCLC serum.

The second NAb-assay was used in the analysis of serum samples from clinical study CT-P16 1.1 and was  validated  by  BDS.  The  method  validation  followed  the  current  guidance  and  was  considered acceptable.

## Pivotal clinical PK study in healthy Asian male subjects (CT-P16 1.1.)

The primary endpoints AUC0-inf and AUC0-last were based on PK samples collected up to day 99. The PK sampling period was long enough to characterise the whole PK profile of bevacizumab. All subjects' AUC0-last covered over 80% of AUC0-inf.

All 90% CIs for test-to-reference/comparator of the primary PK parameters (i.e. AUC0-inf, AUC0-last and Cmax)  were  within  the  pre-specified  acceptance  range  of  80.00  to  125.00  (including  100.00) demonstrating that the PK of the CT-P16 is comparable with the EU-Avastin and US-Avastin. In the comparison of the AUCs between EU-Avastin and US-Avastin, the 90% CIs were between the range 80.00-125.00 but the range did not include 100.00. This is, however, not a concern. The secondary PK parameters (i.e. Tmax , Vz, λz, t ½, CL, %AUCext) were also comparable between studied treatments.

4 subjects (1 subject in the CT-P16 and EU-Avastin group and 2 subjects in the US-Avastin group) were excluded from the PK analysis of AUC0-inf . The reason was that the interval used to determine λz was less than 1.5 -fold the estimated half-life. 5 subjects (1 subject in the CT-P16 group and 4 subjects in the US-Avastin group were excluded from the PK analysis of AUC0-last.  The reason was that the subjects withdrew before the last planned PK sampling time (i.e. day 99), after received full IMP. These exclusion criteria from the PK statistical analyses were already presented in the SAP. The applicant has conducted

<div style=\"page-break-after: always\"></div>

sensitivity  analysis  of the  affected  AUCs  including  the  excluded  subjects.  The  90%  CIs of  geometric LS mean ratios were entirely contained within the predefined equivalence margin of 80.00 to 125.00 (also  for  AUCs  between  EU-Avastin  and  US-Avastin).  The  bevacizumab  has  a  linear  PK,  so  the PK biosimilarity demonstrated in Asians can be extrapolated to the non-Asians.

There were three subjects in the CT-P16 group, one subject in the EU-Avastin group and five subjects in the US-Avastin group, who had pre-dose bevacizumab concentrations above BLQ. Although the pre-dose concentrations  of  bevacizumab  were  low,  the  applicant  was  requested  to  discuss  reasons  for  the bevacizumab in pre-dose samples. In the response to D120 questions, the applicant provided a very detailed discussion on the topic. The applicant has an opinion that the probable reason for the 9 predose bevacizumab concentrations could be low levels of non-specific binding in the wells of the assay plate or due to an unknown active interferent present in the serum of the subjects. The applicant also conducted a sensitivity analysis of primary PK parameters (i.e. Cmax, AUC0-last, and AUC0-inf), excluding the subjects with pre-treatment measurable concentrations of bevacizumab, and the PK biosimilarity conclusions remained unchanged.

The applicant was asked to provide the certificates of analysis for the EU-Avastin batch B7234H13 and for  the  US-Avastin  batch  3115919.  In  the  response  to  D180  questions,  the  applicant  provided  the certificates of analysis for both reference products used in the study CT-P16 1.1. The protein contents were within specification limits, and highly similar between test and reference products (test CT-P16: 25.3 mg/mL, reference EU-Avastin: 25.3 mg/mL, reference US-Avastin: 25.4 mg/mL).

## Supportive clinical PK study in healthy Japanese male subjects (CT-P16 1.2)

All 90% CIs for the test-to-reference ratios of the AUCs were within the pre-specified acceptance range of 80.00 to 125.00 (including 100.00) demonstrating the PK similarity between CT-P16 and EU-Avastin. In the original ANCOVA analysis, the 90% CI for the test-to reference ratio of Cmax was within the range of 80.00 to 125.00; however, not including 100.00. A sensitivity analysis for the Cmax parameter which excludes one subject who had Cmax much lower and Tmax much later than other subjects, resulted in a 90% CI included 100.00. Based on the serum bevacizumab concentration (µg/ml) vs time (h) profile of this  excluded subject, it can be agreed with the applicant that the subject had received most likely subcutaneous infusion instead of IV infusion.

The mean secondary PK parameters (t1/2 , λz, CL, Vz, and %AUCext) were comparable between the two treatment groups. The inter-subject variability was low in all PK parameters also in this study.

It  was  reported  that  the studied  population was healthy first- or second -generation Japanese male subjects.  However,  in  the  inclusion  criteria,  there  is  no  item  that  subjects  must  be  Japanese. Furthermore, in the demographic data, it was reported that all subjects were Asian male and not Hispanic or  Latino.  There  are  51  different  Asian  countries  (in  addition  to  Japan  e.g.  China,  Indonesia,  India, Thailand). Consequently, it is not clear if all subjects were Japanese. This study is a supportive PK study, and for EU registration purposes it is not a concern, if there have been also subjects with ethnicity other than Japanese.

The applicant was asked to provide the certificate of analysis for the EU-Avastin batch N7397H12 used in the study CT-P16 1.2. The applicant provided the requested data in the response to D180 questions. The protein content of EU-Avastin was within specification limits, and highly similar between test and reference products (test CT-P16: 25.0 mg/mL, reference EU-Avastin: 24.7 mg/mL).

## Comparative efficacy and safety study in nsNSCLC patients (CT-P16 3.1)

In the phase III clinical study, the observed Ctrough concentrations were comparable between CT-P16 group and EU-Avastin group from baseline through induction cycle 6.

<div style=\"page-break-after: always\"></div>

All clinical studies support the biosimilarity in clinical PK between CT-P16 and EU-Avastin.

No clinical studies in special populations and no in vitro or in vivo drug-drug interaction studies were conducted with the CT-P16 and this is acceptable.

In the proposed CT-P16 SmPC the Section '5.2 Pharmacokinetic properties' is similar as in the Avastin SmPC, which is acceptable.

## 2.4.4. Conclusions on clinical pharmacology

The primary PK endpoints were within predefined limits, and CT-P16 can be considered biosimilar to EU-Avastin based on the presented PK data.

CT-P16 has been developed as a biosimilar to Avastin (bevacizumab), and their similarity has been demonstrated  through  a  series  of  physicochemical  and  biological  assays.  No  separate  clinical pharmacodynamic  or  PK/PD  studies  have  been  undertaken,  which  is  considered  acceptable  for  a biosimilar development programme.

## 2.4.5. Clinical efficacy

## 2.4.5.1. Dose response study

Not applicable for biosimilars.

## 2.4.5.2. Main study

Study CT-P16 3.1: A Double-Blind, Randomized, Active-Controlled, Parallel-Group, Phase 3 Study  to  Compare  Efficacy  and  Safety  of  CT-P16  and  EU-Approved  Avastin  as  First-Line Treatment for Metastatic or Recurrent Non-Squamous Non-Small Cell Lung Cancer

## Methods

Study CT-P16 3.1 is an ongoing double-blind, randomised, active-controlled, parallel-group, Phase 3 study to compare the efficacy, PK, and overall safety of CT-P16 (15 mg/kg) and EU-Avastin (15 mg/kg) when co-administered with paclitaxel and carboplatin as first-line treatment in patients with metastatic or recurrent non-squamous non-small cell lung cancer (nsNSCLC). Patients were randomly assigned in a 1:1 ratio to CT-P16 or EU-Avastin, and the patients were stratified by country, sex (female vs. male), disease status (recurrence vs. metastatic),  and  Eastern  Cooperative  Oncology  Group  (ECOG) performance score (0 vs. 1).

The  study  comprises  four  periods.  On  completion  of  the  Screening  Period,  eligible  patients  were randomised to receive intravenous CT-P16 or EU-Avastin every 3 weeks up to 6 cycles. All patients concomitantly received intravenous paclitaxel and carboplatin every 3 weeks up to 6 cycles (at least 4 cycles).  If  a  patient  had  progressive  disease  (PD)  during  or  after  the  completion  of  the  Induction Study Period (assessed at the end of Cycle 6) or did not enter the Maintenance Study Period due to any reason, the patient was to complete the end-of-treatment (EOT) visit, then directly enter the Follow-Up Period.

After  the  completion  of  6  cycles  during  the  Induction  Study  Period,  patients  with  controlled  disease (complete response [CR], partial response [PR], or stable disease [SD], assessed at the end of Cycle 6) entered  the  Maintenance  Study  Period,  during  which  patients  receive  CT-P16  or  EU-Avastin  as monotherapy every 3  weeks until  PD  or  intolerable  toxicity,  whichever  occurs  first,  after  which  the

<div style=\"page-break-after: always\"></div>

patients perform the EOT visit and then enter the Follow-Up Period. An EOT visit occurs 3 weeks after the last dose of the Induction Study Period or Maintenance Study Period regardless of the reason of discontinuation.

All patients who enter the Follow-Up Period due to any reason are followed every 9 weeks until death or the end of study, whichever occurs first. If PD was not confirmed during the Induction Study Period or Maintenance Study Period, tumour response evaluation is performed every 9 weeks during the FollowUp Period. The Follow-Up Period is expected to last for up to approximately 3 years from the enrolment of the last patient.

The general design of the study is outlined in Figure 2 below.

Figure 2. Study design for Study CT-P16 3.1

<!-- image -->

- CT-P16or EU-Approved Avastin:15 mg/kgevery 3weeksIV
- Paclitaxel: 200 mg/m²every 3 weeks IV
- Carboplatin: Area under the curve 6 every 3 weeks IV
- Induction StudyPeriod: maximum 6 cycles
- Maintenance Study Period: until disease progression, or intolerable toxicity, whichever occurs first
- Follow-Up Period: up to approximately 3 years from the last patient enrolled
- Randomization will be stratified by country, sex (female vs. male), disease status (recurrence vs. metastatic), and ECOG performance score (0 vs. 1).

Abbreviations: ECOG, Eastern Cooperative Oncology Group; IV, intravenous; PD, progressive disease.

As indicated above, the study is currently ongoing. In the Response to the D120 List of Questions, the applicant provided data from a data lock corresponding to the time when the last enrolled patient had been followed up for 1 year.

## · Study Participants

Study CT-P16 3.1 is conducted in patients with stage IV or recurrent nsNSCLC. The main eligibility criteria were as follows:

## Inclusion criteria

1. Patient (male or female) was ≥ 18 years of age.
2. Patient  had  confirmed  predominantly  nsNSCLC  by  haematoxylin  and  eosin  staining  or immunohistochemistry.
3. Patient  had  recurrent  disease  or  Stage  IV  diagnosis  according  to  the  American  Joint Committee on Cancer 8 th  edition on Lung Cancer Staging. Stage IV was defined as follows:
- a. Separate tumour nodule(s) in a contralateral lobe, or

<div style=\"page-break-after: always\"></div>

- b. Tumour with pleural or pericardial nodules, or
- c. Malignant pleural or pericardial effusion related to tumour, or
- d. Single or multiple extrathoracic metastases in a single organ or in multiple organs.
4. Patient had at least 1 measurable lesion by RECIST version 1.1. Target lesions situated in a previously irradiated area were considered measurable if recurrence had been demonstrated in such lesions.
- a. Tumour lesions: ≥ 10 mm in long axis by CT scan, or
- b. Malignant lymph nodes: ≥ 15 mm in short axis by CT scan
5. Patient had an ECOG performance status of 0 or 1.
6. Patient had a life expectancy &gt; 6 months based on clinical judgement.
7. Patient had negative result in both epidermal growth factor receptor (EGFR) mutation and anaplastic  lymphoma  kinase  (ALK)  rearrangement  confirmed  by  biopsy  or  cytology specimens.
8. Patient had adequate organ function as determined from relevant haematology and clinical chemistry laboratory assessments.
9. Patient  and/or  their  legally  authorised  representative  had  been  informed  and  was  given ample time and opportunity to read and/or understand the nature and purpose of this study and had signed the ICF before any study-specific procedures.

## Exclusion criteria

1. Patient  had  predominantly  squamous  cell  histology  NSCLC.  If  small  cell  elements  were present, the patient was ineligible.
2. Patient had clinically significant third-space fluid; for example, ascites or pleural effusions that could not be controlled by drainage or other procedures prior to Day 1 of Cycle 1.
3. Patient had untreated CNS metastases or CNS metastasis with bleeding risk at investigator's discretion and/or leptomeningeal disease. However, treated and clinically stable (asymptomatic; off steroids) brain metastases were allowed.
4. Patient had invasion of major blood vessels. Patient with a tumour cavitation, in the opinion of the investigator, who was likely to bleed was excluded as well.
5. Patient  had  received  previous  anticancer  systemic  therapy  including  one  or  more  of  the following:
- a. Cytotoxic chemotherapy for metastatic nsNSCLC
- b. Cytotoxic chemotherapy for non-metastatic nsNSCLC within 12 months prior to Day 1 of Cycle 1
- c. Antineoplastic biological therapy, immunotherapy, or targeted therapy
- d. Bevacizumab (or a bevacizumab-proposed biosimilar product).
6. Patient had received previous surgical procedure including one or more of the following:
- a. Surgery for metastatic nsNSCLC
- b. Surgery for non-metastatic nsNSCLC within 6 months prior to Day 1 of Cycle 1

<div style=\"page-break-after: always\"></div>

- c. Open biopsy or open pleurodesis within 28 days prior to Day 1 of Cycle 1
- d. Core biopsy or other minor surgical procedure (eg, placement of vascular access device, closed pleurodesis, thoracentesis, and mediastinoscopy) within 14 days prior to Day 1 of Cycle 1.
7. Patient had received previous anticancer radiotherapy including one or more of the following:
- a. Radiotherapy for metastatic nsNSCLC (but radiotherapy as part of the palliative therapy and/or treatment for CNS metastases completed at least 14 days prior to Day 1 of Cycle 1 was allowed)
- b. Radiotherapy for non-metastatic nsNSCLC within 6 months prior to Day 1 of Cycle 1
- c. Any toxicity related with radiotherapy prior to Day 1 of Cycle 1.
8. Patient had a medical history of other significant concurrent disease, with a comprehensive list of representative examples provided in the protocol.

Study CT-P16 3.1 is a global multi-centre trial conducted in a total of 164 study centres in 21 countries (Belarus, Brazil, Bulgaria, Chile, Croatia, Georgia, Hungary, India, Japan, Malaysia, Mexico, Peru, Poland, Portugal, Republic of Korea, Romania, Russian Federation, Serbia, Thailand, Ukraine, Vietnam).

## · Treatments

During the Induction Study Period, patients received 15 mg/kg IV of either CT-P16 or EU-Avastin every 3 weeks up to 6 cycles. Patients received paclitaxel 200 mg/m 2  IV and carboplatin AUC 6.0 IV every 3 weeks up to 6 cycles (at least 4 cycles). After the Induction Study Period, either CT-P16 or EU-Avastin as a monotherapy (15 mg/kg IV) was maintained every 3 weeks until either PD or intolerable toxicity occurrence, whichever occurred first.

Study treatments (CT-P16 or EU-Avastin, carboplatin, and paclitaxel) were administered on the same day. If one of them had to be delayed, study treatment had to be delayed. If one of them had to be permanently discontinued, study treatment had to be discontinued. Uncoupling of study treatment was not allowed until at least 4 cycles of the Induction Study Period had been completed; thus, paclitaxel and/or carboplatin could be discontinued at Cycle 5 or 6 of the Induction Study Period.

Treatment during the Induction Study Period and Maintenance Study Period could be delayed for up to 3 weeks from the planned schedule if warranted by adverse events or laboratory findings (haematological or non-haematological toxicity); specific instructions were provided in the study protocol. If treatment was  delayed  more  than  3  weeks,  the  patient  had  to  be  discontinued.  Dose  modifications  were  not permitted for bevacizumab but were allowed for paclitaxel and carboplatin.

During the Induction Study Period, study treatment was administered in the following order:

- Hydration (according to local practice)
- Dexamethasone 20 mg

Oral, approximately 12 and 6 hours prior to administration of paclitaxel or IV infusion, 30 to 60 minutes prior to administration of paclitaxel

- Diphenhydramine (or its equivalent) 50 mg

IV infusion 30 to 60 minutes prior to administration of paclitaxel

- Cimetidine 300 mg or ranitidine 50 mg

<div style=\"page-break-after: always\"></div>

IV infusion 30 to 60 minutes prior to administration of paclitaxel

- Paclitaxel 200 mg/m 2

IV infusion over approximately 3 hours

- Carboplatin AUC 6.0

IV infusion over approximately 30 minutes after administration of paclitaxel

- CT-P16 or EU-Avastin 15 mg/kg

IV infusion over 30 to 90 minutes after administration of carboplatin

An antiemetic could be used based on local practice, and the dose of dexamethasone, diphenhydramine, and cimetidine could be adjusted at the investigator's discretion.

CT-P16 or EU-Avastin was diluted in a total volume of 100 mL of 0.9% sodium chloride and administered by IV infusion with an infusion pump. The dose was delivered over 90 minutes (±15 minutes) at the Cycle 1 of the Induction Study Period. If the infusion was well tolerated, the infusion of Cycle 2 of the Induction Study Period could be administered over 60 minutes (±10 minutes). If the 60-minute infusion was well tolerated, all subsequent infusions could be administered over 30 minutes (±10 minutes). The study drug was required to be handled by delegated unblinded staff.

## · Objectives

The primary objective of study CT-P16 3.1 was to demonstrate that CT-P16 was similar to EU-Avastin in terms of efficacy as determined by objective response rate (ORR) during the Induction Study Period.

The secondary objectives of the study are:

- To evaluate additional efficacy profiles including ORR during the Whole Study Period, response duration, time to progression (TTP), progression-free survival (PFS), and overall survival (OS)
- To evaluate the PK of trough serum concentration (Ctrough)
- To evaluate safety profile including immunogenicity
- To evaluate quality of life (QoL)

## · Outcomes/endpoints

The  primary  efficacy  endpoint  was  the  ORR  based  on  the  best  overall  response  (BOR)  during  the Induction  Study  Period  by  Response  Evaluation  Criteria  in  Solid  Tumors  (RECIST)  version  1.1. Categorisation of overall response at each visit was based on the following response categories: complete response (CR), partial response (PR), stable disease (SD), progressive disease (PD), and inevaluable (NE). ORR was defined as the proportion of patients with a confirmed BOR of CR or PR (the 'responder'). All  other  patients  in  the  ITT  or  PP  population  except  responders  were  considered  non-responders, including patients without post-baseline tumour assessment. For CR or PR, BOR was confirmed by the subsequent assessment based on RECIST v.1.1. For a BOR of SD, measurements had to meet its criteria at least once after start of study treatment for a minimum interval of 6 weeks (42 days) considering +/- 6 days, which is equivalent to a minimum time of 36 days.

The secondary efficacy endpoints were:

- ORR based on BOR during the Whole Study Period by RECIST version 1.1

<div style=\"page-break-after: always\"></div>

- Response  duration:  the  time  between  initial  response  (complete  response  [CR]  or  partial response [PR]) and PD/recurrence or death from any cause, whichever occurred first
- TTP: the time from randomisation to determined PD/recurrence
- PFS:  the  time  from  randomisation  to  determined  PD/recurrence  or  death  from  any  cause, whichever occurred first
- OS: the time from randomisation to death from any cause

An independent tumour review committee (ITRC) was used to review the images for tumour responses. In addition to the ITRC, images were separately reviewed by local investigators. Local results were used for eligibility and treatment practice purposes. Central and local image review results were analysed and listed separately.

Quality of life was assessed with the Questionnaire Core 30 (QLQ-C30) and Quality of Life Questionnaire Lung Cancer-specific module (QLQ-LC13), using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ).

## · Sample size

A sample size of 305 patients per group was planned to provide 80% power to show similarity in efficacy between  CT-P16  and  EU-Avastin  based  on  the  expected  ORR  of  38%  with  an  equivalence  margin of -12.5 to 12.5 using a 95% CI (two one-sided alpha 0.025) of the difference in ORR. Approximately 678 patients (339 in each group) were planned to be enrolled for the anticipated drop-out rate of 10%.

## · Randomisation and Blinding (masking)

An interactive web response system (IWRS) was used for the randomisation. An unblinded statistician generated  a  computer-generated  randomisation  schedule  for  IWRS,  which  linked  sequential  patient randomisation numbers to treatment codes.

Patients who qualified for randomisation were randomly assigned on Day 1 of Cycle 1 of the Induction Study Period in a 1:1 ratio to receive CT-P16 or EU-Avastin. The randomisation was balanced by using permuted blocks and was stratified by country, sex (female vs. male), disease status (recurrence vs. metastatic), and ECOG performance score (0 vs. 1).

The study was double-blinded during the study period.

The blind should be broken for the individual patients only if specific emergency treatment would be dictated  by  knowing the  study  drug  status of  the  patient.  The investigator  could,  in  an  emergency, determine the identity of the study drug by using the applicable procedure in the IWRS.

The  randomisation  codes  of  10  patients  were  unblinded  to  patients,  investigators,  and  study  site personnel before data cut-off date as per the investigator's request for the administration of second line treatment at the investigator's discretion; there was no specific emergency related to patient safety. The identification of the study drugs for the patients was revealed by the investigator's decision using the applicable procedure in the IWRS and the date, time, and reason for the unblinding were documented in the appropriate field of the eCRF and source documents.

As planned in the protocol, the overall randomisation code was broken on 16 July 2021 for reporting purpose after database lock (15 July 2021) to generate the first CSR, dated 13 September 2021. The unblinded analyses were performed as per statistical analysis plan (SAP) version 1.0 (finalised on 14 July 2021). The unblinded personnel was pre-defined before breaking the study blind. The database was

<div style=\"page-break-after: always\"></div>

locked on 03 December 2021 to generate the second CSR and the unblinded analyses were performed as per SAP version 2.0 (finalised on 02 December 2021). The study has been blinded and will be blinded to  the investigators, patients, and pre-defined CELLTRION, Inc. and PPD blinded personnel until the completion of the study and the database sets finalised for study termination.

The randomisation codes for all the other patients, investigators, or study site personnel will not be revealed until all final clinical data are entered into the database and the database is locked and released for analysis.

## · Statistical methods

## Analysis Populations

The MAA submission contained the CSR that was the first of three planned reports for this study, and included efficacy data obtained up to end of Maintenance Cycle 3 date prior to cut-off date (22 April 2021) for the confirmation of BOR during the Induction Period. Also, PK and QoL data up to end of Induction Cycle 6 were included. In the Response to the D120 List of Questions, the applicant provided the second CSR; the cut-off date of 21 September 2021 for this CSR corresponds to the time when the last enrolled patient had completed 1 year of follow-up. The second CSR also contained analyses for time-dependent secondary endpoints.

All analyses were conducted using SAS® software Version 9.4 or higher.

The primary population for the efficacy analysis was ITT population consisting of patients who were successfully screened and randomly assigned to study drug (regardless of whether any study treatment dosing was completed).

A supportive efficacy analysis was performed using the PP population consisting of randomly assigned patients who had at least 1 response evaluation after receiving at least 1 full dose of study drug (CT-P16 or EU-Avastin) in the Induction Study Period and who did not have any major protocol deviations that could have affected the interpretation of the primary endpoint including being treated with opposite treatment  to  which  the  patients  was  assigned,  non-compliance  of  inclusion  or  exclusion  criteria, significant GCP non-compliance, prohibited therapies or missing primary efficacy assessment.

Additionally, the primary analysis was performed excluding patients with major protocol deviation related to COVID-19 in ITT population as supportive analysis and the patients were flagged in listings.

Final determinations of the PP population were made at the data review meeting before unblinding. In both analysis populations patients were analysed as per the randomised treatment.

The primary endpoint was objective response rate (ORR) based on the best overall response (BOR) during the Induction Study Period. For CR or PR, BOR had to be confirmed by the subsequent assessment. BOR was categorised as CR, PR, SD, PD, or NE. The ORR was defined as the proportion of patients with a confirmed BOR of CR or PR (the 'responder'). All other patients in the ITT or PP population except responders  were  considered  as  non-responders,  including  patients  without  post-baseline  tumour assessment. Central assessment of tumour response was considered primary, while local assessment was used as a sensitivity analysis.

The similarity criterion had been set such that the confidence limits of the 95% confidence interval (CI) of the difference of ORR from each treatment group was entirely within the interval (-12.5, 12.5).

The primary analysis (ORR based on central review) was performed with a logistic regression model considering region (Europe, Middle East, and Africa [EMEA] vs. America vs. Asia), sex (female vs. male), disease status at baseline (recurrence vs. metastatic), and ECOG performance status at baseline (0 vs.

<div style=\"page-break-after: always\"></div>

1) as covariates with treatment groups (CT-P16 and EU-Avastin) as a fixed effect. In calculation for the ORR in each treatment group, the applicant assigned weights for the fixed model effects (corresponding to the levels of stratification factors) proportionally based on the distribution of stratification factor levels in the population studied.

Tipping point analysis was conducted using central review data based on exact binomial approach in the ITT population to evaluate the sensitivity of conclusion to the missing data (no response evaluation or evaluated as 'NE') assumptions. Tipping point analyses were conducted under Missing Not at Random (MNAR) scenarios. Imputation was done by gradually shifting the number of responders by treatment group to make MNAR scenarios. In response D120 LoQ, also an analysis of ORR corresponding to MAR assumption  was  provided  to  give  a  base  case  to  the  aforementioned  tipping  point  analysis.  In  this analysis,  missing  responses  that  were  considered  uninformative  were  multiple  imputed  based  on patients' stratification factors.

## Results

## · Participant flow

A total of 1.530 patients were screened for the study. Of these, 841 patients were screen failed; the most frequently reported primary reason for screening failure was inclusion/exclusion criteria not met (773 patients).

A total of 689 patients were randomly assigned to study drug and initiated the Induction Study Period (342 patients in the CT-P16 treatment group and 347 patients in the EU-Avastin treatment group). Of these,  499  (72.4%)  patients  completed  the  Induction  Study  Period  (258  [75.4%]  in  the  CT-P16 treatment group and 241 [69.5%] in the EU-Avastin treatment group). The most frequently reported reason for study treatment discontinuation in the Induction Study Period was PD (21 [6.1%] patients and  32  [9.2%]  patients  in  the  CT-P16  and  EU-Avastin  treatment  groups,  respectively).  Among  the patients who had completed the Induction Study Period, a total of 33 (4.8%) patients did not enter to Maintenance Study Period (19 [5.6%] patients in the CT-P16 treatment group and 14 [4.0%] patients in the EU-Avastin treatment group, respectively) and the most frequently reported reason for the study treatment  discontinuation  was  PD  (14  [4.1%]  patients  and  14  [4.0%]  patients  in  the  CT-P16  and EU-Avastin treatment groups, respectively).

A total of 466 (67.6%) patients initiated the Maintenance Study Period (239 [69.9%] patients in the CT-P16  treatment  group  and  227  [65.4%]  patients  in  the  EU-Avastin  treatment  group).  Based  on updated data received with the D120 responses, 392 (56.9%) patients discontinued the Maintenance Study Period (206 [60.2%] patients in CT-P16 treatment group and 186 [53.6%] patients in EU-Avastin treatment  group).  The  most  frequently  reported  reason  for  study  treatment  discontinuation  in  the Maintenance Study Period was PD (154 [45.0%] patients and 127 [36.6%] patients in the CT-P16 and EU-Avastin treatment groups, respectively).

Overall patient disposition is summarised in Figure 3 below and Table 8.

<div style=\"page-break-after: always\"></div>

Figure 3. Patient disposition in study CT-P16 3.1 (data lock 21 Sep 2021)

<!-- image -->

<div style=\"page-break-after: always\"></div>

Table 8. Patient disposition in study CT-P16 3.1 (data lock 21 Sep 2021)

|                                                                        | CI-P16 (N=342)         | EU-approved Avastin (N=347)   | Total (N=689)          |
|------------------------------------------------------------------------|------------------------|-------------------------------|------------------------|
|                                                                        | Number (%) of patients | Number (%) of patients        | Number (%) of patients |
| Total number ofpatients                                                |                        |                               |                        |
| Screened                                                               |                        |                               | 1,530                  |
| Screening failure                                                      |                        |                               | 841                    |
| Primary reason for screening failure                                   |                        |                               |                        |
| Inclusion/exclusion criteria not met                                   |                        |                               | 773                    |
| Patient withdrew consent                                               |                        |                               | 53                     |
| Other                                                                  |                        |                               | 15                     |
| Randomized                                                             | 342                    | 347                           | 689                    |
| Initiated Induction Study Period                                       | 342 (100.0)            | 347 (100.0)                   | 689 (100.0)            |
| Completed Induction Study Period                                       | 258 (75.4)             | 241 (69.5)                    | 499 (72.4)             |
| Discontinued Induction Study Period                                    | 84 (24.6)              | 106 (30.5)                    | 190 (27.6)             |
| Reason for study treatment discontinuation in Induction Study Period   |                        |                               |                        |
| Adverse event                                                          | 20 (5.8)               | 21 (6.1)                      | 41 (6.0)               |
| Death                                                                  | 20 (5.8)               | 23 (6.6)                      | 43 (6.2)               |
| Lost to Follow-up                                                      | 3 (0.9)                | 3 (0.9)                       | 6 (0.9)                |
| Physician decision                                                     | 3 (0.9)                | 6 (1.7)                       | 9 (1.3)                |
| Progressive disease                                                    | 21 (6.1)               | 32 (9.2)                      | 53 (7.7)               |
| Protocol violation                                                     | 2 (0.6)                | 1 (0.3)                       | 3 (0.4)                |
| Withdrawal by patient                                                  | 15 (4.4)               | 20 (5.8)                      | 35 (5.1)               |
| Initiated Maintenance Study Period                                     | 239 (69.9)             | 227 (65.4)                    | 466 (67.6)             |
| Discontinued Maintenance Study Period                                  | 206 (60.2)             | 186 (53.6)                    | 392 (56.9)             |
| Reason for study treatment discontinuation in Maintenance Study Period |                        |                               |                        |
| Adverse event                                                          | 16 (4.7)               | 12 (3.5)                      | 28 (4.1)               |
| Death                                                                  | 13 (3.8)               | 14 (4.0)                      | 27 (3.9)               |
| Lost to Follow-up                                                      | 2 (0.6)                | 0                             | 2 (0.3)                |
| Physician decision                                                     | 11 (3.2)               | 15 (4.3)                      | 26 (3.8)               |
| Progressive disease                                                    | 154 (45.0)             | 127 (36.6)                    | 281 (40.8)             |
| Protocol violation                                                     | 1 (0.3)                | 2 (0.6)                       | 3 (0.4)                |

<div style=\"page-break-after: always\"></div>

|                                              | CT-P16 (N=342)          | EU-approved Avastin (N=347)   | Total (N=689)           |
|----------------------------------------------|-------------------------|-------------------------------|-------------------------|
|                                              | Number (%o) of patients | Number (%o) of patients       | Number (%o) of patients |
| Withdrawal by patient                        | 6 (1.8)                 | 14 (4.0)                      | 20 (2.9)                |
| Others                                       | 3 (0.9)                 | 2 (0.6)                       | 5 (0.7)                 |
| Initiated Follow-Up Period                   | 161 (47.1)              | 158 (45.5)                    | 319 (46.3)              |
| Reason for ending participation in the study |                         |                               |                         |
| Death                                        | 164 (48.0)              | 168 (48.4)                    | 332 (48.2)              |
| Lost to Follow-up                            | 19 (5.6)                | 11 (3.2)                      | 30 (4.4)                |
| Withdrawal by patient                        | 44 (12.9)               | 45 (13.0)                     | 89 (12.9)               |
| Other                                        | 2 (0.6)                 | 2 (0.6)                       | 4 (0.6)                 |

As seen in Table 8, the reason for ending participation in the study was death in a total of 332 patients. Among these patients, the  reported  reason  for  death  was  disease  progression  in  220 patients  (110 patients in the CT-P16 group and 110 patients in the EU-Avastin group), adverse event in 37 patients (17 patients in  the  CT-P16  group  and  20  patients  in  the  EU-Avastin  group),  concurrent  illness  in  7 patients (3 patients in the CT-P16 group and 4 patients in the EU-Avastin group), unknown in 28 patients (13 patients in the CT-P16 group and 15 patients in the EU-Avastin group), and other in 40 patients (21 patients in the CT-P16 group and 19 patients in the EU-Avastin group).

A total  of  68  (9.9%)  patients  had  at  least  1  major  protocol  deviation.  Patients  with  major  protocol deviation were excluded from the PP population. The most frequently reported major protocol deviation was missing primary efficacy assessment (21 [6.1%] patients and 39 [11.2%] patients in the CT-P16 and EU-Avastin treatment groups, respectively). These patients did not have any tumour assessment result at post-baseline in central and/or local review. Only one patient had a major protocol deviation due to COVID-19. Major protocol deviations are summarised in 9.

Table 9. Major Protocol Deviations in Study CT-P16 3.1 (ITT Population)

|                                                   | CT-P16 (N=342)         | EU-approved Avastin (N=347)   | Total (N=689)          |
|---------------------------------------------------|------------------------|-------------------------------|------------------------|
|                                                   | Number (%) of patients | Number (%) of patients        | Number (%) of patients |
| Patients with at least 1 major protocol deviation | 24 (7.0)               | 44 (12.7)                     | 68 (9.9)               |
| Mis-randomizations                                | 2 (0.6)                | 2 (0.6)                       | 4 (0.6)                |
| Non-compliance of Inclusion or Exclusion criteria | 0                      | 3 (0.9)                       | 3 (0.4)                |
| Significant GCP Non-compliance                    | 0                      | 0                             | 0                      |
| ReceivingAnyProhibited Therapies                  | 0                      | 0                             | 0                      |
| Missing Primary Efficacy Assessment               | 21 (6.1)               | 39 (11.2)                     | 60 (8.7)               |
| Other Deviation Affecting Primary Endpoint        | 1 (0.3)                | 0                             | 1 (0.1)                |

Abbreviations: GCP, Good Clinical Practice; ITT, Intent-to-Treat.

The applicant was requested to clarify the notable imbalance between treatment groups with respect to the proportion of subjects excluded from the PP population, in particular due to missing primary efficacy assessment, and the reasons for the missing primary efficacy assessment. In the D120 responses, the

<div style=\"page-break-after: always\"></div>

applicant clarified that an imbalance between the treatment groups was particularly observed in missing primary efficacy assessment being due to 'patient withdrawal' (1 [0.3%] patient and 14 [4.0%] patients in the CT-P16 and EU-Avastin treatment groups, respectively).

## · Recruitment

The first patient was randomised into the study on 01 February 2019, and the study remains ongoing.

## · Conduct of the study

The original protocol (Version 1.0) was dated 12 June 2018. The protocol was amended 12 times during the course of the study. One of the amendments was global, resulting in Protocol Version 2.0; other amendments were country-specific. The amendments primarily concerned additional specifications and minor adjustments in eligibility criteria.

According to the applicant, the study was conducted according to the ICH  E6 (R2) risk and quality processes  described  in  the  applicable  procedural  documents.  The  quality  management  approach implemented in this study was documented and complied with the current ICH GCP guidelines on quality and  risk  management.  Monitoring  activities  comprised  a  combination  of  centralised  and  risk-based monitoring activities as well as periodic on-site monitoring visits. According to audit certificates provided by the applicant,  8  study  sites  were  subject  to  routine  clinical  site  audits.  Based  on  major  protocol deviations reported by the applicant, no instances of significant GCP non-compliance were identified (Table 14).

The study was not subject to GCP inspections by regulatory authorities.

## · Baseline data

The study enrolled a predominantly Caucasian population. Median age was 62 years, 35% were female and  65%  male,  and  69%  were  either  former  or  current  smokers.  Disease  status  at  baseline  was metastatic in 92% of patients. The demographic characteristics and stratification factors are summarised in 10, and baseline disease characteristics are summarised in Table 11.

<div style=\"page-break-after: always\"></div>

Table 10. Demographic Characteristics and Stratification Factors at Screening in CT-P16 3.1 (ITT Population)

|                                                  | CT-P16 (N=342)   | EU-Avastin (N=347)   | Total (N=689)   |
|--------------------------------------------------|------------------|----------------------|-----------------|
| Demographic Characteristics                      |                  |                      |                 |
| Age (years)                                      |                  |                      |                 |
| Mean ± SD                                        | 61.3 ± 9.01      | 61.5 ± 9.42          | 61.4± 9.21      |
| Median                                           | 62.0             | 62.0                 | 62.0            |
| Minimum, maximum                                 | 32,82            | 26,82                | 26,82           |
| Female fertility status', n (%)                  |                  |                      |                 |
| Surgically sterilized                            | 13 (10.9%)       | 7 (5.6%)             | 20 (8.2%)       |
| Post-menopausal                                  | 95 (79.8%)       | 104 (83.2%)          | 199 (81.6%)     |
| Potentially able to bear children                | 11 (9.2%)        | 14 (11.2%)           | 25 (10.2%)      |
| Race, n (%)                                      |                  |                      |                 |
| American Indian or Alaska Native                 | 9 (2.6%)         | 9 (2.6%)             | 18 (2.6%)       |
| Asian                                            | 59 (17.3%)       | 55 (15.9%)           | 114 (16.5%)     |
| Black or African American                        | 2 (0.6%)         | 1 (0.3%)             | 3 (0.4%)        |
| Native Hawaiian or Other Pacific Islander        | 0                | 0                    | 0               |
| White or Caucasian                               | 264 (77.2%)      | 264 (76.1%)          | 528 (76.6%)     |
| Not allowed by Investigator Country Regulations2 | 0                | 0                    | 0               |
| Other                                            | 8 (2.3%)         | 18 (5.2%)            | 26 (3.8%)       |
| Ethnicity, n (%)                                 |                  |                      |                 |
| Hispanic or Latino                               | 57 (16.7%)       | 66 (19.0%)           | 123 (17.9%)     |
| Non-Hispanic or non-Latino                       | 282 (82.5%)      | 275 (79.3%)          | 557 (80.8%)     |
| Not Allowed by Investigator Country Regulations? | 0                | 2 (0.6%)             | 2 (0.3%)        |
| Unknown*                                         | 3 (0.9%)         | 4 (1.2%)             | 7 (1.0%)        |
| Smoking history, n (%)                           |                  |                      |                 |

<div style=\"page-break-after: always\"></div>

|                                | CI-P16 (N=342)   | EU-Avastin (N=347)   | (N=689)       |
|--------------------------------|------------------|----------------------|---------------|
| Cumrent smoker                 | 75 (21.9%)       | 88 (25.4%)           | 163 (23.7%)   |
| Fomer smoker                   | 163 (47.7%)      | 148 (42.7%)          | 311 (45.1%)   |
| Never smoker                   | 104 (30.4%)      | 111 (32.0%)          | 215 (31.2%)   |
| Height (cm)                    |                  |                      |               |
| n                              | 342              | 346                  | 688           |
| Mean± SD                       | 166.85 ±9.866    | 166.53 ± 10.034      | 166.69 ±9.945 |
| Median                         | 167.00           | 168.00               | 167.00        |
| Minimum,maximum                | 133.0, 194.0     | 138.0,194.0          | 133.0.194.0   |
| Weight (kg) at baseline        |                  |                      |               |
| n                              | 342              | 346                  | 688           |
| Mean ± SD                      | 68.76± 15.767    | 69.78± 15.283        | 69.27 ±15.523 |
| Median                         | 67.00            | 69.00                | 68.00         |
| Minimum,maximum                | 36.0, 131.0      | 35.0,126.0           | 35.0,131.0    |
| Stratificationfactors          |                  |                      |               |
| Disease status, n (%)          |                  |                      |               |
| Recurence                      | 25 (7.3%)        | 33 (9.5%)            | 58 (8.4%)     |
| Metastatic                     | 317 (92.7%)      | 314 (90.5%)          | 631 (91.6%)   |
| ECOG performance status, n (%) |                  |                      |               |
| Grade 0                        | 105 (30.7%)      | 110 (31.7%)          | 215 (31.2%)   |
| Grade 1                        | 237 (69.3%)      | 237 (68.3%)          | 474 (68.8%)   |
| Sex, n (%)                     |                  |                      |               |
| Male                           | 223 (65.2%)      | 222 (64.0%)          | 445 (64.6%)   |
| Female                         | 119 (34.8%)      | 125 (36.0%)          | 244 (35.4%)   |
| Region,n (%)                   |                  |                      |               |
| EMEA                           | 226 (66.1%)      | 230 (66.3%)          | 456 (66.2%)   |
| America                        | 59 (17.3%)       | 62 (17.9%)           | 121 (17.6%)   |
| Asia                           | 57 (16.7%)       | 55 (15.9%)           | 112 (16.3%)   |

Note: Height and weight results sumumarized were the screening assessment values.ECOG performance status result summarized was the assessment value prior to shudy treatment administration at Induction Cycle 1.

2 When the race information of patients was not allowed to be disclosed due to country regulation

1 Fertility status was collected for female patient only. Percentages were caleulated by using the number of female patients as the denominator

3 When the ethnicity information of patients was not allowed to disclose due to country regulation

5 The randomization was stratified by country. sex, ECOG, and disease status at screening. However, the primary analysis for the primary endpoint was performed considering region, sex, ECOG, and disease status as covariates. Use ofregion instead of country in statistical models was discussed at the DRM Abbreviation: SD, standard deviation

4 When patients did not know their ethnicity

<div style=\"page-break-after: always\"></div>

Table 11. Baseline Disease Characteristics in Study CT-P16 3.1 (ITT Population)

|                                                | CT-P16 (N=342)   | EU-Avastin (N=347)   | Total (N=689)   |
|------------------------------------------------|------------------|----------------------|-----------------|
| Disease Status, n (%)                          |                  |                      |                 |
| Recurrence                                     | 25 (7.3%)        | 33 (9.5%)            | 58 (8.4%)       |
| Metastatic                                     | 317 (92.7%)      | 314 (90.5%)          | 631 (91.6%)     |
| Final pathological diagnosis, n (%)            |                  |                      |                 |
| Adenocarcinoma                                 | 336 (98.2%)      | 340 (98.0%)          | 676 (98.1%)     |
| Large cell carcinoma                           | 3 (0.9%)         | 2 (0.6%)             | 5 (0.7%)        |
| Non-Small Cell Carcinoma, NOS                  | 1 (0.3%)         | 1 (0.3%)             | 2 (0.3%)        |
| Squamous cell carcinoma                        | 0                | 0                    | 0               |
| Small cell carcinoma                           | 0                | 0                    | 0               |
| Adenosquamous carcinoma                        | 2 (0.6%)         | 2 (0.6%)             | 4 (0.6%)        |
| Other                                          | 0                | 2 (0.6%)             | 2 (0.3%)        |
| Current histologic grade, n (%)                |                  |                      |                 |
| GX:Grade of differentiation cannot be assessed | 131 (38.3%)      | 118 (34.0%)          | 249 (36.1%)     |
| G1: Well differentiated                        | 32 (9.4%)        | 33 (9.5%)            | 65 (9.4%)       |
| G2: Moderately differentiated                  | 85 (24.9%)       | 91 (26.2%)           | 176 (25.5%)     |
| G3: Poorly differentiated                      | 83 (24.3%)       | 88 (25.4%)           | 171 (24.8%)     |
| G4: Undifferentiated                           | 9 (2.6%)         | 15 (4.3%)            | 24 (3.5%)       |
| Current clinical stage, n (%)                  |                  |                      |                 |
| Stage IA                                       | 0                | 0                    | 0               |
| Stage IB                                       | 0                | 0                    | 0               |
| Stage IIA                                      | 0                | 0                    | 0               |
| Stage IIB                                      | 0                | 0                    | 0               |
| Stage IIIA                                     | 0                | 0                    | 0               |
| Stage IIIB                                     | 0                | 1 (0.3%)             | 1 (0.1%)        |
| Stage IIIC                                     | 0                | 0                    | 0               |
| Stage IVA                                      | 147 (43.0%)      | 164 (47.3%)          | 311 (45.1%)     |

<div style=\"page-break-after: always\"></div>

|                                         | CT-P16 (N=342)   | EU-Avastin (N=347)   | (N=689)      |
|-----------------------------------------|------------------|----------------------|--------------|
| Stage IVB                               | 170 (49.7%)      | 149 (42.9%)          | 319 (46.3%)  |
| Recurrent                               | 25 (7.3%)        | 33 (9.5%)            | 58 (8.4%)    |
| Current N Stage                         |                  |                      |              |
| NO                                      | 60 (17.5%)       | 66 (19.0%)           | 126 (18.3%)  |
| N1                                      | 25 (7.3%)        | 40 (11.5%)           | 65 (9.4%)    |
| N2                                      | 138 (40.4%)      | 133 (38.3%)          | 271 (39.3%)  |
| N3                                      | 116 (33.9%)      | 104 (30.0%)          | 220 (31.9%)  |
| NX                                      | 3 (0.9%)         | 4 (1.2%)             | 7 (1.0%)     |
| EGFR (epidermal growth factor receptor) |                  |                      |              |
| Negative                                | 342 (100.0%)     | 345 (99.4%)          | 687 (99.7%)  |
| Positive                                | 0                | 2 (0.6%)             | 2 (0.3%)     |
| Not Done                                | 0                | 0                    | 0            |
| ALK（anaplastic lymphoma kinase)         |                  |                      |              |
| Negative                                | 342 (100.0%)     | 347 (100.0%)         | 689 (100.0%) |
| Positive                                | 0                | 0                    | 0            |
| Not Done                                | 0                | 0                    | 0            |

Abbreviation: NOS,not otherwise specified

## · Numbers analysed

The number of patients in the statistical analysis sets is displayed in Table 12 . Out of 689 patients in the ITT Population, 621 (90.1%) patients were included in the PP Population. The primary reason for excluding a patient from the PP Population was a major protocol deviation of a missing primary efficacy assessment (21 patients in the CT-P16 group and 39 patients in the EU-Avastin group).

Table 12. Number of Patients in Statistical Analysis Sets in Study CT-P16 3.1 (ITT Population)

| Number of Patients (%)     | CT-P16 (N=342)   | EU-Avastin (N=347)   | Total (N=689)   |
|----------------------------|------------------|----------------------|-----------------|
| Number of Patients (%)     | n (%)            | n (%)                | n (%)           |
| Intent-to-Treat Population | 342 (100.0%)     | 347 (100.0%)         | 689 (100.0%)    |
| Per-Protocol Population    | 318 (93.0%)      | 303 (87.3%)          | 621 (90.1%)     |

## · Outcomes and estimation

## Analyses of primary endpoint: ORR

The  ORR  based  on  BOR  during  the  Induction  Study  Period  from  central  review  for  the  ITT  and PP populations is summarised in Table 13.

<div style=\"page-break-after: always\"></div>

Table 13. Objective Response Rates and Best Overall Response during the Induction Study Period in Study CT-P16 3.1 (Central) (ITT and PP Populations)

|                                      | ITT (Primary)                | ITT (Primary)                | PP (Supportive)              | PP (Supportive)              |
|--------------------------------------|------------------------------|------------------------------|------------------------------|------------------------------|
|                                      | CT-P16 (N=342)               | EU-Avastin (N=347)           | CI-P16 (N=318)               | EU-Avastin (N=303)           |
| Number of Responders (%)             | 145 (42.4%)                  | 146 (42.1%)                  | 144 (45.3%)                  | 143 (47.2%)                  |
| Number of Non- Responders (%)        | 197 (57.6%)                  | 201 (57.9%)                  | 174 (54.7%)                  | 160 (52.8%)                  |
| Objective Response Rate (%) (95% CI) | 42.40 (37.16 - 47.64)        | 42.07 (36.88 - 47.27)        | 45.28 (39.81 - 50.75)        | 47.19 (41.57-52.82)          |
| Risk Difference Estimatel (95% CI)   | 0.40 (-7.02,7.83)            | 0.40 (-7.02,7.83)            | -1.90 (-9.80, 6.00)          | -1.90 (-9.80, 6.00)          |
| Best overall response, n (%)         | Best overall response, n (%) | Best overall response, n (%) | Best overall response, n (%) | Best overall response, n (%) |
| Complete response                    | 2 (0.6%)                     | 3 (0.9%)                     | 2 (0.6%)                     | 3 (1.0%)                     |
| Partial response                     | 143 (41.8%)                  | 143 (41.2%)                  | 142 (44.7%)                  | 140 (46.2%)                  |
| Stable disease                       | 156 (45.6%)                  | 140 (40.3%)                  | 154 (48.4%)                  | 138 (45.5%)                  |
| Progressive disease                  | 17 (5.0%)                    | 19 (5.5%)                    | 17 (5.3%)                    | 19 (6.3%)                    |
| Inevaluable                          | 3 (0.9%)                     | 3 (0.9%)                     | 3 (0.9%)                     | 3 (1.0%)                     |
| Missing                              | 21 (6.1%)                    | 39 (11.2%)                   | 0                            | 0                            |

Note: Objective response rate was defined as the proportion ofpatients whose best overall response was CR or PR (considered as the *Responder'). All other patients except responders were considered as non-responder including patients without postbaseline disease assessment.

(EMEA vs. America Vs.Asia), sex (female Vs. male). disease status at baseline (recurrence Vs. metastatic). and ECoG performance score at baseline (O vs. 1) as covariates.

Abbreviations: CI, confidence interval; CR, complete response; ECOG, Easterm Cooperative Oncology Group; ITT, intent-to-treat; PP,per-protocol; PR, partial response

In the ITT population, the 95% CI for difference (CT-P16 and EU-Avastin) in ORR during the Induction Study Period was within the equivalence margin of -12.5 to 12.5 (-7.02 to 7.83). The ORRs were similar in  the  CT-P16  and  EU-Avastin  treatment  groups  (42.40%  [95%  CI:  37.16  -  47.64]  and  42.07% [95% CI: 36.88 - 47.27], respectively)  and  the  risk  difference  (CT-P16  -  EU-Avastin)  estimate  was 0.4%. For BORs, a similar proportion of patients in the CT-P16 and EU-Avastin treatment groups had CR (2 [0.6%] patients and 3 [0.9%] patients in the CT-P16 and EU-Avastin treatment groups, respectively) and PR (143 [41.8%] patients and 143 [41.2%] patients in the CT-P16 and EU-Avastin treatment groups, respectively) in the ITT population.

In the PP population, the ORRs and the BORs were similar to those in the ITT population. The 95% CI for difference was also within the equivalence margin of -12.5 to 12.5 (-9.80 to 6.00), which supports the result of the primary analysis. The ORRs were similar in the CT-P16 and EU-Avastin treatment groups (45.28% [95% CI: 39.81 - 50.75] and 47.19% [95% CI: 41.57 - 52.82], respectively) and the risk difference (CT-P16 - EU-Avastin) estimate was -1.9%. A similar proportion of patients in the CT-P16 and EU-Avastin  treatment  groups  had  CR  (2  [0.6%]  patients  and  3  [1.0%]  patients  in  the  CT-P16  and

<div style=\"page-break-after: always\"></div>

EU-Avastin treatment groups, respectively) and PR (142 [44.7%] patients and 140 [46.2%] patients in the CT-P16 and EU-Avastin treatment groups, respectively).

In order to evaluate the impact of missing data on the efficacy primary endpoint results, tipping point analyses were conducted for the primary efficacy endpoint (central review data) for ITT Population. Overall 66 patients were considered as missing cases in the tipping point analysis: 60 patients (21 [6.1%] patients and 39 [11.2%] patients in the CT-P16 and EU-Avastin treatment groups, respectively) with missing primary efficacy assessment and 6 patients (3 patients each in the CT-P16 and EU-Avastin, respectively) with best overall response of NE.

In the tipping point analysis, the two-sided 95% CIs for the difference in proportion between CT-P16 and EU-Avastin  treatment  groups  were  contained  within  the  equivalence  margin  of  (-12.5,  12.5)  when differences in the imputed number of responders between the two treatment groups were 15 or below. The  differences  in  the  imputed  number  of  responders  of  up  to  15  did  not  alter  the  conclusion  of therapeutic equivalence between the two treatment groups. The tipping point analyses are summarised in Table 14.

In response to D120 LoQ, to address the possible impact of missing data and their reasons on the ORR results, an additional analysis was provided based on the applicant's interpretation of missing at random assumption.  Among  those  with  missing  efficacy  evaluation,  the  reported  reasons  were:  15  patient withdrawal  (1  and  14  in  CT-P16  and  EU-Avastin,  respectively),  5  lost  to  follow-up,  1  investigator's decision and 1 protocol violation. These were considered uninformative cases as were the additional 6 patients with BOR of unevaluable. The patients who discontinued treatment due to AE (6 in CT-P16 and 5 in EU-Avastin) or death (10 in CT-P16 and 15 in EU-Avastin) before tumour assessment were analysed in two ways: In scenario 1, the subset of 10 cases of death due to clinical progression by investigator's opinion (5 in CT-P16, 5 in EU-Avastin) were considered as non-responders while the rest were considered uninformative. In scenario 2, all of the discontinuations due to AE or death before scheduled tumour assessment were considered as uninformative cases.

The two scenarios analysed resulted in very similar estimates of risk difference of ORR for CT-P16 vs. and EU-Avastin: -2.34% [95% CI: -10.21 - 5.54] according to scenario 1 (all patients with missing tumour assessment considered uninformative except for deaths potentially due to PD that were analysed as non-response) and -2.36 [95% CI: -10.27 - 5.55] according to scenario 2 (with all patients with missing tumour assessment considered uninformative).

<div style=\"page-break-after: always\"></div>

Figure 4. Tipping Point Results for Objective Response Rate during Induction Study Period (Central) (ITT Population)

<!-- image -->

Note: The 95% confidence intervals of the difference between two proportions (CT-P16 and EU-Avastin group) Were estimated by exact binomial approach

Blue dots indicate that the two-sided 95% CI for the difference in proportion between CT-P16 and EU-Avastin is included in the equivalence margin of (-12.5, 12.5).

Red dots indicate that the two-sided 95% CI for the difference in proportion between CT-P16 and EU-Avastin is not included in the equivalence margin of (-12.5. 12.5).

[1] Shift for the number of responders in CT-P16 and EU-Avastin. Assumed number of responder for patients with no response evaluation result or Inevaluable (NE).

Table 14. Tipping Point Results for Objective Response Rate during Induction Study Period (Central) (ITT Population)

|                                               | ShiftfortheNumberofRespondersinEU-Avastin   | ShiftfortheNumberofRespondersinEU-Avastin   | ShiftfortheNumberofRespondersinEU-Avastin   | ShiftfortheNumberofRespondersinEU-Avastin   | ShiftfortheNumberofRespondersinEU-Avastin   | ShiftfortheNumberofRespondersinEU-Avastin   | ShiftfortheNumberofRespondersinEU-Avastin   | ShiftfortheNumberofRespondersinEU-Avastin   | ShiftfortheNumberofRespondersinEU-Avastin   | ShiftfortheNumberofRespondersinEU-Avastin   |
|-----------------------------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|
| Shift for the Number of Responders in CT-P161 | 0                                           | 5                                           | 10                                          | 15                                          | 20                                          | 25                                          | 30                                          | 35                                          | 40                                          | 42                                          |
| 0                                             | (-7.13, 7.78)                               | (-8.59, 6.33)                               | (-10.05,4.88)                               | (-11.50, 3.46)                              | (-12.97, 2.04)t                             | (-14.38, 0.61)t                             | (-15.80, - 0.46)t                           | (-17.23, - 1.75)t                           | (-18.65, - 2.88)t                           | (-19.22,- 3.78)t                            |
| 5                                             | (-5.70, 9.22)                               | (-7.16, 7.78)                               | (-8.61, 6.36)                               | (-10.09,4.94)                               | (-11.50, 3.51)                              | (-12.93, 2.08)t                             | (-14.36, 0.66)t                             | (-15.78,- 0.46)t                            | (-17.20, - 1.56)t                           | (-17.77, - 2.00)t                           |
| 10                                            | (-4.26, 10.67)                              | (-5.72,9.25)                                | (-7.20, 7.83)                               | (-8.61,6.41)                                | (-10.05,4.98)                               | (-11.48,3.55)                               | (-12.91, 2.12)t                             | (-14.33,0.69)t                              | (-15.75, - 0.46)t                           | (-16.32,- 0.90)t                            |
| 15                                            | (-2.82,12.13)                               | (-4.31, 10.72)                              | (-5.72,9.30)                                | (-7.16, 7.88)                               | (-8.59, 6.45)                               | (-10.02, 5.02)                              | (-11.45, 3.59)                              | (-12.88, 2.16)                              | (-14.30,0.73)                               | (-14.87, 0.15)                              |
| 20                                            | (-1.40, 13.60)t                             | (-2.83, 12.18)                              | (-4.26, 10.76)                              | (-5.70, 9.34)                               | (-7.14, 7.92)                               | (-8.57, 6.49)                               | (-10.00, 5.06)                              | (-11.42, 3.63)                              | (-12.85, 2.19)t                             | (-13.42, 1.62)t                             |
| 24                                            | (-0.22, 14.77)t                             | (-1.65,13.35)                               | (-3.09, 11.93)                              | (-4.53, 10.51)                              | (-5.97,9.09)                                | (-7.40, 7.66)                               | (-8.83, 6.23)                               | (-10.26, 4.80)                              | (-11.68,3.36)                               | (-12.25, 2.79)                              |

conducted under MNAR (Missing Not at Random) scenarios. The 95% confidence intervals of the difference between two proportions (CT-P16 and EU-Avastin group) wereestimatedbyexactbinomialapproach.

1 Assumed number of responder for patients with no response evaluation result or Inevaluable (NE)'.

t Two-sided 95% CI for the difference in proportion between CT-P16 and EU-Avastin is not included in the equivalence margin of (-12.5, 12.5).

<div style=\"page-break-after: always\"></div>

ORR's  based  on  local  investigator  reviews  were  presented  as  a  sensitivity  analysis;  the  results  are displayed in Table 15 for the ITT population, and Table 16 for the PP population. For both analyses, the 95% CI for difference between CT-P16 and EU-Avastin in ORR during the Induction Study Period was within the equivalence margin of -12.5 to 12.5 (ITT: 4.87% [95 %CI: -2.53 to 12.26]; PP: 2.90% [95 % CI: -4.99 to 10.79]). Whereas the 95% CI's for both the ITT and PP populations were contained within the pre-specified equivalence margin, it is noted that the point estimates for the treatment difference were larger than in results based on central review.

Table 15. Objective Response Rate During the Induction Study Period: Local Review (ITT Population)

|                                                                | CT-P16 (N=342)        | EU-Approved Avastin (N=347)   |
|----------------------------------------------------------------|-----------------------|-------------------------------|
| Best overall response, n (%)                                   |                       |                               |
| Complete response                                              | 0                     | 2 (0.6)                       |
| Partial response                                               | 150 (43.9)            | 134 (38.6)                    |
| Stable disease                                                 | 158 (46.2)            | 147 (42.4)                    |
| Progressive disease                                            | 10 (2.9)              | 23 (6.6)                      |
| Inevaluable                                                    | 3 (0.9)               | 4 (1.2)                       |
| Missing                                                        | 21 (6.1)              | 37 (10.7)                     |
| Objective response rate (%) (95% CI)                           | 43.86 (38.60 - 49.12) | 39.19 (34.06 -44.33)          |
| Risk difference (CT-P16 - EU-approved Avastin) estimatel       | 4.87                  | 4.87                          |
| 95% CI for difference (CT-P16 - EU-approved Avastin) estimatel | (-2.53,12.26)         | (-2.53,12.26)                 |

Abbreviations: CI, confidence interval; CR, complete fesponse; ECOG, Eastem Cooperative Oncology Group: EMEA, Europe, the Middle East, and Affica; ITT, Intent-to-Treat; PR, partial response.

Logistic regression model including treatment groups (CT-P16 and EU-Approved Avastin) as a fixed effect and region (EMEA vs. America vs. Asia), sex (female vs. male), disease status at baseline (recurrence vs. metastatic), and ECOG performance score at baseline (0 vs. 1) as covariates was used.

Note: Objective response rate was defined as the proportion of patients whose best overall response was CR or PR (considered as the *Responder'). All other patients except responders were considered as non-responder including patients without post-baseline disease assessment.

<div style=\"page-break-after: always\"></div>

Table 16. Objective Response Rate During the Induction Study Period: Local Review (PP Population)

|                                                                | CT-P16 (N=318)        | EU-Approved Avastin (N=303)   |
|----------------------------------------------------------------|-----------------------|-------------------------------|
| Best overall response, n (%)                                   |                       |                               |
| Complete response                                              | 0                     | 2 (0.7)                       |
| Partial response                                               | 148 (46.5)            | 131 (43.2)                    |
| Stable disease                                                 | 157 (49.4)            | 143 (47.2)                    |
| Progressive disease                                            | 10 (3.1)              | 23 (7.6)                      |
| Inevaluable                                                    | 3 (0.9)               | 4 (1.3)                       |
| Missing                                                        | 0                     | 0                             |
| Objective response rate (%) (95% CI)                           | 46.54 (41.06 - 52.02) | 43.89 (38.31 -49.48)          |
| Risk difference (CT-P16 - EU-approved Avastin) estimatel       | 2.90                  |                               |
| 95% CI for difference (CT-P16 - EU-approved Avastin) estimate! | (-4.99, 10.79)        | (-4.99, 10.79)                |

Abbreviations: CI, confidence interval: CR, complete response: ECOG, Eastem Cooperative Oncology Group: EMEA, Europe, the Middle East, and Africa; PP, Per-Protocol; PR, partial response.

and region (EMEA vs. America vs. Asia), sex (female vs. male), disease status at baseline (recurrence vs. metastatic). and ECoG perfomance score at baseline (O vs. 1) as covariates was used.

Note: Objective response rate was defined as the proportion of patients whose best overall response was CR or PR (considered as the 'Responder'). All other patients except responders were considered as non-responder including patients without post-baseline disease assessment.

A post-hoc analysis was also carried out to assess the concordance between the ITRC and the local investigator assessments of tumour response.

Table 17. Concordance between Local and Central Results for Responder and Non-Responder (ITT population)

|                    |                  | Central Assessment   | Central Assessment   |
|--------------------|------------------|----------------------|----------------------|
|                    | Local Assessment | Responder            | Non-responder        |
| CT-P16 (N=342)     | Responder        | 113 (33.04%)         | 37 (10.82%)          |
| CT-P16 (N=342)     | Non-responder    | 32 (9.36%)           | 160 (46.78%)         |
| CT-P16 (N=342)     | Concordance Rate | 79.82%               | 79.82%               |
| EU-Avastin (N=347) | Responder        | 104 (29.97%)         | 32 (9.22%)           |
| EU-Avastin (N=347) | Non-responder    | 42 (12.10%)          | 169 (48.70%)         |
| EU-Avastin (N=347) | Concordance Rate | 78.67%               | 78.67%               |

Note: Patients with best overall response of Complete Response (CR) or Partial Response (PR) are considered as 'Responder'. All other patients except responders are considered as Non-Responder' including patients without post-baseline disease assessment.

<div style=\"page-break-after: always\"></div>

In addition, a post-hoc analysis of ITRC ORR based on response result at each cycle was conducted. Results are displayed in Table 18 and Table 19.

Table 18. ORR, Point Estimates with 95% CI at Induction Cycle 6 (Central)

| Visit Category               | ITT Population       | ITT Population       | PP Population         | PP Population         |
|------------------------------|----------------------|----------------------|-----------------------|-----------------------|
| Visit Category               | CT-P16 (N=342)       | EU-Avastin (N=347)   | CT-P16 (N=318)        | EU-Avastin (N=303)    |
| Induction Cycle 6            |                      |                      |                       |                       |
| Responder                    | 146 (42.7%)          | 151 (43.5%)          | 143 (45.0%)           | 148 (48.8%)           |
| Non-Responder                | 196 (57.3%)          | 196 (56.5%)          | 175 (55.0%)           | 155 (51.2%)           |
| ORR (%) (95% CI)             | 42.69 (37.45 -47.93) | 43.52 (38.30- 48.73) | 44.97 (39.50 - 50.44) | 48.84 (43.22 - 54.47) |
| Risk Difference (%) (95% CI) | -0.77 (-8.21,6.68)   | -0.77 (-8.21,6.68)   | -3.79 (-11.69. 4.11)  | -3.79 (-11.69. 4.11)  |

Note: Objective response rate is defined as the proportion of patients whose overall response is CR or PR (the Responder). All other patients except responders is considered as non-responder including patients without post-baseline disease assessment.

Abbreviations: CI, confidence interval; CR, complete response; ORR, objective response rate; PR, partial response

<div style=\"page-break-after: always\"></div>

Table 19. ORR Result of Each Cycle based on Overall Response (Central)

| Visit                             | ITT Population         | ITT Population         | PP Population          | PP Population          |
|-----------------------------------|------------------------|------------------------|------------------------|------------------------|
| Category                          | CT-P16 (N=342)         | EU-Avastin (N=347)     | CT-P16 (N=318)         | EU-Avastin (N=303)     |
| Induction Cycle 2                 | Induction Cycle 2      | Induction Cycle 2      | Induction Cycle 2      | Induction Cycle 2      |
| ORR (%) (95% CI)                  | 29.53 (24.70 - 34.37)  | 25.94 (21.33 - 30.55)  | 31.45 (26.34 - 36.55)  | 29.70 (24.56 - 34.85)  |
| Induction Cycle 4                 | Induction Cycle 4      | Induction Cycle 4      | Induction Cycle 4      | Induction Cycle 4      |
| ORR (%) (95% CI)                  | 39.77 (34.58 - 44.95)  | 36.60 (31.53 - 41.67)  | 42.45 (37.02 - 47.89)  | 41.58 (36.03 - 47.13)  |
| Induction Cycle 6                 | Induction Cycle 6      | Induction Cycle 6      | Induction Cycle 6      | Induction Cycle 6      |
| ORR (%) (95% CI)                  | 42.69 (37.45 - 47.93)  | 43.52 (38.30 -48.73)   | 44.97 (39.50 - 50.44)  | 48.84 (43.22- 54.47)   |
| Induction Study Period            | Induction Study Period | Induction Study Period | Induction Study Period | Induction Study Period |
| ORR (%) (95% CI)                  | 42.40 (37.16 - 47.64)  | 42.07 (36.88 - 47.27)  | 45.28 (39.81 - 50.75)  | 47.19 (41.57-52.82)    |
| Risk Difference Estimate (95% CI) | 0.40 (-7.02.7.83)      | 0.40 (-7.02.7.83)      | -1.90 (-9.80. 6.00)    | -1.90 (-9.80. 6.00)    |
| Minatenance Cycle 3               | Minatenance Cycle 3    | Minatenance Cycle 3    | Minatenance Cycle 3    | Minatenance Cycle 3    |
| ORR (%) (95% CI)                  | 24.85 (20.27 -29.43)   | 25.07 (20.51 -29.63)   | 26.73 (21.87 -31.59)   | 27.72 (22.68 -32.76)   |

Note: Objective response rate is defined as the proportion of patients whose overall response is CR or PR (the'Responder'). All other patients except responders is considered as non-responder including patients without post-baseline disease assessment.

1 Logistic regression model included treatment groups (CT-P16 and EU-Avastin) as a fixed effect and region (EMEA vs. America vs. Asia), sex (female vs. male), disease status at baseline (recurrence vs. metastatic). and ECOG performance score at baseline (O vs. 1) as covariates.

Abbreviations: CI, confidence interval; CR, complete response; ORR, objective response rate; PR, partial response.

Evaluation of efficacy is primarily based on longitudinal assessment of changes in target tumour sizes but neither statistical summaries nor visualisation of these raw data were included in original submission. In  D120 LoQ, the applicant was requested to provide a descriptive analysis for evolution of sum of diameter of target lesion by treatment group and further by whether or not response was achieved.

<div style=\"page-break-after: always\"></div>

Figure 5. Spaghetti Plot for Change from Baseline (%) of Sum of Diameter for Target Lesion - CT-P16 (ITT Population)

<!-- image -->

CT-P16

Figure 6. Spaghetti Plot for Change from Baseline (%) of Sum of Diameter for Target Lesion - EU-Avastin (ITT Population)

<!-- image -->

The changes in individual patients' target tumour sizes are visualised in CT-P16 and EU-Avastin groups in Figure 5 and 6, respectively. In addition, summary of statistics of target tumour % changes of diameter were provided by the applicant at start of induction cycle 2, 4 and 6. By induction cycle 2, those that achieved RECIST v1.1 response (BOR of CR or PR) in CT-P16 and EU-Avastin had, on average, mean reduction of 37.1% and 31.5% in tumour size, respectively. Among the RECIST v1.1 non-responders, the respective mean reductions were 12.8% and 14.0%.

## Analyses of secondary endpoints: PFS and OS

PFS was defined as time from randomisation to determined progression disease (PD)/recurrence or death from any cause, whichever occurs first. PD/recurrence or death that occurred on or before beginning another new anticancer therapy was regarded as an event. Censoring was defined as following:

<div style=\"page-break-after: always\"></div>

Table 20. Reasons for censoring and censoring dates

| Reason for Censoring                              | Censoring Date                                       |
|---------------------------------------------------|------------------------------------------------------|
| No tumor assessment after randomization           | The date ofrandomization                             |
| No event and no anticancer therapy                | Last tumor assessment date                           |
| Initiation of new anticancer therapy              | Last tumor assessment date before anticancer therapy |
| Event after missing two or more tumor assessment2 | Last tumor assessment date before event              |

Note: The last tumor assessment date on which tumor assessment was neither *missing nor ^inevaluable* were used for censoring date.

1 A patient was considered as taking a new anticancer therapy if there was any record of salvage treatment, which included chemotherapy/immunotherapy/targeted therapy, radiotherapy and surgery.

Otherwise, it was considered as a censoring case.

In  the  ITT  population,  72.5%  (248/342)  patients  and  70.9%  (246/347)  patients  had  died  or  had PD/recurrence  in  the  CT-P16  and  EU-Avastin  treatment  groups,  respectively.  The  median  PFS  were 7.9 [95% CI: 6.9 - 8.3] months and 7.2 [95% CI: 6.5 - 8.3] months for the CT-P16 and EU-Avastin treatment groups, respectively. The hazard ratio of PFS was 0.92 (95% CI: 0.77 - 1.10).

In  the  PP  population,  72.3%  (230/318)  patients  and  73.3%  (222/303)  patients  had  died  or  had PD/recurrence  in  the  CT-P16  and  EU-Avastin  treatment  groups,  respectively.  The  median  PFS  was 8.3 [95% CI: 7.2 - 8.5] months and 8.1 [95% CI: 6.8 - 8.6] months for the CT-P16 and EU-Avastin treatment groups, respectively. The hazard ratio of PFS was 0.93 (95% CI: 0.76 - 1.12).

The summary of PFS (Central) for the Study CT-P16 3.1 is presented below in Table 21. A Kaplan-Meier plot of PFS from central review is presented for the ITT population in Figure 7 and for the PP population in Figure 8.

<div style=\"page-break-after: always\"></div>

Table 21. Summary of Progression Free Survival (Central)

|                                                  | ITT Population                      | ITT Population                      | PP Population                       | PP Population                       |
|--------------------------------------------------|-------------------------------------|-------------------------------------|-------------------------------------|-------------------------------------|
|                                                  | CT-P16 (N=342)                      | EU-Avastin (N=347)                  | CT-P16 (N=318)                      | EU-Avastin (N=303)                  |
| Number of Patientswith Events                    | 248 (72.5%)                         | 246 (70.9%)                         | 230 (72.3%)                         | 222 (73.3%)                         |
| PD/Recurence                                     | 186 (54.4%)                         | 188 (54.2%)                         | 183 (57.5%)                         | 185 (61.1%)                         |
| Death                                            | 62 (18.1%)                          | 58 (16.7%)                          | 47 (14.8%)                          | 37 (12.2%)                          |
| Number of Patients with Censoring                | 94 (27.5%)                          | 101 (29.1%)                         | 88 (27.7%)                          | 81 (26.7%)                          |
| No Tumor Assessment                              | 6 (1.8%)                            | 18 (5.2%)                           | 0                                   | 0                                   |
| No Event and No Anticancer Therapy               | 46 (13.5%)                          | 46 (13.3%)                          | 46 (14.5%)                          | 45 (14.9%)                          |
| Initiation of New Anticancer Therapy             | 42 (12.3%)                          | 37 (10.7%)                          | 42 (13.2%)                          | 36 (11.9%)                          |
| Event after Missing Two or More Tumor Assessment | 0                                   | 0                                   | 0                                   | 0                                   |
| Survival Time (Mlonths)                          | Survival Time (Mlonths)             | Survival Time (Mlonths)             | Survival Time (Mlonths)             | Survival Time (Mlonths)             |
| 25 Percentile (95% CI)                           | 5.5 [4.1, 6.2)                      | 4.8 [3.7, 6.1)                      | 6.2 [4.6, 6.3)                      | 6.0 [4.7, 6.3)                      |
| Median (95% CI)                                  | 7.9 [6.9. 8.3)                      | 7.2 [6.5, 8.3)                      | 8.3 [7.2. 8.5)                      | 8.1 [6.8, 8.6)                      |
| 75 Percentile (95% CI)                           | 11.5 [10.6, 12.6)                   | 12.5 [10.7, 13.6)                   | 11.8 [10.8,12.8)                    | 12.8 [11.0, 14.5)                   |
| Hazard Ratio (95% CI)²                           | 0.92 (0.77, 1.10)                   | 0.92 (0.77, 1.10)                   | 0.93 (0.76, 1.12)                   | 0.93 (0.76, 1.12)                   |
| Estimates of Survival Rates(95% C1)              | Estimates of Survival Rates(95% C1) | Estimates of Survival Rates(95% C1) | Estimates of Survival Rates(95% C1) | Estimates of Survival Rates(95% C1) |
| 6months                                          | 0.73 (0.68. 0.78)                   | 0.71 (0.65. 0.75)                   | 0.76 (0.71, 0.80)                   | 0.75 (0.70.0.80)                    |
| 12 months                                        | 0.23 (0.18.0.28)                    | 0.27 (0.22.0.32)                    | 0.24 (0.19.0.29)                    | 0.29 (0.23.0.34)                    |
| 24 months                                        | 0.09 (0.05.0.15)                    | 0.06 (0.02. 0.12)                   | 0.10 (0.06.0.15)                    | 0.06 (0.02.0.12)                    |
| 36 months                                        | NE (NE, NE)                         | NE (NE. NE)                         | NE (NE, NE)                         | NE (NE. NE)                         |

Estimates and corresponding 95% CIs are based onKaplan-Meier method.

2 Adjusted stratified Cox regression modelis used to estimate the hazard ratio and its 95% CI for receiving CT-P16 compared with receiving EU-Avastin using region (EMEA vs. America vs. Asia). sex (female vs. male). disease status at baseline (recurrence vs. metastatic), and ECOG performance score at baseline (O vs. 1) as stratification factors.

Abbreviations: CI, confidence interval; ITT, intent-to-treat; N.E., not estimable; PD, progressive disease; PP, per-protocol

<div style=\"page-break-after: always\"></div>

Figure 7. Kaplan-Meier Plot of Progression-Free Survival in Study CT-P16 3.1 (Central) (ITT Population)

<!-- image -->

Figure 8. Kaplan-Meier Plot of Progression-Free Survival in Study CT-P16 3.1 (Central) (PP Population)

<!-- image -->

In response to the D180 LoQ, the applicant performed PFS analysis where death cases that occurred during the Follow-Up Period were regarded as an  event and patients who  withdrew from the study without any event or anticancer therapy were censored at the last date of tumour assessment as they were  in  the  original  analysis.  The  applicant  also  performed  PFS  analysis  in  which  study  treatment withdrawal and anticancer therapy with no PD/recurrence or death were newly considered as an event in  addition  to  censoring  logic  implemented  in  the  previous  sensitivity  analysis.  With  respect  to  the comparison between CT-P16 and EU-Avastin, the results of these additional analyses were similar to the original PFS analysis.

<div style=\"page-break-after: always\"></div>

OS was defined as time from randomisation to death from any cause. Death was regarded as an event and non-death was censored at the last known alive date.

In the ITT population, 48.0% (164/342) patients and 48.4% (168/347) patients had died in the CT-P16 and EU-Avastin treatment groups, respectively. The median OS was 17.1 [95% CI: 14.6 - 18.7] months and 15.6 [95% CI: 13.4 - 18.0] months for the CT-P16 and EU-Avastin treatment groups, respectively. The hazard ratio of OS was 0.95 (95% CI: 0.77 - 1.19).

In  the  PP  population,  147  (46.2%)  patients  and  145  (47.9%)  patients  had  died  in  the  CT-P16  and EU-Avastin treatment groups, respectively. The median OS was 17.5 [95% CI: 15.5 - 19.2] months and 17.0 [95% CI: 14.6 - 20.5] months for the CT-P16 and EU-Avastin treatment groups, respectively. The hazard ratio of OS was 0.96 (95% CI: 0.76 - 1.22).

The summary of OS for Study CT-P16 3.1 is presented below in Table 22. Kaplan-Meier plots of OS are presented for the ITT population in Figure 9 and for the PP population in Figure 10.

Table 22. Summary of Overall Survival

|                                      | ITT Population                       | ITT Population                       | PP Population                        | PP Population                        |
|--------------------------------------|--------------------------------------|--------------------------------------|--------------------------------------|--------------------------------------|
|                                      | CT-P16 (N=342)                       | EU-Avastin (N=347)                   | CT-P16 (N=318)                       | EU-Avastin (N=303)                   |
| Number of Patients with Events       | 164 (48.0%)                          | 168 (48.4%)                          | 147 (46.2%)                          | 145 (47.9%)                          |
| Death                                | 164 (48.0%)                          | 168 (48.4%)                          | 147 (46.2%)                          | 145 (47.9%)                          |
| NumberofPatientswith Censoring       | 178 (52.0%)                          | 179 (51.6%)                          | 171 (53.8%)                          | 158 (52.1%)                          |
| Non-Death                            | 178 (52.0%)                          | 179 (51.6%)                          | 171 (53.8%)                          | 158 (52.1%)                          |
| Survival Time (Mlonths)              | Survival Time (Mlonths)              | Survival Time (Mlonths)              | Survival Time (Mlonths)              | Survival Time (Mlonths)              |
| 25 Percentile (95% CI)               | 9.1 [8.0, 10.9)                      | 8.4 [7.1, 9.7)                       | 10.6 [8.7, 11.3)                     | 9.3 [8.2, 10.8)                      |
| Median (95% CI)                      | 17.1 [14.6, 18.7)                    | 15.6 [13.4, 18.0)                    | 17.5 [15.5. 19.2)                    | 17.0 [14.6.20.5)                     |
| 75* Percentile (95% CI)              | N.E [25.0. N.E)                      | 26.3 [25.3. N.E)                     | N.E [25.0. N.E)                      | 26.9 [25.3. N.E)                     |
| Hazard Ratio (95% CI)²               | 0.95 (0.77,1.19)                     | 0.95 (0.77,1.19)                     | 0.96 (0.76,1.22)                     | 0.96 (0.76,1.22)                     |
| Estimates of Survival Rates (95% CI) | Estimates of Survival Rates (95% CI) | Estimates of Survival Rates (95% CI) | Estimates of Survival Rates (95% CI) | Estimates of Survival Rates (95% CI) |
| 12 months                            | 0.66 (0.60. 0.71)                    | 0.62 (0.56. 0.67)                    | 0.69 (0.63.0.74)                     | 0.65 (0.59.0.70)                     |
| 24 months                            | 0.36 (0.29.0.43)                     | 0.36 (0.29.0.43)                     | 0.38 (0.31. 0.46)                    | 0.37 (0.30. 0.45)                    |
| 36 months                            | NE (NE. NE)                          | NE (NE, NE)                          | NE (NE. N.E)                         | NE (N.E. N.E)                        |

2 Adjusted stratified Cox regression model is used to estimate the hazard ratio and its 95% CI for receiving CT-P16 compared with receiving EU-Avastin using region (EMEA vs. America vs. Asia). sex (female Vs. male). disease status at baseline (recurrence Vs. metastatic). and ECOG perfommance score at baseline (O vs. 1) as stratification factors.

Estimates and corresponding 95% CIs are based on Kaplan-Meier method.

Abbreviations: CI, confidence interval; ITT, intent-to-treat; N.E., not estimable; PP, per-protocol

<div style=\"page-break-after: always\"></div>

Figure 9. Kaplan-Meier Plot of Overall Survival in Study CT-P16 3.1 (ITT Population)

<!-- image -->

Figure 10. Kaplan-Meier Plot of Overall Survival in Study CT-P16 3.1 (PP Population)

<!-- image -->

## · Ancillary analyses

Forest plots for risk difference based on ITRC ORR by stratification factors as well as other subgroups deemed relevant by the applicant are displayed in Figure 11 for the ITT population and in Figure 12 for the PP population.

<div style=\"page-break-after: always\"></div>

Figure 11. Forest Plot of Risk Difference of ORR (Central) by Subgroup (ITT Population)

| Subgroup                        | CT-P16 Events/N (%)   | CT-P16 Events/N (%)   | EU-Approved Avastin Events/N (%)   | EU-Approved Avastin Events/N (%)   | RiskDifference(95%CI)   |
|---------------------------------|-----------------------|-----------------------|------------------------------------|------------------------------------|-------------------------|
|                                 |                       | (42.4%)               |                                    |                                    |                         |
| All subjects                    | 145/342               |                       | 146/347                            | (42.1%)                            | 0.40 (-7.02, 7.83)      |
| Age                             |                       |                       |                                    |                                    |                         |
| <65                             | 91/203                | (44.8%)               | 90/213                             | (42.3%)                            | 2.62 (-7.04,12.27)      |
| >=65                            | 54/139                | (38.8%)               | 56/134                             | (41.8%)                            | -3.19 (-14.96, 8.58)    |
| Race                            |                       |                       |                                    |                                    |                         |
| AmericanIndian OrAlaskaNative   | 4/9                   | (44.4%)               | 3/9                                | (33.3%)                            | NE (NE, NE)             |
| Asian                           | 21/59                 | (35.6%)               | 25/55                              | (45.5%)                            | NE (NE,NE)              |
| BlackOrAfricanAmerican          | 0/2                   | (0.0%)                | 0/1                                | (0.0%)                             | NE(NE,NE)               |
| White                           | 114/264               | (43.2%)               | 112/264                            | (42.4%)                            | 0.75 (-7.77,9.28)       |
| Other                           | 6/8                   | (75.0%)               | 6/18                               | (33.3%)                            | 42.47 (5.24, 79.69)     |
| Sex                             |                       |                       |                                    |                                    |                         |
| F                               | 57/119                | (47.9%)               | 55/125                             | (44.0%)                            | 4.20 (-8.61, 17.01)     |
| M                               | 88/223                | (39.5%)               | 91/222                             | (41.0%)                            | -1.52 (-10.65, 7.60)    |
| Smoking History                 |                       |                       |                                    |                                    |                         |
| Current Smoker                  | 29/75                 | (38.7%)               | 32/88                              | (36.4%)                            | 1.99 (-13.07, 17.04)    |
| Former Smoker                   | 61/163                | (37.4%)               | 65/148                             | (43.9%)                            | -6.07 (-17.09, 4.96)    |
| Never Smoker                    | 55/104                | (52.9%)               | 49/111                             | (44.1%)                            | 7.21 (-6.51, 20.93)     |
| Disease Status                  |                       |                       |                                    |                                    |                         |
| Recurrence                      | 10/25                 | (40.0%)               | 12/33                              | (36.4%)                            | NE (NE,NE)              |
| Metastatic                      | 135/317               | (42.6%)               | 134/314                            | (42.7%)                            | 0.04 (-7.73, 7.81)      |
| PriorRadiation Therapy          |                       |                       |                                    |                                    |                         |
| Yes                             | 16/41                 | (39.0%)               | 9/42                               | (21.4%)                            | NE (NE, NE)             |
| No                              | 129/301               | (42.9%)               | 137/305                            | (44.9%)                            | -2.11 (-10.08, 5.85)    |
| PriorAnti-CancerSystemicTherapy |                       |                       |                                    |                                    |                         |
| Yes                             | 2/6                   | (33.3%)               | 2/10                               | (20.0%)                            | NE (NE,NE)              |
| No                              | 143/336               | (42.6%)               | 144/337                            | (42.7%)                            | -0.02 (-7.55, 7.50)     |
| Region                          |                       |                       |                                    |                                    |                         |
| EMEA                            | 97/226                | (42.9%)               | 96/230                             | (41.7%)                            | 1.10 (-8.03, 10.22)     |
| America                         | 29/59                 | (49.2%)               | 25/62                              | (40.3%)                            | NE(NE,NE)               |
| Asia                            | 19/57                 | (33.3%)               | 25/55                              | (45.5%)                            | NE (NE, NE)             |
| ECOGStatus                      |                       |                       |                                    |                                    |                         |
| Grade0                          | 52/105                | (49.5%)               | 54/110                             | (49.1%)                            | 0.48 (-13.14, 14.09)    |
| Grade 1                         | 93/237                | (39.2%)               | 92/237                             | (38.8%)                            | 0.41 (-8.38, 9.19)      |

Note: ORR=Objective Response Rate, CI=Confidence Interval, NE=Not Estimable, N=Number of patients in subgroup.

<!-- image -->

In order to estimate Risk Difference and its 95% CI, Logistic Regression model including treatment groups (CT-P16 and EU-Approved Avastin) as a fixed effect and region (EMEA vs. America vs. Asia), sex (female adjusted for the model.When there is only one response level(responder or non-responder)within eachlevel of covariates or there is a convergence failure in the LogisticRegression model,RiskDifference and its 95%CI were presented as'NE (NE,NE)'.

Figure 12. Forest Plot of Risk Difference of ORR (Central) by Subgroup (PP Population)

| Subgroup                        | CT-P16 Events/N (%)   | CT-P16 Events/N (%)   | EU-Approved Avastin   | EU-Approved Avastin   | Risk Difference (95% CI)   |
|---------------------------------|-----------------------|-----------------------|-----------------------|-----------------------|----------------------------|
| All subjects                    | 144/318               | (45.3%)               | 143/303               | (47.2%)               | -1.90 (-9.80, 6.00)        |
| Age                             |                       |                       |                       |                       |                            |
| <65                             | 90/192                | (46.9%)               | 88/191                | (46.1%)               | 0.57 (-9.58,10.72)         |
| >=65                            | 54/126                | (42.9%)               | 55/112                | (49.1%)               | -7.03 (-19.89, 5.82)       |
| Race                            |                       |                       |                       |                       |                            |
| AmericanIndianOrAlaskaNative    | 4/8                   | (50.0%)               | 3/6                   | (50.0%)               | NE (NE, NE)                |
| Asian                           | 20/54                 | (37.0%)               | 25/46                 | (54.3%)               | NE (NE,NE)                 |
| BlackOrAfricanAmerican          | 0/2                   | (0.0%)                | 0/1                   | (0.0%)                | NE (NE,NE)                 |
| White                           | 114/246               | (46.3%)               | 109/234               | (46.6%)               | -0.32 (-9.34, 8.70)        |
| Other                           | 6/8                   | (75.0%)               | 6/16                  | (37.5%)               | 38.33 (-0.03, 76.70)       |
| Sex                             |                       |                       |                       |                       |                            |
| F                               | 57/108                | (52.8%)               | 54/112                | (48.2%)               | 4.59 (-8.87, 18.05)        |
| M                               | 87/210                | (41.4%)               | 89/191                | (46.6%)               | -5.23 (-14.96, 4.51)       |
| Smoking History                 |                       |                       |                       |                       |                            |
| CurrentSmoker                   | 29/70                 | (41.4%)               | 31/75                 | (41.3%)               | -0.12 (-16.36,16.12)       |
| Former Smoker                   | 60/154                | (39.0%)               | 64/133                | (48.1%)               | -8.83(-20.41,2.75)         |
| Never Smoker                    | 55/94                 | (58.5%)               | 48/95                 | (50.5%)               | 5.48 (-9.16, 20.12)        |
| Disease Status                  |                       |                       |                       |                       |                            |
| Recurrence                      | 10/23                 | (43.5%)               | 11/29                 | (37.9%)               | NE (NE, NE)                |
| Metastatic                      | 134/295               | (45.4%)               | 132/274               | (48.2%)               | -2.60 (-10.87, 5.66)       |
| PriorRadiationTherapy           |                       |                       |                       |                       |                            |
| Yes                             | 16/36                 | (44.4%)               | 9/34                  | (26.5%)               | NE (NE, NE)                |
| No                              | 128/282               | (45.4%)               | 134/269               | (49.8%)               | -4.60 (-13.01, 3.81)       |
| PriorAnti-CancerSystemicTherapy |                       |                       |                       |                       |                            |
| Yes                             | 2/6                   | (33.3%)               | 2/9                   | (22.2%)               | NE (NE, NE)                |
| No                              | 142/312               | (45.5%)               | 141/294               | (48.0%)               | -2.32 (-10.32,5.69)        |
| Region                          |                       |                       |                       |                       |                            |
| EMEA                            | 97/213                | (45.5%)               | 95/203                | (46.8%)               | -1.51 (-11.16, 8.13)       |
| America                         | 29/53                 | (54.7%)               | 23/54                 | (42.6%)               | NE(NE,NE)                  |
| Asia                            | 18/52                 | (34.6%)               | 25/46                 | (54.3%)               | NE (NE, NE)                |
| ECOGStatus                      |                       |                       |                       |                       |                            |
| Grade0                          | 52/101                | (51.5%)               | 52/96                 | (54.2%)               | -2.56 (-16.71, 11.60)      |
| Grade 1                         | 92/217                | (42.4%)               | 91/207                | (44.0%)               | -1.58 (-11.02, 7.86)       |

Note: ORR=Objective Response Rate, CI=Confidence Interval, NE=Not Estimable, N=Number of patients in subgroup.

adjusted for the model.When thereis only oneresponse level(responder or non-responder)within eachlevel of covariates or there is aconvergence failurein theLogisticRegression model,RiskDifference and its 95%CI were presented as *NE (NE,NE)'.

## · Summary of main efficacy results

The following tables summarise the efficacy results from the main studies supporting the present application. These summaries should be read in conjunction with the discussion on clinical efficacy as

<!-- image -->

<div style=\"page-break-after: always\"></div>

well as the biosimilarity assessment (see later sections).

Table 23. Summary of efficacy for trial CT-P16 3.1

| Title: Double-Blind, Randomized, Active-Controlled, Parallel-Group, Phase 3 Study to Compare Efficacy and Safety of CT-P16 and EU-Approved Avastin as First-Line Treatment for Metastatic or Recurrent Non-Squamous Non-Small Cell Lung Cancer   | Title: Double-Blind, Randomized, Active-Controlled, Parallel-Group, Phase 3 Study to Compare Efficacy and Safety of CT-P16 and EU-Approved Avastin as First-Line Treatment for Metastatic or Recurrent Non-Squamous Non-Small Cell Lung Cancer   | Title: Double-Blind, Randomized, Active-Controlled, Parallel-Group, Phase 3 Study to Compare Efficacy and Safety of CT-P16 and EU-Approved Avastin as First-Line Treatment for Metastatic or Recurrent Non-Squamous Non-Small Cell Lung Cancer                                                                                                                                                                                                                                                                    |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                                                                                                 | Project code: CT-P16 3.1 EudraCT number: 2018-002147-28                                                                                                                                                                                          | Project code: CT-P16 3.1 EudraCT number: 2018-002147-28                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Design                                                                                                                                                                                                                                           | Randomised, parallel-group, double-blind, multicentre study                                                                                                                                                                                      | Randomised, parallel-group, double-blind, multicentre study                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Design                                                                                                                                                                                                                                           | Duration of main phase:                                                                                                                                                                                                                          | Repeat dose until progression disease or intolerable toxicity (approximately 3 years from the enrolment of the last patient) Screening Period: within 28 days prior to randomisation (extended to 8 weeks of Screening Period for patients with CNS metastases to provide sufficient time for CNS treatment) Induction Study Period: every 3 weeks up to 6 cycles Maintenance Study Period: every 3 weeks until PD or intolerable toxicity Follow-Up Period: every 9 weeks until death or the end of study        |
| Hypothesis                                                                                                                                                                                                                                       | To demonstrate that CT-P16 is equivalent to EU-Avastin                                                                                                                                                                                           | To demonstrate that CT-P16 is equivalent to EU-Avastin                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Treatment groups                                                                                                                                                                                                                                 | CT-P16                                                                                                                                                                                                                                           | Induction Study Period: 15 mg/kg IV of CT-P16 will be administered on Day 1 of each cycle and will be repeated every 3 weeks until 6 cycles. Paclitaxel 200 mg/m 2 IV and carboplatin area under the curve (AUC) 6 IV also will be administered on Day 1 of each cycle and will be repeated every 3 weeks up to 6 cycles (at least 4 cycles) Maintenance Period: CT-P16 as a monotherapy maintained every 3 weeks until progressive disease (PD) or intolerable toxicity occurrence Number randomised=342         |
| Treatment groups                                                                                                                                                                                                                                 | EU-Avastin                                                                                                                                                                                                                                       | Induction Study Period: 15 mg/kg IV of EU-Avastin will be administered on Day 1 of each cycle and will be repeated every 3 weeks until 6 cycles. Paclitaxel 200 mg/m 2 IV and carboplatin area under the curve (AUC) 6 IV also will be administered on Day 1 of each cycle and will be repeated every 3 weeks up to 6 cycles (at least 4 cycles) Maintenance Period: EU-Avastin as a monotherapy maintained every 3 weeks until progressive disease (PD) or intolerable toxicity occurrence Number randomised=347 |

<div style=\"page-break-after: always\"></div>

| Endpoints and definitions                      | Primary efficacy endpoint                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | ORR during the Induction Study Period                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | defined as an objective response rate based on BOR by RECIST v1.1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | defined as an objective response rate based on BOR by RECIST v1.1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Endpoints and definitions                      | Secondary efficacy endpoint                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | ORR during the Whole Study Period                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | defined as an objective response rate based on BOR by RECIST v1.1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | defined as an objective response rate based on BOR by RECIST v1.1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Endpoints and definitions                      | Secondary efficacy endpoint                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Response duration                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | defined as the time between initial response (CR or PR) and PD/recurrence or death due to any cause, whichever occurs first                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | defined as the time between initial response (CR or PR) and PD/recurrence or death due to any cause, whichever occurs first                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Endpoints and definitions                      | Secondary efficacy endpoint                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | TTP                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | defined as the time from randomisation until PD/recurrence                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | defined as the time from randomisation until PD/recurrence                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Endpoints and definitions                      | Secondary efficacy endpoint                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | PFS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | defined as the time from randomisation until PD/recurrence or death due to any cause, whichever occurs first                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | defined as the time from randomisation until PD/recurrence or death due to any cause, whichever occurs first                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Endpoints and definitions                      | Secondary efficacy endpoint                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | OS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | defined as the time from randomisation until death due to any cause                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | defined as the time from randomisation until death due to any cause                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Database lock                                  | 15 July 2021                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 15 July 2021                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 15 July 2021                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 15 July 2021                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Results and Analysis                           | Results and Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Results and Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Results and Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Results and Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Analysis description                           | Primary Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | Primary Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | Primary Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | Primary Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Analysis population and time point description |  Efficacy population - Intent-to-treat (ITT) Population: The ITT population is defined as all patients randomly assigned to study drug, regardless of whether or not any study treatment dosing is completed and successfully screened. Patients were assigned to treatment groups based on randomisation. The primary population for the primary efficacy analysis was the ITT population. - Per-Protocol Population: The PP population is defined as all randomly assigned patients who have at least one response evaluation after receiving at least one full dose of study drug (CT P16 or EU Approved Avastin) in the Induction Study Period and who do not have any major protocol deviation. A major protocol deviation was one that may affect the interpretation of primary endpoint and it was defined in the SAP. Final determinations of the PP population were made at the blinded data review meeting before unblinding. Patients were assigned to treatment groups based on randomisation. A supportive efficacy analysis was repeated using the PP population.  Tumour evaluation was assessed at Screening and every 2 cycles during the Induction Study Period and every 3 cycles during the Maintenance Study Period, and at the EOT visit. During the Follow-Up Period, it will be performed every 9 weeks until PD, death, withdrawal or start of new anti-cancer therapy if PD is not confirmed during the Induction or Maintenance Study Periods. |  Efficacy population - Intent-to-treat (ITT) Population: The ITT population is defined as all patients randomly assigned to study drug, regardless of whether or not any study treatment dosing is completed and successfully screened. Patients were assigned to treatment groups based on randomisation. The primary population for the primary efficacy analysis was the ITT population. - Per-Protocol Population: The PP population is defined as all randomly assigned patients who have at least one response evaluation after receiving at least one full dose of study drug (CT P16 or EU Approved Avastin) in the Induction Study Period and who do not have any major protocol deviation. A major protocol deviation was one that may affect the interpretation of primary endpoint and it was defined in the SAP. Final determinations of the PP population were made at the blinded data review meeting before unblinding. Patients were assigned to treatment groups based on randomisation. A supportive efficacy analysis was repeated using the PP population.  Tumour evaluation was assessed at Screening and every 2 cycles during the Induction Study Period and every 3 cycles during the Maintenance Study Period, and at the EOT visit. During the Follow-Up Period, it will be performed every 9 weeks until PD, death, withdrawal or start of new anti-cancer therapy if PD is not confirmed during the Induction or Maintenance Study Periods. |  Efficacy population - Intent-to-treat (ITT) Population: The ITT population is defined as all patients randomly assigned to study drug, regardless of whether or not any study treatment dosing is completed and successfully screened. Patients were assigned to treatment groups based on randomisation. The primary population for the primary efficacy analysis was the ITT population. - Per-Protocol Population: The PP population is defined as all randomly assigned patients who have at least one response evaluation after receiving at least one full dose of study drug (CT P16 or EU Approved Avastin) in the Induction Study Period and who do not have any major protocol deviation. A major protocol deviation was one that may affect the interpretation of primary endpoint and it was defined in the SAP. Final determinations of the PP population were made at the blinded data review meeting before unblinding. Patients were assigned to treatment groups based on randomisation. A supportive efficacy analysis was repeated using the PP population.  Tumour evaluation was assessed at Screening and every 2 cycles during the Induction Study Period and every 3 cycles during the Maintenance Study Period, and at the EOT visit. During the Follow-Up Period, it will be performed every 9 weeks until PD, death, withdrawal or start of new anti-cancer therapy if PD is not confirmed during the Induction or Maintenance Study Periods. |  Efficacy population - Intent-to-treat (ITT) Population: The ITT population is defined as all patients randomly assigned to study drug, regardless of whether or not any study treatment dosing is completed and successfully screened. Patients were assigned to treatment groups based on randomisation. The primary population for the primary efficacy analysis was the ITT population. - Per-Protocol Population: The PP population is defined as all randomly assigned patients who have at least one response evaluation after receiving at least one full dose of study drug (CT P16 or EU Approved Avastin) in the Induction Study Period and who do not have any major protocol deviation. A major protocol deviation was one that may affect the interpretation of primary endpoint and it was defined in the SAP. Final determinations of the PP population were made at the blinded data review meeting before unblinding. Patients were assigned to treatment groups based on randomisation. A supportive efficacy analysis was repeated using the PP population.  Tumour evaluation was assessed at Screening and every 2 cycles during the Induction Study Period and every 3 cycles during the Maintenance Study Period, and at the EOT visit. During the Follow-Up Period, it will be performed every 9 weeks until PD, death, withdrawal or start of new anti-cancer therapy if PD is not confirmed during the Induction or Maintenance Study Periods. |
| Descriptive statistics estimate variability    | and Primary analysis (ITT population; Central ITRC review)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | and Primary analysis (ITT population; Central ITRC review)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | and Primary analysis (ITT population; Central ITRC review)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | and Primary analysis (ITT population; Central ITRC review)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Descriptive statistics estimate variability    | Number (%) of patients                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Number (%) of patients                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Number (%) of patients                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Number (%) of patients                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Descriptive statistics estimate variability    | Treatment group (ITT Population)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | CT-P16 (N=342)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | CT-P16 (N=342)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | EU-Avastin (N=347)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Descriptive statistics estimate variability    | Number of Responders (%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 145 (42.4%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 145 (42.4%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 146 (42.1%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |

<div style=\"page-break-after: always\"></div>

|                                                 | Number of Non- Responders (%)                       | 197 (57.6%)                                         | 201 (57.9%)                                         |
|-------------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|
|                                                 | Objective Response Rate (%) (95% CI)                | 42.40 (37.16 - 47.64)                               | 42.07 (36.88 - 47.27)                               |
|                                                 | Risk Difference Estimate (95% CI)                   | 0.40                                                | 0.40                                                |
|                                                 | Best overall response, n (%)                        | Best overall response, n (%)                        | Best overall response, n (%)                        |
|                                                 | Complete response                                   | 2 (0.6%)                                            | 3 (0.9%)                                            |
|                                                 | Partial response                                    | 143 (41.8%)                                         | 143 (41.2%)                                         |
|                                                 | Stable disease                                      | 156 (45.6%)                                         | 140 (40.3%)                                         |
|                                                 | Progressive disease                                 | 17 (5.0%)                                           | 19 (5.5%)                                           |
|                                                 | Inevaluable                                         | 3 (0.9%)                                            | 3 (0.9%)                                            |
|                                                 | Missing                                             | 21 (6.1%)                                           | 39 (11.2%)                                          |
| Descriptive statistics and estimate variability | Supportive analysis (PP population; Central review) | Supportive analysis (PP population; Central review) | Supportive analysis (PP population; Central review) |
|                                                 | Number (%) of patients                              | Number (%) of patients                              | Number (%) of patients                              |
|                                                 | Treatment group (PP Population)                     | CT-P16 (N=318)                                      | EU-Avastin (N=303)                                  |
|                                                 | Number of Responders (%)                            | 144 (45.3%)                                         | 143 (47.2%)                                         |
|                                                 | Number of Non- Responders (%)                       | 174 (54.7%)                                         | 160 (52.8%)                                         |
|                                                 | Objective Response Rate (%) (95% CI)                | 45.28 (39.81 - 50.75)                               | 47.19 (41.57 - 52.82)                               |
|                                                 | Risk Difference Estimate (95% CI)                   | -1.90 (-9.80, 6.00)                                 | -1.90 (-9.80, 6.00)                                 |
|                                                 | Best overall response, n (%)                        | Best overall response, n (%)                        | Best overall response, n (%)                        |
|                                                 | Complete response                                   | 2 (0.6%)                                            | 3 (1.0%)                                            |
|                                                 | Partial response                                    | 142 (44.7%)                                         | 140 (46.2%)                                         |
|                                                 | Stable disease                                      | 154 (48.4%)                                         | 138 (45.5%)                                         |
|                                                 | Progressive disease                                 | 17 (5.3%)                                           | 19 (6.3%)                                           |
|                                                 | Inevaluable                                         | 3 (0.9%)                                            | 3 (1.0%)                                            |
|                                                 | Missing                                             | 0                                                   | 0                                                   |

## 2.4.5.3. Clinical studies in special populations

Not applicable for biosimilars.

<div style=\"page-break-after: always\"></div>

## 2.4.5.4. In vitro biomarker test for patient selection for efficacy

Not applicable.

## 2.4.5.5. Analysis performed across trials (pooled analyses and meta-analysis)

Not applicable.

## 2.4.5.6. Supportive studies

Not applicable.

## 2.4.6. Discussion on clinical efficacy

As outlined above, data used to support biosimilarity of CT-P16 with EU-Avastin from a clinical efficacy perspective stems from one clinical study (Study CT-P16 3.1), conducted in patients with metastatic or recurrent non-squamous non-small cell lung cancer.

## Design and conduct of clinical studies

Study  CT-P16  3.1  is  an  ongoing  double-blind,  randomised,  active-controlled,  parallel-group  study comparing CT-P16 (15 mg/kg) and EU-Avastin (15 mg/kg) when co-administered with paclitaxel and carboplatin as first-line treatment in patients with metastatic or recurrent nsNSCLC. Eligible patients were randomised in a 1:1 ratio to receive intravenous CT-P16 or EU-Avastin every 3 weeks. All patients concomitantly received intravenous paclitaxel and carboplatin every 3 weeks up to 6 cycles (at least 4 cycles).  After  the  completion of  6  cycles  during  the  Induction  Study  Period, patients  with  controlled disease (complete response [CR], partial response [PR], or stable disease [SD], assessed at the end of Cycle 6) entered the Maintenance Study Period, during which patients receive CT-P16 or EU-Avastin as monotherapy every 3 weeks until PD or intolerable toxicity.

The basic design of the study is acceptable and consistent with expectations for a clinical biosimilarity study. The eligibility criteria adequately define an appropriate target population for the clinical study, and similar eligibility criteria have been applied in multiple prior studies for bevacizumab biosimilars. Dose selection for study drugs was in accordance with the authorised posology for Avastin.

The primary objective of study CT-P16 3.1 was to demonstrate that CT-P16 was similar to EU-Avastin in terms of efficacy as determined by objective response rate (ORR) during the Induction Study Period. Secondary objectives include ORR during the Whole Study Period, response duration, time to progression (TTP), progression-free survival (PFS), and overall survival (OS). The primary and secondary objectives are consistent with expectations for a clinical biosimilarity trial; demonstration of similarity based on ORR is consistent with regulatory precedent and is endorsed as an appropriate primary objective. In addition  to  a  BOR  approach,  ORR  has  been  reported  by  treatment  cycle;  this  additional  analysis  is endorsed  as  providing  relevant  additional  information  for  assessment  of  biosimilarity.  Data  for  the secondary endpoints were not included in the initial submission but were received within the applicant's responses to the D120 List of Questions.

A key requirement for an equivalence study is assay sensitivity, i.e. ability to detect a true difference between the outcomes between the comparative treatments. Despite the 'standard' response definitions as per RECIST 1.1 the actual performance of the measure may differ between studies and may depend on design and quality considerations. An Independent Tumour Review Committee (ITRC) was used for the primary analysis. Images for tumour assessment were reviewed separately centrally and locally, and both  image  review  results  were  analysed  and  listed  separately.  Based  on  the  imaging  charter,  the

<div style=\"page-break-after: always\"></div>

operations were deemed to be consistent with conventional expectations for an ITRC. The reported rates of  inter-rater  concordance  are  considered  acceptable  and  indicate  adequate  sensitivity  to  detect differences in radiographic outcomes between patients and thus between treatment groups.

The equivalence margin of -12.5% to 12.5% is similar to the margin previously applied in MAAs for other bevacizumab biosimilars for demonstrating similar efficacy in first-line NSCLC indication. According to the  meta-analysis  across  4  trials,  randomised  bevacizumab,  added  to  chemotherapy,  increases  the probability  of  objective  response  by  at  least  12.89  percentage  points  (based  on  lower  limit  of  95% confidence  intervals).  Thereby,  the  proposed  margin  is  believed  to  preserve  at  least  some  positive fraction of the originator's efficacy. No clinical justification for the equivalence margin is given by the applicant. According to the Clinical Overview, the equivalence margin was agreed with EMA via CHMP Scientific Advice (EMEA/H/SA/3334/1/2016/III), however, there is no discussion about the equivalence margin for a nsNSCLC population and thereby the accuracy of the applicant's statement could not be ascertained. Given the several recent precedents for the acceptability of an equivalence margin similar to that proposed by the applicant, the issue was not pursued.

The sample size rationale, parameters and results appear consistent. The sample size is adequate for the purpose.

The measures for the blinding of the study seem adequate and for the safety precaution the IWRS system seems relevant  as  well  as  the  policy  for  the  unblinding.  The  number  of  cases  when  treatment  was unblinded at individual patient level is low and, as such, unlikely to risk to credibility of the results.

The number of stratification factors exceeds the recommended number of ICH guideline E9 Statistical Principles  for  Clinical  Trials.  The  number  of  randomisation  strata  is  168  and the  number  of  patients randomised must have been very small in a considerable proportion of strata. As such it is questionable whether the randomisation procedure was optimal in ensuring balanced treatment groups with respect to the key factors. However, as the randomisation actually resulted in reasonable balance with respect each of the stratification factors, this potential methodological caveat can be ignored.

Randomisation was stratified by country and, as per ICH E9 Statistical Principles for Clinical Trials, factors on which randomisation has been stratified should be accounted for later in the analysis. In this study, the  countries  were  pooled  into  three  geographic  regions  for  the  statistical  analysis.  In  the  D120 responses, the applicant provided an adequate rationale for pooling the countries into the regions for the purpose of the statistical analysis and summarised the numbers of study subjects from each region.

Due to the excessive number of strata and low assumed number of patients in many of them, a fully stratified statistical analysis of outcome would not be feasible. Instead a parsimonious model, e.g. logistic regression,  must  be  used  to  account  for  stratification  factors  in  the  statistical  comparison  between treatment groups. The logistic regression model assumes that the odds (hence probability) of response may differ depending - in addition to treatment assignment - on the covariates: geographic region where the patient participates in the study, sex, baseline disease status and baseline ECOG performance status. When a single response rate for a treatment group or difference between treatment groups is estimated from a logistic regression model the result is specific to the chosen levels of the covariates or the weights used for averaging. In calculation for the ORR in each treatment group, the applicant assigned weights for the fixed model effects (corresponding to the levels of stratification factors) proportionally based on the distribution of stratification factor levels in the population studied. This is considered appropriate.

Evaluation of efficacy is primarily based on longitudinal assessment of changes in target tumour sizes but neither statistical summaries nor visualisation of these raw data were included in original submission. In  D120 LoQ, the applicant was requested to provide a descriptive analysis for evolution of sum of diameter of target lesion by treatment group and further by whether or not response was achieved.

<div style=\"page-break-after: always\"></div>

A total of 1.530 patients were screened for the study. Of these, 841 patients were screen failed, most commonly for not meeting inclusion/exclusion criteria. A total of 689 patients were randomly assigned to study drug and initiated the Induction Study Period (342 patients in the CT-P16 treatment group and 347  patients  in  the  EU-Avastin  treatment  group).  Of  these,  499  (72.4%)  patients  completed  the Induction Study Period (258 [75.4%] in the CT-P16 treatment group and 241 [69.5%] in the EU-Avastin treatment group). A total of 466 (67.6%) patients initiated the Maintenance Study Period (239 [69.9%] patients in the CT-P16 treatment group and 227 [65.4%] patients in the EU-Avastin treatment group). Of these, 392 (56.9%) patients discontinued the Maintenance Study Period (206 [60.2%] patients in CT-P16 treatment group and 186 [53.6%] patients in EU-Avastin treatment group). Overall, the most common reason for discontinuation during both the induction and maintenance periods was PD. The number  of  patients  discontinuing  due  to  PD  during  the  Induction  Period  was  slightly  higher  in  the EU-Avastin  group  than  the  CT-P16  group;  however,  during  the  Maintenance  Period,  the  number  of patients discontinuing due to PD was conversely higher in the CT-P16 group. Overall, the reasons for discontinuation were balanced between treatment groups.

The reason for ending participation in the study was death in a total of 332 patients. Among these patients, the reported reason for death was disease progression in 220 patients (110 patients in the CT-P16 group and 110 patients in the EU-Avastin group), adverse event in 37 patients (17 patients in the CT-P16 group and 20 patients in the EU-Avastin group), concurrent illness in 7 patients (3 patients in the CT-P16 group and 4 patients in the EU-Avastin group), unknown in 28 patients (13 patients in the CT-P16 group and 15 patients in the EU-Avastin group), and other in 40 patients (21 patients in the CT-P16 group and 19 patients in the EU-Avastin group).

A total of 68 (9.9%) patients had at least 1 major protocol deviation and are consequently not included in the PP population. The most frequently reported major protocol deviation was missing primary efficacy assessment (21 [6.1%] patients and 39 [11.2%] patients in the CT-P16 and EU-Avastin treatment groups, respectively). This imbalance has been taken into consideration through tipping point analyses. The applicant was also requested to clarify reasons behind the notable imbalance between treatment groups. In the D120 responses, the applicant clarified that an imbalance between the treatment groups was particularly observed in missing primary efficacy assessment due to 'patient withdrawal' (1 [0.3%] patient and 14 [4.0%] patients in the CT-P16 and EU-Avastin treatment groups, respectively). Although the  difference  between  groups  was  in  itself  not  completely  insubstantial,  it  was  agreed  that  the distribution of these withdrawals across sites, with mostly single withdrawals for any given centre, is consistent with the imbalance occurring by chance.

There were 12 amendments to the original study protocol. In addition to one global protocol amendment, a number of country-specific amendments were introduced into the study protocol. Of the 11 countryspecific amendments, 6 are dated prior to enrolment of first patient into the study. Overall, these are not considered to have any significant effect on the reliability or integrity of the study.

Based on major protocol deviations  reported by  the  applicant,  no  instances  of  significant  GCP  noncompliance were identified. The study was not subject to GCP inspections by regulatory authorities.

The study enrolled a predominantly Caucasian population. Median age was 62 years, 35% were female and  65%  male,  and  69%  were  either  former  or  current  smokers.  Disease  status  at  baseline  was metastatic in 92% of patients. Two thirds of the participants were enrolled in EMEA regions. Despite the criticism of possible over-stratification, the treatment groups were in good balance with respect to the stratification factors, and overall, no significant imbalances were noted between the treatment groups with respect to demographic and baseline characteristics.

The numbers of subjects in the ITT population correspond to the pre-defined sample size (339 in each group).  The  overall  proportion  (90.1  %)  of  subjects  considered  to  comprise  the  PP  population  is reasonable given the importance of protocol-compliance in an equivalence setting. There is, however, a

<div style=\"page-break-after: always\"></div>

notable imbalance between treatment groups with respect to the proportion of subjects excluded from the PP population, in particular due to missing primary efficacy assessment. As indicated above, the applicant provided adequate clarification regarding the imbalance.

## Efficacy data and additional analyses

Study CT-P16 3.1 met its primary endpoint. In the ITT population, the risk difference in ORR during the Induction Period was 0.40%, and the 95% confidence interval [-7.02 - 7.83] was contained within the pre-specified equivalence margin of -12.5 - 12.5. The reported ORR's (42.40% [95% CI: 37.16 - 47.64] for CT-P16 and 42.07% [95% CI: 36.88 - 47.27] for EU-Avastin) are in line with those reported in other recent trials for bevacizumab biosimilars.

The number of patients with missing primary efficacy assessment and hence excluded from Per Protocol population was considerably lower for CT-P16 than EU-Avastin (21 [6.1%] vs. 39 [11.2%]). In the ITT analyses  these  missing  assessments  are  defaulted  to  non-response  which  contributes  to  the comparison between the treatment groups.

In addition to central review (central independent reviewer) of ORR during the Induction Study Period, as a sensitivity analysis the ORR during Induction Study Period was also reviewed on local level by investigators. In these analyses, the point estimates for the treatment difference were larger than in the central review, although the 95% CI's were still contained within the pre-specified equivalence margin. The applicant was requested to explain the difference, and in its response to the D120 LoQ, the applicant elaborated on local and central tumour assessment and explained differences thereof as requested. Additionally, according to a post-hoc analysis conducted by the applicant, local and central assessment showed similar extent of concordance between the two treatment groups (79.82% and 78.67% for CT-P16  and  EU-Avastin,  respectively).  Therefore,  it  is  considered  implausible  that  the  observed differences impair conclusion on biosimilarity, and no further concern is raised in this regard.

Tipping point analysis was conducted (using central review data) in the ITT population to evaluate the sensitivity of conclusion to the missing data (no response evaluation or evaluated as 'NE') assumptions. According to the applicant, the differences in the imputed number of responders of up to 15 did not alter the conclusion from the primary analysis that appears hence to be robust and not significantly impacted by missing data. The applicant states that these analyses were conducted under Missing Not at Random (MNAR) scenarios: imputation was done by gradually shifting the number of responders by treatment group to make MNAR scenarios.

In response to D120 LoQ, the applicant provided a summary of reported reasons for missing efficacy assessment and analyses that correspond to missing at random assumption and discussed whether or not the reasons for the assessment being missing is predictive of the outcome. Lack of post-baseline tumour assessment due to death as the reported reason was somewhat more common in EU-Avastin group as compared with CT-P16. Even larger was the difference between number of patients without post-baseline tumour assessment due to patient withdrawal. Although speculative, these differences may be due to a chance imbalance between the treatment groups in the underlying life expectancy. While it is questionable whether early deaths, treatment withdrawals and losses to follow-up can be considered as uninformative about the likelihood of response as per RECIST v1.1, the applicant's missing-at-random analysis provides a helpful benchmark: Whereas the primary analysis may have underestimated the ORR of  EU-Avastin  as  compared  with  CT-P16  by  considering  all  of  the  early  deaths  and  withdrawals  as evidence of non-response, the missing at random analysis corresponds to a somewhat opposite scenario that likely is overly optimistic about EU-Avastin's ORR relative to CT-P16. Both analyses lead to the same conclusion concerning similar efficacy.

<div style=\"page-break-after: always\"></div>

Based on the analysis provided in response to D120 LoQ, the distribution and patterns of individual target tumour size % changes during the induction period, based on centralised assessment of radiographs, were visually similar between CT-P16 and EU-Avastin. Not only were the proportions of responders as RECIST v1.1 similar in the two treatment groups but also the degree of shrinkage (or growth) among responders and non-responders appeared similar in both treatment groups.

The concordance of local and central assessment of tumour response can be considered acceptable and in line with the level concordance typically reported in NSCLC clinical trials applying RECIST 1.1.

The post-hoc analysis of ORR by treatment cycle showed similar response rates between the treatment groups in the ITT population. A difference of about 4% was noted in the PP population for Induction Cycle 6, but the 95% CI's for the Induction Cycle 6 risk differences were contained with the pre-specified equivalence margin for both populations.

Analyses for time-dependent endpoints (PFS, OS) were provided within the applicant's response to the D120 LoQ and additional PFS analyses were provided in response to the D180 LoQ. In general, the analyses,  following  a  data  lock  when  the  last  enrolled  patient  had  completed  1  year  of  follow-up, demonstrate very similar results in both treatment groups and can in principle be considered to provide additional support for the claim of biosimilarity between CT-P16 and EU-Avastin.

Changes on quality of life -related endpoints were generally small, with high interindividual variability. No robust conclusion can be made, but no concerning differences between treatment groups can be identified.  The  worsening  alopecia  and  peripheral  neuropathy  can  reasonably  be  ascribed  to  the concomitant chemotherapy.

Based on a forest plot for risk difference based on ITRC ORR by stratification factors as well as other relevant subgroups, the results with respect to absolute response rates or treatment differences appear consistent across the subgroups explored.

## 2.4.7. Conclusions on the clinical efficacy

Clinical efficacy data to support biosimilarity of CT-P16 with EU-Avastin stems from the ongoing study CT-P16 3.1, conducted in patients with metastatic or recurrent nsNSCLC. The design and other general characteristics of the study are considered fit for the purpose of demonstrating biosimilarity. The primary endpoint was ORR (based on BOR) during the Induction Study Period. For the ITT and the PP populations, the reported CT-P16 - EU-Avastin risk differences of 0.40 (95% CI -7.02, 7.83) and -1.90 (95% CI 9.80, 6.00), respectively, were entirely contained within the pre-specified equivalence margin of -12.5 to 12.5. As such, the primary analysis can be considered to support biosimilarity, and available sensitivity analyses support this view. The analyses for time-dependent endpoints (PFS, OS) can also be considered supportive of biosimilarity.

In conclusion, CT-P16 can be considered biosimilar to EU-Avastin from a clinical efficacy perspective.

## 2.4.8. Clinical safety

The safety information is based primarily on data from Study CT-P16 3.1 in nsNSCLC patients, from Study CT-P16 1.1 in healthy subjects (pivotal PK study) and supportive information from CT-P16 1.2 in healthy Japanese subjects. Study CT-P16 3.1 in nsNSCLC patients is ongoing and has been completed up to 1 year from the last enrolled patient. Clinical data up to the cut-off date (21 September 2021) has been provided by the applicant that includes complete data for all patients through Induction Study Period  and  data  for  a  total  of  148  (21.5%)  patients  who  have  completed  1  year  of  treatment  ( ≥ Maintenance Cycle 12).

<div style=\"page-break-after: always\"></div>

## 2.4.8.1. Patient exposure

## Overall extent of exposure

The clinical Safety Population includes data from 876 subjects; 689 nsNSCLC patients in Study CT-P16 3.1, 141 healthy male subjects in Study CT-P16 1.1 and 46 healthy male subjects in Study CT-P16  1.2.  Patients  with  nsNSCLC  received  either  CT-P16  or  EU-Avastin  (15  mg/kg)  every 3 weeks up to 18 weeks (6 cycles) in combination therapy with paclitaxel and carboplatin (6 cycles [at least 4 cycles]) during the Induction Study Period. Following the combination therapy, patients continued with CT-P16 or EU-Avastin (15 mg/kg) every 3 weeks as monotherapy in the Maintenance Study Period until  disease  progression  or  intolerable  toxicity,  whichever  occurred  first.  In  addition,  187  healthy subjects received a single dose (5 mg/kg) of CT-P16, EU-Avastin or US-Avastin in studies CT-P16 1.1 and 1.2.

## Exposure in Study CT-P16 3.1

The number of patients who received the study drug during the Induction Study Period and up to the maintenance cycle 12 is summarised in Table 24 and the number of patients that received chemotherapy during the Induction Study Period in Table 25.

Table 24. Overall Exposure to CT-P16 or EU-Avastin in Study CT-P16 3.1 up to the Maintenance Cycle 12 (Safety Population)

|                        | CT-P16 (N-345)   | EU-Avastin (N=344)   | Total (N=689)   |
|------------------------|------------------|----------------------|-----------------|
| InductionStudvPeriod   |                  |                      |                 |
| Induction Cycle 1      | 345 (100.0)      | 344 (100.0)          | 689 (100.0)     |
| Induction Cycle 2      | 330 (95.7)       | 317 (92.2)           | 647 (93.9)      |
| Induction Cycle 3      | 309 (89.6)       | 277 (80.5)           | 586 (85.1)      |
| Induction Cycle 4      | 292 (84.6)       | 269 (78.2)           | 561 (81.4)      |
| Induction Cycle 5      | 272 (78.8)       | 248 (72.1)           | 520 (75.5)      |
| Induction Cycle 6      | 263 (76.2)       | 240 (69.8)           | 503 (73.0)      |
| MaintenanceStudyPeriod |                  |                      |                 |
| Maintenance Cycle 1    | 242 (70.1)       | 224 (65.1)           | 466 (67.6)      |
| Maintenance Cycle 2    | 234 (67.8)       | 217 (63.1)           | 451 (65.5)      |
| Maintenance Cycle 3    | 223 (64.6)       | 204 (59.3)           | 427 (62.0)      |
| Maintenance Cycle 4    | 184 (53.3)       | 153 (44.5)           | 337 (48.9)      |
| Maintenance Cycle 5    | 175 (50.7)       | 150 (43.6)           | 325 (47.2)      |
| Maintenance Cycle 6    | 167 (48.4)       | 140 (40.7)           | 307 (44.6)      |
| Maintenance Cycle 7    | 133 (38.6)       | 108 (31.4)           | 241 (35.0)      |
| Maintenance Cycle S    | 126 (36.5)       | 107 (31.1)           | 233 (33.8)      |
| Maintenance Cycle 9    | 118 (34.2)       | 105 (30.5)           | 223 (32.4)      |
| Maintenance Cycle 10   | 84 (24.3)        | 88 (25.6)            | 172 (25.0)      |
| Maintenance Cycle 11   | 78 (22.6)        | 84 (24.4)            | 162 (23.5)      |
| Maintenance Cycle 12   | 70 (20.3)        | 78 (22.7)            | 148 (21.5)      |

date (21 September 2021) were analysed under the CT-P16 treatment group.

<div style=\"page-break-after: always\"></div>

Table 25. Overall Exposure to Chemotherapy in Study CT-P16 3.1 during the Induction Study Period (Safety Population)

|                   | CT-P16 (N=345)   | EU-Avastin (N=344)   | Total (N=689)   |
|-------------------|------------------|----------------------|-----------------|
| Paclitaxel        |                  |                      |                 |
| Induction Cycle 1 | 345 (100.0)      | 344 (100.0)          | 689 (100.0)     |
| Induction Cycle 2 | 330 (95.7)       | 318 (92.4)           | 648 (94.0)      |
| Induction Cycle 3 | 309 (89.6)       | 278 (80.8)           | 587 (85.2)      |
| Induction Cycle 4 | 293 (84.9)       | 269 (78.2)           | 562 (81.6)      |
| Induction Cycle 5 | 253 (73.3)       | 238 (69.2)           | 491 (71.3)      |
| Induction Cycle 6 | 242 (70.1)       | 224 (65.1)           | 466 (67.6)      |
| Carboplatin       |                  |                      |                 |
| Induction Cycle 1 | 345 (100.0)      | 344 (100.0)          | 689 (100.0)     |
| Induction Cycle 2 | 330 (95.7)       | 318 (92.4)           | 648 (94.0)      |
| Induction Cycle 3 | 309 (89.6)       | 277 (80.5)           | 586 (85.1)      |
| Induction Cycle 4 | 293 (84.9)       | 269 (78.2)           | 562 (81.6)      |
| Induction Cycle 5 | 256 (74.2)       | 241 (70.1)           | 497 (72.1)      |
| Induction Cycle 6 | 249 (72.2)       | 226 (65.7)           | 475 (68.9)      |

Note: Patients who received at least 1 dose of CT-P16 at any time during the treatment period up to cut-off date (21 September 2021) were analysed under the CT-P16 treatment group.

Administered dose intensities during the induction and maintenance study periods in the Study CT-P16 3.1 is summarised in Table 26 and Table 27.

Table 26. Dose Intensity During the Induction Study Period (Safety Population)

|                                                                        | CT-P16 (N=345)                                                         | EU-approved Avastin (N=344)                                            | Total (N=689)                                                          |
|------------------------------------------------------------------------|------------------------------------------------------------------------|------------------------------------------------------------------------|------------------------------------------------------------------------|
| Administered doseintensity during theInductionStudyPeriod (mg/kg/week) | Administered doseintensity during theInductionStudyPeriod (mg/kg/week) | Administered doseintensity during theInductionStudyPeriod (mg/kg/week) | Administered doseintensity during theInductionStudyPeriod (mg/kg/week) |
|                                                                        | 345                                                                    | 344                                                                    | 689                                                                    |
| Mean (standard deviation)                                              | 4.69 (0.410)                                                           | 4.73 (0.366)                                                           | 4.71 (0.389)                                                           |
| Median(minimum,maximum)                                                | 4.87 (2.6, 5.4)                                                        | 4.88 (3.3, 5.3)                                                        | 4.88 (2.6, 5.4)                                                        |
| Relative dose intensity during the Induction Study Period (%)          | Relative dose intensity during the Induction Study Period (%)          | Relative dose intensity during the Induction Study Period (%)          | Relative dose intensity during the Induction Study Period (%)          |
| 11                                                                     | 345                                                                    | 344                                                                    | 689                                                                    |
| Mean (standard deviation)                                              | 93.83 (8.208)                                                          | 94.56 (7.322)                                                          | 94.20 (7.781)                                                          |
| Median (minimum, maximum)                                              | 97.37 (51.9, 107.7)                                                    | 97.67 (66.2, 105.0)                                                    | 97.67 (51.9, 107.7)                                                    |

Abbreviation:PP,Per-Protocol.

<div style=\"page-break-after: always\"></div>

Table 27. Dose Intensity During the Maintenance Study Period (Safety Population)

|                                                        | CT-P16 (N=345)                                         | EU-approved Avastin (N=344)                            | Total (N=689)       |
|--------------------------------------------------------|--------------------------------------------------------|--------------------------------------------------------|---------------------|
| 11                                                     | 242                                                    | 224                                                    | 466                 |
| Mean (standard deviation)                              | 4.84 (0.299)                                           | 4.84 (0.310)                                           | 4.84 (0.304)        |
| Median (minimum, maximum)                              | 4.97 (3.2, 5.2)                                        | 4.99 (3.3, 5.3)                                        | 4.98 (3.2, 5.3)     |
| Relative dose intensity (%o) during maintenance cycles | Relative dose intensity (%o) during maintenance cycles | Relative dose intensity (%o) during maintenance cycles |                     |
| 11                                                     | 242                                                    | 224                                                    | 466                 |
| Mean (standard deviation)                              | 96.78 (5.981)                                          | 96.82 (6.194)                                          | 96.80 (6.077)       |
| Median (minimum,maximum)                               | 99.36 (64.9, 103.5)                                    | 99.82 (66.7, 105.0)                                    | 99.63 (64.9, 105.0) |

The mean (SD) administered dose intensity of paclitaxel in the Study CT-P16 3.1 was 61.95 (6.493) mg/m 2 /week and 62.35 (6.087) mg/m 2 /week, and the mean (SD) relative dose intensity was 94.59% (7.702) and 95.24% (7.194) in the CT-P16 and EU-Avastin treatment groups, respectively.

The mean (SD) administered dose intensity of carboplatin in the Study CT-P16 3.1 was 1.85 (0.200) AUC/week and 1.86 (0.181) AUC/week, and the mean (SD) relative dose intensity was 93.60% (8.464) and 94.14% (7.575) in the CT-P16 and EU-Avastin treatment groups, respectively.

## Baseline Demographics in Study CT-P16 3.1

For the demographics and baseline characteristics of Study CT-P16 3.1, please see section 2.4.5.

The  most  frequently  reported  medical  history  SOCs  were  vascular  disorder  (157  [45.9%]  and 157 [45.2%] patients), gastrointestinal disorders (100 [29.2%] and 104 [30.0%] patients), and surgical and medical procedures (107 [31.3%] patients and 86 [24.8%] patients) in CT-P16 and EU-Avastin treatment groups, respectively. The most frequently reported medical history PTs were hypertension (119 [34.8%] and 125 [36.0%] patients), renal cyst (38 [11.1%] and 39 [11.2%] patients, and chronic obstructive  pulmonary disease (34 [9.9%] and 41 [11.8%] patients) in the CT-P16 and EU-Avastin treatment groups, respectively.

Overall, 64 (9.3%) patients (27 [7.9%] patients and 37 [10.7%] patients in the CT-P16 and EU-Avastin treatment groups, respectively) had at least 1 previous surgical procedure. The most frequently reported previous surgical procedure was lung lobectomy (20 [5.8%] patients and 32 [9.2%] patients in the CT-P16 and EU-Avastin treatment groups, respectively).

Overall,  83  (12.0%)  patients  (41  [12.0%]  patients  and  42  [12.1%]  patients  in  the  CT-P16  and EU-Avastin treatment groups, respectively) had at  least 1 previous radiotherapy. Most of previous radiotherapy was indicated for metastatic nsNSCLC. The most frequently reported lesion location of previous  radiotherapy  was  brain  (30  [8.8%]  patients  and  28  [8.1%]  patients  in  the  CT-P16  and EU-Avastin treatment groups, respectively).

Overall, 16 (2.3%) patients (6 [1.8%] patients and 10 [2.9%] patients in the CT-P16 and EU-Avastin treatment  groups,  respectively)  had  at  least  1  previous  anti-cancer  systemic  therapy.  Cytotoxic chemotherapy was the only type of previous anti-cancer systemic therapy (6 [1.8%] patients and 10 [2.9%] patients in the CT-P16 and EU-Avastin treatment groups, respectively). The most frequently reported previous anti-cancer systemic therapy was cisplatin (4 [1.2%] patients and 6 [1.7%] patients in the CT-P16 and EU-Avastin treatment groups, respectively).

<div style=\"page-break-after: always\"></div>

## 2.4.8.2. Adverse events

An overview of the adverse events in Study CT-P16 3.1 is shown in Table 28.

Table 28. Overview of Adverse Events in the Study CT-P16 3.1 (Safety Population)

|                                                                            | 2\"d CSR (Cut-off Date: 21 September 2021)   | 2\"d CSR (Cut-off Date: 21 September 2021)   | 2\"d CSR (Cut-off Date: 21 September 2021)   | 2\"d CSR (Cut-off Date: 21 September 2021)   | 2\"d CSR (Cut-off Date: 21 September 2021)   | 2\"d CSR (Cut-off Date: 21 September 2021)   |
|----------------------------------------------------------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|
|                                                                            | Induction Study Period                      | Induction Study Period                      | Maintenance Study Period                    | Maintenance Study Period                    | Whole Study Period                          | Whole Study Period                          |
|                                                                            | CT-P16 (N=345)                              | EU- Avastin (N=344)                         | CT-P16 (N=345)                              | EU- Avastin (N=344)                         | CT-P16 (N=345)                              | EU- Avastin (N=344)                         |
| Total number of TEAEs                                                      | 2284                                        | 2032                                        | 665                                         | 535                                         | 2957                                        | 2576                                        |
| Number (%) of subjects with≥1 TEAE                                         | 328 (95.1)                                  | 315 (91.6)                                  | 175 (50.7)                                  | 155 (45.1)                                  | 332 (96.2)                                  | 320 (93.0)                                  |
| Related                                                                    | 144 (41.7)                                  | 147 (42.7)                                  | 82 (23.8)                                   | 76 (22.1)                                   | 178 (51.6)                                  | 174 (50.6)                                  |
| Unrelated                                                                  | 313 (90.7)                                  | 300 (87.2)                                  | 147 (42.6)                                  | 126 (36.6)                                  | 318 (92.2)                                  | 307 (89.2)                                  |
| Number (%) of subjects with ≥ 1 grade 3 or higher TEAE                     | 121 (35.1)                                  | 119 (34.6)                                  | 49 (14.2)                                   | 34 (9.9)                                    | 151 (43.8)                                  | 144 (41.9)                                  |
| Related                                                                    | 37 (10.7)                                   | 42 (12.2)                                   | 16 (4.6)                                    | 10 (2.9)                                    | 52 (15.1)                                   | 49 (14.2)                                   |
| Unrelated                                                                  | 100 (29.0)                                  | 94 (27.3)                                   | 36 (10.4)                                   | 24 (7.0)                                    | 126 (36.5)                                  | 115 (33.4)                                  |
| Number (%) of subjects with≥1 TESAE                                        | 48 (13.9)                                   | 55 (16.0)                                   | 20 (5.8)                                    | 22 (6.4)                                    | 69 (20.0)                                   | 73 (21.2)                                   |
| Related                                                                    | 14 (4.1)                                    | 19 (5.5)                                    | 4 (1.2)                                     | 4 (1.2)                                     | 18 (5.2)                                    | 23 (6.7)                                    |
| Unrelated                                                                  | 38 (11.0)                                   | 38 (11.0)                                   | 16 (4.6)                                    | 18 (5.2)                                    | 55 (15.9)                                   | 54 (15.7)                                   |
| Number (%) of subjects with ≥ 1 TEAE leading to study drug discontinuation | 34 (9.9)                                    | 35 (10.2)                                   | 21 (6.1)                                    | 19 (5.5)                                    | 55 (15.9)                                   | 55 (16.0)                                   |
| Related                                                                    | 12 (3.5)                                    | 15 (4.4)                                    | 10 (2.9)                                    | 6 (1.7)                                     | 22 (6.4)                                    | 21 (6.1)                                    |
| Unrelated                                                                  | 22 (6.4)                                    | 20 (5.8)                                    | 11 (3.2)                                    | 13 (3.8)                                    | 33 (9.6)                                    | 34 (9.9)                                    |
| Number (%) of subjects with ≥ 1 TEAE leading to death                      | 16 (4.6)                                    | 16 (4.7)                                    | 6 (1.7)                                     | 8 (2.3)                                     | 23 (6.7)                                    | 24 (7.0)                                    |
| Related                                                                    | 3 (0.9)                                     | 6 (1.7)                                     | 0                                           | 1 (0.3)                                     | 3 (0.9)                                     | 7 (2.0)                                     |
| Unrelated                                                                  | 13 (3.8)                                    | 10 (2.9)                                    | 6 (1.7)                                     | 7 (2.0)                                     | 20 (5.8)                                    | 17 (4.9)                                    |

Note: At each level of summarization, subjects were counted once if they reported 1 or more events. Numbers that changed from the 1\"t CSR to the 2nd CSR are highlighted in yellow.

1 Whole Study Period includes data from Follow-up Period in addition to Induction Study Period and Maintenance Study Period

## Study CT-P16 3.1

The most common adverse events in Study CT-P16 3.1 are shown in Table 29.

At least 1 TEAE was reported for 96.2% and 93.0% of patients in the CT-P16 and EU-Avastin groups, respectively. The most frequently reported TEAE was alopecia (220 [63.8%] patients and 218 [63.4%] patients in the CT-P16 and EU-Avastin treatment groups, respectively).

<div style=\"page-break-after: always\"></div>

Overall, the frequency of TEAEs was somewhat higher in the CT-P16 group compared to EU-Avastin group both during the induction (95.1% vs 91.6%) and maintenance study periods (50.7% vs 45.1%). At least 5% difference was reported for CT-P16 vs. EU-Avastin in SOCs blood and lymphatic system disorders (50.4% vs. 42.2%), general disorders and administration site conditions (41.2% vs. 34.9%) and nervous system disorders (52.5% vs. 47.4%). Most notably, in SOC blood and lymphatic system disorders, anaemia was reported for 31.6% vs 27.0%, leukopenia for 8.4% vs 6.7%, neutropenia for 21.7% vs 16.0% and thrombocytopenia for 18.3% vs 13.7% of patients in the CT-P16 and EU-Avastin groups, respectively.

Table 29. Summary of TEAEs Reported for at Least 5% of Patients by PT in Either Treatment Group by SOC and PT in Study CT-P16 3.1 (Safety Population)

| Period                                               | Induction Study Period   | Induction Study Period   | Maintenance Study Period   | Maintenance Study Period   | Whole Study Periodl   | Whole Study Periodl   |
|------------------------------------------------------|--------------------------|--------------------------|----------------------------|----------------------------|-----------------------|-----------------------|
| SOC PT                                               | CT-P16 (N=345)           | EU- Arastin (N=344)      | CT-P16 (N=345)             | EU- Avastin (N=344)        | CT-P16 (N=345)        | EU- Avastin (N=344)   |
| Total numberof TEAEs                                 | 2284                     | 2032                     | 665                        | 535                        | 2957                  | 2576                  |
| Number (%) of patients with atleast l TEAE           | 328 (95.1)               | 315 (91.0)               | 175 (50.7)                 | 155 (45.1)                 | 332 (96.2)            | 320 (93.0)            |
| Blood And Lymphatic System Disorders                 | 166 (48.1)               | 143 (41.6)               | 30 (8.7)                   | 19 (5.5)                   | 174 (50.4)            | 145 (42.2)            |
| Anaemia                                              | 102 (29.6)               | 91 (26.5)                | 16 (4.6)                   | 12 (3.5)                   | 109 (31.6)            | 93 (27.0)             |
| Leukopenia                                           | 26 (7.5)                 | 23 (6.7)                 | 4 (1.2)                    | 3 (0.9)                    | 29 (8.4)              | 23 (6.7)              |
| Neutropenia                                          | 71 (20.6)                | 54 (15.7)                | 7 (2.0)                    | 5 (1.5)                    | 75 (21.7)             | 55 (16.0)             |
| Thrombocytopenia                                     | 56 (16.2)                | 45 (13.1)                | 11 (3.2)                   | 5 (1.5)                    | 63 (18.3)             | 47 (13.7)             |
| Gastrointestinal Disorder's                          | 133 (38.6)               | 133 (38.7)               | 45 (13.0)                  | 28 (8.1)                   | 155 (44.9)            | 140 (40.7)            |
| Constipation                                         | 24 (7.0)                 | 27 (7.8)                 | 15 (4.3)                   | 8 (2.3)                    | 38 (11.0)             | 33 (9.6)              |
| Diarrhoea                                            | 39 (11.3)                | 41 (11.9)                | 8 (2.3)                    | 8 (2.3)                    | 43 (12.5)             | 47 (13.7)             |
| Nausea                                               | 69 (20.0)                | 65 (18.9)                | 7 (2.0)                    | 2 (0.6)                    | 74 (21.4)             | 65 (18.9)             |
| Vomiting                                             | 25 (7.2)                 | 25 (7.3)                 | 6 (1.7)                    | 6 (1.7)                    | 29 (8.4)              | 30 (8.7)              |
| General disorders and administration site conditions | 115 (33.3)               | 99 (28.8)                | 55 (15.9)                  | 33 (9.0)                   | 142 (41.2)            | 120 (34.9)            |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| Period                                          | Induction Study Period   | Induction Study Period   | Maintenance Study Period   | Maintenance Study Period   | Whole Study Periodl   | Whole Study Periodl   |
|-------------------------------------------------|--------------------------|--------------------------|----------------------------|----------------------------|-----------------------|-----------------------|
| SOC PT                                          | CT-P16 (N=345)           | EU- Avastin (N=344)      | CI-P16 (N=345)             | EU- Avastin (N=344)        | CT-P16 (N=345)        | EU- Avastin (N=344)   |
| Asthenia                                        | 53 (15.4)                | 46 (13.4)                | 15 (4.3)                   | (9:7) 6                    | 63 (18.3)             | 54 (15.7)             |
| Fatigue                                         | 37 (10.7)                | 33 (9.6)                 | 15 (4.3)                   | 10 (2.9)                   | 45 (13.0)             | 39 (11.3)             |
| Pyrexia                                         | 14 (4.1)                 | 14 (4.1)                 | 12 (3.5)                   | 5 (1.5)                    | 22 (6.4)              | 17 (4.9)              |
| Infections and infestations                     | 63 (18.3)                | 57 (16.6)                | 31 (9.0)                   | 39 (11.3)                  | 85 (24.6)             | 88 (25.6)             |
| Pneumonia                                       | 13 (3.8)                 | 11 (3.2)                 | 2 (0.6)                    | 8 (2.3)                    | 15 (4.3)              | 18 (5.2)              |
| Urinary tract infection                         | 13 (3.8)                 | 6 (1.7)                  | 10 (2.9)                   | 4 (1.2)                    | 20 (5.8)              | 9 (2.6)               |
| Investigations                                  | 105 (30.4)               | 94 (27.3)                | 51 (14.8)                  | 42 (12.2)                  | 130 (37.7)            | 115 (33.4)            |
| Alanine aminotransferase increased              | 14 (4.1)                 | 14 (4.1)                 | 11 (3.2)                   | 9 (2.6)                    | 23 (6.7)              | 19 (5.5)              |
| Aspartate aminotransferase increased            | 12 (3.5)                 | 14 (4.1)                 | 12 (3.5)                   | 4 (1.2)                    | 22 (6.4)              | 17 (4.9)              |
| Gamma- glutamyltransferase increased            | 12 (3.5)                 | 10 (2.9)                 | 11 (3.2)                   | (9:7) 6                    | 22 (6.4)              | 19 (5.5)              |
| Neutrophil count decreased                      | 16 (4.6)                 | 19 (5.5)                 | 0                          | 1 (0.3)                    | 16 (4.6)              | 19 (5.5)              |
| Platelet count decreased                        | 27 (7.8)                 | 23 (6.7)                 | 5 (1.4)                    | 3 (0.9)                    | 29 (8.4)              | 23 (6.7)              |
| Weight decreased                                | 21 (6.1)                 | 21 (6.1)                 | 15 (4.3)                   | 10 (2.9)                   | 34 (9.9)              | 28 (8.1)              |
| Metabolism and nutrition disorders              | 84 (24.3)                | 73 (21.2)                | 41 (11.9)                  | 28 (8.1)                   | 104 (30.1)            | 88 (25.0)             |
| Decreased Appetite                              | 30 (8.7)                 | 34 (9.9)                 | 12 (3.5)                   | 11 (3.2)                   | 42 (12.2)             | 41 (11.9)             |
| Musculoskeletal and connective tissue disorders | 74 (21.4)                | 61 (17.7)                | 25 (7.2)                   | 25 (7.3)                   | 90 (26.1)             | 78 (22.7)             |
| Arthralgia                                      | 28 (8.1)                 | 20 (5.8)                 | 7 (2.0)                    | 8 (2.3)                    | 34 (9.9)              | 28 (8.1)              |
| Myalgia                                         | 11 (3.2)                 | 15 (4.4)                 | 4 (1.2)                    | 5 (1.5)                    | 15 (4.3)              | 18 (5.2)              |
| Pain in extremity                               | 16 (4.6)                 | 15 (4.4)                 | 2 (0.6)                    | 4 (1.2)                    | 18 (5.2)              | 19 (5.5)              |
| Nervous system disorders                        | 173 (50.1)               | 152 (44.2)               | 19 (5.5)                   | 24 (7.0)                   | 181 (52.5)            | 163 (47.4)            |
| Headache                                        | 15 (4.3)                 | 10 (2.9)                 | 6 (1.7)                    | 11 (3.2)                   | 21 (6.1)              | 20 (5.8)              |
| Neuropathy peripheral                           | 52 (15.1)                | 47 (13.7)                | 3 (0.9)                    | 6 (1.7)                    | 53 (15.4)             | 50 (14.5)             |
| Paraesthesia                                    | 34 (9.9)                 | 28 (8.1)                 | 1 (0.3)                    | 1 (0.3)                    | 35 (10.1)             | 29 (8.4)              |
| Peripheral sensory neuropathy                   | 33 (9.6)                 | 34 (9.9)                 | 3 (0.9)                    | 3 (0.9)                    | 35 (10.1)             | 35 (10.2)             |
| Renal and urinary disorders                     | 33 (9.0)                 | 36 (10.5)                | 30 (8.7)                   | 29 (8.4)                   | 59 (17.1)             | 56 (16.3)             |
| Proteinuria                                     | 19 (5.5)                 | 20 (5.8)                 | 26 (7.5)                   | 23 (6.7)                   | 41 (11.9)             | 37 (10.8)             |
| Respiratory, thoracic and mediastinal disorders | 61 (17.7)                | 59 (17.2)                | 31 (9.0)                   | 33 (9.0)                   | 82 (23.8)             | 80 (23.3)             |
| Cough                                           | 12 (3.5)                 | 9 (2.6)                  | 7 (2.0)                    | 16 (4.7)                   | 17 (4.9)              | 24 (7.0)              |
| Dyspnoea                                        | 7 (2.0)                  | 12 (3.5)                 | 16 (4.6)                   | 10 (2.9)                   | 22 (6.4)              | 21 (6.1)              |

<div style=\"page-break-after: always\"></div>

| Period                                 | Induction Study Period   | Induction Study Period   | Maintenance StudyPeriod   | Maintenance StudyPeriod   | Whole Srudy Period   | Whole Srudy Period   |
|----------------------------------------|--------------------------|--------------------------|---------------------------|---------------------------|----------------------|----------------------|
| SOC PT                                 | CT-P16 (N=345)           | EU- Arastin (N=344)      | CT-P16 (N=345)            | EU- Avastin (N=344)       | CT-P16 (N=345)       | EU- Avastin (N=344)  |
| Epistaxis                              | 14 (4.1)                 | 18 (5.2)                 | 0                         | 2 (0.6)                   | 14 (4.1)             | 19 (5.5)             |
| Skin and subcutaneous tissue disorders | 229 (66.4)               | 223 (64.8)               | 11 (3.2)                  | 9 (2.0)                   | 231 (67.0)           | 225 (65.4)           |
| Alopecia                               | 220 (63.8)               | 218 (63.4)               | 1 (0.3)                   | 1 (0.3)                   | 220 (63.8)           | 218 (63.4)           |
| Vascular disorders                     | 35 (10.1)                | 36 (10.5)                | 17 (4.9)                  | 11 (3.2)                  | 47 (13.6)            | 39 (11.3)            |
| Hypertension                           | 26 (7.5)                 | 29 (8.4)                 | 13 (3.8)                  | 11 (3.2)                  | 34 (9.9)             | 33 (9.6)             |

Note: TEAEs with PT reported at least 5% of incident rate in either treatment group are summarized. At each level of summarization, patients are counted once if they reported one or more events.

1 Whole Study Period includes data from Follow-up Period in addition to Induction Study Period and MaintenanceStudyPeriod

Abbreviations: PT, preferred term; SOC, system organ class; TEAE, treatment-emergent adverse event

At least 1 related TEAE was reported for 178 (51.6%) and 174 (50.6%) patients in the CT-P16 and the EU-Avastin treatment groups, respectively. The  most commonly  reported related TEAE  by  SOC was blood and lymphatic system disorders (52 [15.1%] and 45 [13.1%] patients, respectively). The most commonly  reported  related  TEAE  by  PT  was  proteinuria  (36  [10.4%]  and  32  [9.3%]  patients, respectively) (Table 30).

<div style=\"page-break-after: always\"></div>

Table 30. Summary of Study Drug-Related TEAEs (Reported for at Least 5% of Patients by PT in Either Treatment Group) by SOC and PT in Study CT-P16 3.1 (Safety Population)

| Period                                   | Induction Study Period   | Induction Study Period   | Maintenance Study Period   | Maintenance Study Period   | Whole Study Period   | Whole Study Period   |
|------------------------------------------|--------------------------|--------------------------|----------------------------|----------------------------|----------------------|----------------------|
| SOC PT                                   | CT-P16 (N=345)           | EU- Avastin (N=344)      | CT-P16 (N=345)             | EU- Avastin (N=344)        | CT-P16 (N=345)       | EU- Avastin (N=344)  |
| Number (%)ofpatients with atleast l TEAE | 328 (95.1)               | 315 (91.0)               | 175 (50.7)                 | 155 (45.1)                 | 332 (96.2)           | 320 (93.0)           |
| Related                                  | 144 (41.7)               | 147 (42.7)               | 82 (23.8)                  | 76 (22.1)                  | 178 (51.6)           | 174 (50.6)           |
| Unrelated                                | 313 (90.7)               | 300 (87.2)               | 147 (42.6)                 | 126 (36.6)                 | 318 (92.2)           | 307 (89.2)           |
| Blood and lymphatic system disorders     | 42 (12.2)                | 38 (11.0)                | 11 (3.2)                   | 13 (3.8)                   | 52 (15.1)            | 45 (13.1)            |
| Anaemia                                  | 22 (6.4)                 | 24 (7.0)                 | 4 (1.2)                    | 7 (2.0)                    | 25 (7.2)             | 29 (8.4)             |
| Neutropenia                              | 11 (3.2)                 | 16 (4.7)                 | 2 (0.6)                    | 5 (1.5)                    | 13 (3.8)             | 18 (5.2)             |
| Thrombocytopenia                         | 15 (4.3)                 | 7 (2.0)                  | 7 (2.0)                    | 3 (0.9)                    | 22 (6.4)             | 9 (2.6)              |
| Renaland urinary disorders               | 18 (5.2)                 | 20 (5.8)                 | 25 (7.2)                   | 22 (6.4)                   | 40 (11.0)            | 36 (10.5)            |
| Proteinuria                              | 16 (4.6)                 | 16 (4.7)                 | 23 (6.7)                   | 21 (6.1)                   | 36 (10.4)            | 32 (9.3)             |
| Skin and subcutaneous tissue disorders   | 31 (9.0)                 | 30 (8.7)                 | 8 (2.3)                    | 4 (1.2)                    | 37 (10.7)            | 34 (9.9)             |
| Alopecia                                 | 23 (6.7)                 | 21 (6.1)                 | 0                          | 0                          | 23 (6.7)             | 21 (6.1)             |
| Vascular disorders                       | 21 (6.1)                 | 21 (6.1)                 | 12 (3.5)                   | 10 (2.9)                   | 31 (9.0)             | 27 (7.8)             |
| Hypertension                             | 18 (5.2)                 | 19 (5.5)                 | 9 (2.6)                    | 10 (2.9)                   | 25 (7.2)             | 25 (7.3)             |

Note: TEAEs with PT reported at least 5% of incident rate in either treatment group are summarized. At each

1 Whole Study Period inchudes data from Follow-up Period in addition to Induction Study Period and Maintenance StudyPeriod

Abbreviations: PT, preferred term; SOC, system organ class: TEAE, treatment-emergent adverse event

Grade ≥ 3 TEAEs was reported for 151 (43.8%) a nd  144  (41.9%)  patients  in  the  CT-P16  and  the EU-Avastin  treatment  groups,  respectively  (Table  36 ). The most common ≥ Grade  3  TEAE  was neutropenia, reported for 36 (10.4%) and 25 (7.3%) patients in the CT-P16 and EU-Avastin groups, respectively. Notably, dyspnoea was reported for 7 vs 0 patients (6 vs 0 during maintenance study period) and pulmonary embolism for 6 vs 3 of patients (2 vs 0 during maintenance study period) in the CT-P16 and EU-Avastin groups, respectively (Table 31).

<div style=\"page-break-after: always\"></div>

Table 31. Summary of TEAEs by Severity of Grade 3 or Higher in Study CT-P16 3.1 (Safety Population)

| Period                                                                                           | Induction Study Period                                                                           | Induction Study Period                                                                           | Maintenance Study Period                                                                         | Maintenance Study Period                                                                         | Whole Study Periodl                                                                              | Whole Study Periodl                                                                              |
|--------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------|
| SOC PT                                                                                           | CT-P16 (N=345)                                                                                   | EU- Avastin (N=344)                                                                              | CT-P16 (N=345)                                                                                   | EU- Avastin (N=344)                                                                              | CT-P16 (N=345)                                                                                   | EU- Avastin (N=344)                                                                              |
| Number (%) ofpatients with≥1 TEAE of grade 3 or higher                                           | 121 (35.1)                                                                                       | 119 (34.6)                                                                                       | 49 (14.2)                                                                                        | 34 (9.9)                                                                                         | 151 (43.8)                                                                                       | 144 (41.9)                                                                                       |
| Grade 3                                                                                          | 86 (24.9)                                                                                        | 82 (23.8)                                                                                        | 37 (10.7)                                                                                        | 22 (6.4)                                                                                         | 103 (29.9)                                                                                       | 94 (27.3)                                                                                        |
| Grade 4                                                                                          | 19 (5.5)                                                                                         | 21 (6.1)                                                                                         | 6 (1.7)                                                                                          | 4 (1.2)                                                                                          | 25 (7.2)                                                                                         | 26 (7.6)                                                                                         |
| Grade 5                                                                                          | 16 (4.6)                                                                                         | 16 (4.7)                                                                                         | 6 (1.7)                                                                                          | 8 (2.3)                                                                                          | 23 (6.7)                                                                                         | 24 (7.0)                                                                                         |
| Grade 3 or higher TEAEs by SOC/PT (reported for≥ 1% of patients by PT in either treatment group) | Grade 3 or higher TEAEs by SOC/PT (reported for≥ 1% of patients by PT in either treatment group) | Grade 3 or higher TEAEs by SOC/PT (reported for≥ 1% of patients by PT in either treatment group) | Grade 3 or higher TEAEs by SOC/PT (reported for≥ 1% of patients by PT in either treatment group) | Grade 3 or higher TEAEs by SOC/PT (reported for≥ 1% of patients by PT in either treatment group) | Grade 3 or higher TEAEs by SOC/PT (reported for≥ 1% of patients by PT in either treatment group) | Grade 3 or higher TEAEs by SOC/PT (reported for≥ 1% of patients by PT in either treatment group) |
| Blood and lymphatic system disorder's                                                            | 54 (15.7)                                                                                        | 50 (14.5)                                                                                        | 4 (1.2)                                                                                          | 1 (0.3)                                                                                          | 58 (16.8)                                                                                        | 51 (14.8)                                                                                        |
| Anaemia                                                                                          | 11 (3.2)                                                                                         | 16 (4.7)                                                                                         | 2 (0.6)                                                                                          | 0                                                                                                | 13 (3.8)                                                                                         | 16 (4.7)                                                                                         |
| Febrile neutropenia                                                                              | 7 (2.0)                                                                                          | 3 (0.9)                                                                                          | 0                                                                                                | 0                                                                                                | 7 (2.0)                                                                                          | 3 (0.9)                                                                                          |
| Leukopenia                                                                                       | 3 (0.9)                                                                                          | 2 (0.6)                                                                                          | 1 (0.3)                                                                                          | 0                                                                                                | 4 (1.2)                                                                                          | 2 (0.6)                                                                                          |
| Neutropenia                                                                                      | 34 (9.9)                                                                                         | 25 (7.3)                                                                                         | 2 (0.6)                                                                                          | 0                                                                                                | 36 (10.4)                                                                                        | 25 (7.3)                                                                                         |

<div style=\"page-break-after: always\"></div>

| Period                                               | Induction Study Period   | Induction Study Period   | Mlaintenance Study Period   | Mlaintenance Study Period   | Whole Study Period   | Whole Study Period   |
|------------------------------------------------------|--------------------------|--------------------------|-----------------------------|-----------------------------|----------------------|----------------------|
| SOC PT                                               | CT-P16 (N=345)           | EU- Avastin (N=344)      | CT-P16 (N=345)              | EU- Avastin (N=344)         | CT-P16 (N=345)       | EU- Avastin (N=344)  |
| Thrombocytopenia                                     | 12 (3.5)                 | 11 (3.2)                 |                             | 1 (0.3)                     | 12 (3.5)             | 12 (3.5)             |
| General disorders and administration site conditions | 16 (4.0)                 | 14 (4.1)                 | 8 (2.3)                     | 3 (0.9)                     | 23 (6.7)             | 18 (5.2)             |
| Asthenia                                             | 4 (1.2)                  | 4 (1.2)                  | 0                           | 1 (0.3)                     | 4 (1.2)              | 5 (1.5)              |
| Fatigue                                              | 6 (1.7)                  | 5 (1.5)                  | 4 (1.2)                     | 0                           | 9 (2.6)              | 6 (1.7)              |
| Infections and infestations                          | 15 (4.3)                 | 16 (4.7)                 | 7 (2.0)                     | 10 (2.9)                    | 22 (6.4)             | 25 (7.3)             |
| COVID-19pneumonia                                    | 1 (0.3)                  | 1 (0.3)                  | 1 (0.3)                     | 3 (0.9)                     | 2 (0.6)              | 4 (1.2)              |
| Pneumonia                                            | 5 (1.4)                  | 10 (2.9)                 | 2 (0.6)                     | 3 (0.9)                     | 7 (2.0)              | 12 (3.5)             |
| Investigations                                       | 20 (5.8)                 | 23 (6.7)                 | 6 (1.7)                     | 1 (0.3)                     | 26 (7.5)             | 24 (7.0)             |
| Neutrophil count decreased                           | 5 (1.4)                  | 11 (3.2)                 | 0                           | 0                           | 5 (1.4)              | 11 (3.2)             |
| Platelet count decreased                             | 5 (1.4)                  | 3 (0.9)                  | 1 (0.3)                     | 0                           | 6 (1.7)              | 3 (0.9)              |
| Weight decreased                                     | 4 (1.2)                  | 1 (0.3)                  | 1 (0.3)                     | 0                           | 5 (1.4)              | 1 (0.3)              |
| Metabolism and nutrition disorders                   | 12 (3.5)                 | 16 (4.7)                 | 3 (0.9)                     | 3 (0.9)                     | 15 (4.3)             | 19 (5.5)             |
| Decreased appetite                                   | 1 (0.3)                  | 3 (0.9)                  |                             | 1 (0.3)                     | 1 (0.3)              | 4 (1.2)              |
| Hypertriglyceridaemia                                | 3 (0.9)                  | 1 (0.3)                  | 1 (0.3)                     | 0                           | 4 (1.2)              | 1 (0.3)              |
| Nervous system disorders                             | 13 (3.8)                 | 10 (2.9)                 | 2 (0.0)                     | 4 (1.2)                     | 15 (4.3)             | 14 (4.1)             |
| Peripheral sensory neuropathy                        | 4 (1.2)                  | 2 (0.6)                  | 0                           | 0                           | 4 (1.2)              | 2 (0.6)              |
| Renal and urinary disorders                          | 4 (1.2)                  | 2 (0.0)                  | 2 (0.0)                     | 2 (0.0)                     | 6 (1.7)              | 4 (1.2)              |
| Proteinuria                                          | 2 (0.6)                  | 1 (0.3)                  | 2 (0.6)                     | 1 (0.3)                     | 4 (1.2)              | 2 (0.6)              |
| Respiratory,thoracic and mediastinal disorders       | 13 (3.8)                 | 8 (2.3)                  | 9 (2.0)                     | 0                           | 24 (7.0)             | 8 (2.3)              |
| Dyspnoea                                             | 1 (0.3)                  | 0                        | 6 (1.7)                     | 0                           | 7 (2.0)              | 0                    |
| Pulmonary embolism                                   | 4 (1.2)                  | 3 (0.9)                  | 2 (0.6)                     | 0                           | 6 (1.7)              | 3 (0.9)              |
| Vascular disorders                                   | 13 (3.8)                 | 13 (3.8)                 | 8 (2.3)                     | 6 (1.7)                     | 19 (5.5)             | 17 (4.9)             |
| Hypertension                                         | 12 (3.5)                 | 11 (3.2)                 | 5 (1.4)                     | 6 (1.7)                     | 15 (4.3)             | 15 (4.4)             |

Note: At each level of summarization, patients are counted once if they reported one or more events and the most severe event is counted.

1 Whole Study Period includes data from Follow-up Period in addition to Induction Study Period and MaintenanceShudyPeriod

Abbreviations: PT, preferred term; SOC, system organ class; TEAE, treatment-emergent adverse event

## Study CT-P16 1.1

Altogether 23 (50.0%), 34 (72.3%), and 26 (54.2%) subjects experienced at least 1 TEAE in the CT-P16, EU-Avastin and US-Avastin treatment groups, respectively.

The  most  frequently  reported  TEAE  by  SOC  was  investigations  for  10  (21.7%),  15  (31.9%)  and 13 (27.1%) subjects in the CT-P16, EU-Avastin and US-Avastin treatment groups, respectively.

<div style=\"page-break-after: always\"></div>

The most frequently reported TEAE by PT was diarrhoea for 3 (6.5%), 6 (12.8%) and 4 (8.3%) subjects, blood CPK increased for 3 (6.5%), 5 (10.6%) and 4 (8.3%) subjects, CRP increased for 2 (4.3%), 5 (10.6%) and 4 (8.3%) subjects and nasopharyngitis for 4 (8.7%), 1 (2.1%) and 6 (12.5%) subjects in the CT-P16, EU-Avastin and US-Avastin treatment groups, respectively.

TEAEs considered by the investigator to be related to the study drug were reported for 9 (19.6%), 20 (42.6%)  and  16  (33.3%)  subjects  in  the  CT-P16,  EU-Avastin  and  US-Avastin  treatment  groups, respectively. The most frequently reported related TEAEs were diarrhoea for 3 (6.5%), 6 (12.8%) and 2 (4.2%), and CRP increased for 1 (2.2%), 4 (8.5%) and 4 (8.3%) subjects in the CT-P16, EU-Avastin and US-Avastin treatment groups, respectively.

Most of the TEAEs were of grade 1 or grade 2 in severity while total of 6 TEAEs observed in 4 subjects (2.8%; 2 subjects [4.3%] in each of the CT-P16 and the EU-Avastin treatment groups) were of grade 3 or 4 severity. Among the TEAEs of grade 3 or 4 in severity, 2 TEAEs of grade 4 (blood CPK increased and hyperuricaemia) observed in the EU-Avastin treatment group were considered possibly related to the study drug. All other TEAEs of grade 3 or 4 severity were considered unrelated to the study drug.

## Study CT-P16 1.2

Overall, 2 (9.1%) subjects in the CT-P16 and 3 (12.5%) subjects in the EU-Avastin treatment group experienced at least 1 TEAE. Treatment emergent adverse events considered related to the study drug were reported for 1 (4.5%) subject in the CT-P16 treatment group [drug eruption] and 1 (4.2%) subject in the EU-Avastin treatment group [nausea and dizziness]). All TEAEs were recovered before or at the end-of-study (EOS) visit.

All TEAEs, regardless of relationship to study drugs, were reported once each. Food allergy and drug eruption were each reported by 1 (4.5%) subject in the CT-P16 treatment group. Nausea and dizziness, AST increased and CPK increased, and periodontitis were reported by 1 (4.2%) subject each in the EU-Avastin treatment group.

One  TEAE  was  grade  4  in  severity  (blood  CPK  increased),  1  TEAE  was  grade  3  in  severity  (AST increased), and 1 TEAE was grade 2 in severity (periodontitis). The TEAEs with grades 2, 3, and 4 were reported in the EU-Avastin treatment group and were considered unrelated to the study drug. All other reported TEAEs were grade 1 in severity. The TEAEs with grade 1 were considered related to the study drug  regardless  of  the  treatment  group  except  for  1  TEAE  of  food  allergy  reported  in  the  CT-P16 treatment group, which was considered unrelated to the study drug.

## 2.4.8.3. Serious adverse event/deaths/other significant events

## Deaths and other serious adverse events

## Study CT-P16 3.1

In Study CT-P16 3.1, 23 (6.7%) patients in CT-P16 and 24 (7.0%) patients in EU-Avastin treatment group died due to TEAE. Of these, 3 (0.9%) deaths in the CT-P16 and 7 (2.0%) in the EU-Avastin group were considered to be study drug-related (Table 32).

<div style=\"page-break-after: always\"></div>

Table 32. Summary of Death Cases Due to Related TEAEs Reported during Study Periods of Study CT-P16 3.1

| Patient No.                       | Study Period                      | Date of TEAE onset (Duration from Last dose)   | Date of Death                     | TEAE PT                           | Relation to Study Drug            |
|-----------------------------------|-----------------------------------|------------------------------------------------|-----------------------------------|-----------------------------------|-----------------------------------|
| Treatment Group: CT-P16           | Treatment Group: CT-P16           | Treatment Group: CT-P16                        | Treatment Group: CT-P16           | Treatment Group: CT-P16           | Treatment Group: CT-P16           |
| Patient 1                         | Induction Study Period            | 2020-08-20 (IC5D21)                            | 2020-08-29                        | Sepsis                            | Definite                          |
| Patient 2                         | Induction Study Period            | 2020-05-21 (IC4D22)                            | 2020-05-22                        | Subarachnoid Haemorrhage          | Probable                          |
| Patient 3                         | Induction Study Period            | 2020-01-10 (IC2D15)                            | 2020-01-10                        | Pulmonary Haemorrhage             | Definite                          |
| TreatmentGroup:EU-approvedAvastin | TreatmentGroup:EU-approvedAvastin | TreatmentGroup:EU-approvedAvastin              | TreatmentGroup:EU-approvedAvastin | TreatmentGroup:EU-approvedAvastin | TreatmentGroup:EU-approvedAvastin |
| Patient 4                         | Induction Study Period            | 2019-04-11 (ICID1)                             | 2019-05-01                        | Cerebral Infarction               | Possible                          |
| Patient 5                         | Maintenance Study Period          | 2019-09-16 (MC2D11)                            | 2019-09-16                        | Sudden Death                      | Possible                          |
| Patient 6                         | Induction Study Period            | 2020-05-14 (IC2D8)                             | 2020-05-14                        | Pulmonary Haemorrhage             | Possible                          |
| Patient 7                         | Induction Study Period            | 2020-05-18 (IC1D11)                            | 2020-05-18                        | Pulmonary Haemorrhage             | Definite                          |
| Patient 8                         | Induction Study Period            | 2020-03-19 (IC2D10)                            | 2020-03-25                        | Lung Abscess                      | Definite                          |
| Patient 9                         | Induction Study Period            | 2020-07-20 (IC2D7)                             | 2020-07-20                        | Cardiac Airest                    | Probable                          |
| Patient 10                        | Induction Study Period            | 2019-11-19 (IC1D5)                             | 2019-11-20                        | Septic Shock                      | Definite                          |

Abbreviations: D, day; IC, Induction Cycle; MC, Maintenance Cycle; PT, preferred term; TEAE, treatment-emergent adverse event.

TESAEs  were  reported  for  69  (20.0%)  and  73  (21.2%)  patients  in  the  CT-P16  and  the  EU-Avastin treatment groups, respectively. The most common TESAE by SOC in all Study Periods was infections and infestations,  reported  for  22  (6.4%)  and  24  (7.0%)  patients.  Of  the  patients  who  reported  at  least 1 TESAE, 18 (5.2%) and 23 (6.7%) patients experienced events considered to be related to the study drug.  The  most  frequently  reported  TESAE  in  both  treatment  groups  was  pneumonia  reported  for 8 (2.3%) and 10 (2.9%) patients in the CT-P16 and EU-Avastin treatment groups, respectively (Table 33).

<div style=\"page-break-after: always\"></div>

Table 33. Summary of TESAEs (Reported for at Least 1% of Patients by PT in Either Treatment Group) by SOC and PT in Study CT-P16 3.1 (Safety Population)

| Period                                         | Induction Study Period   | Induction Study Period   | Maintenance Study Period   | Maintenance Study Period   | Whole Study Period   | Whole Study Period   |
|------------------------------------------------|--------------------------|--------------------------|----------------------------|----------------------------|----------------------|----------------------|
| SOC PT                                         | CT-P16 (N=345)           | EU- Avastin (N=344)      | CT-P16 (N=345)             | EU- Avastin (N=344)        | CT-P16 (N=345)       | EU- Avastin (N=344)  |
| Totalnumber of TESAEs                          | 75                       | 70                       | 22                         | 25                         | 99                   | 95                   |
| Number (%) of patients with≥1 TESAE            | 48 (13.9)                | 55 (16.0)                | 20 (5.8)                   | 22 (6.4)                   | 69 (20.0)            | 73 (21.2)            |
| Related                                        | 14 (4.1)                 | 19 (5.5)                 | 4 (1.2)                    | 4 (1.2)                    | 18 (5.2)             | 23 (6.7)             |
| Uurelated                                      | 38 (11.0)                | 38 (11.0)                | 16 (4.6)                   | 18 (5.2)                   | 55 (15.9)            | 54 (15.7)            |
| Bloodandlymphatic Svstem disorder's            | 11 (3.2)                 | 8 (2.3)                  | 1 (0.3)                    | 0                          | 12 (3.5)             | 8 (2.3)              |
| Febrile neutropenia                            | 6 (1.7)                  | 2 (0.6)                  | 0                          | 0                          | 6 (1.7)              | 2 (0.6)              |
| Neutropenia                                    | 5 (1.4)                  | 1 (0.3)                  | 0                          | 0                          | 5 (1.4)              | 1 (0.3)              |
| Infections and infestations                    | 16 (4.6)                 | 15 (4.4)                 | 6 (1.7)                    | 10 (2.9)                   | 22 (6.4)             | 24 (7.0)             |
| COVID-19 pneumonia                             | 2 (0.6)                  | 1 (0.3)                  | 3 (0.9)                    | 3 (0.9)                    | 5 (1.4)              | 4 (1.2)              |
| Pneumonia                                      | 6 (1.7)                  | 9 (2.6)                  | 2 (0.6)                    | 2 (0.6)                    | 8 (2.3)              | 10 (2.9)             |
| Respiratory,thoracic and mediastinal disorders | 10 (2.9)                 | 7 (2.0)                  | 4 (1.2)                    | 0                          | 16 (4.6)             | 7 (2.0)              |
| Pulmonary embolism                             | 4 (1.2)                  | 1 (0.3)                  | 1 (0.3)                    | 0                          | 5 (1.4)              | 1 (0.3)              |

Note: At each level of summarization. patients are counted once if they reported one or more events.

1 Whole Study Period includes data from Follow-up Period in addition to Induction Study Period and MaintenanceStuidyPeriod

Abbreviations: PT.preferred term: SOC. system organ class: TESAE, treatment-emergent serious adverse event

## Study CT-P16 1.1 and 1.2

No deaths or TESAEs were reported during the studies in healthy subjects.

## Adverse events of special interest

## Study CT-P16 3.1

Hypersensitivity/infusion-related  reactions  (IRR),  gastrointestinal  perforations  and  fistulae,  wound healing complications, hypertension, posterior reversible encephalopathy syndrome (PRES), proteinuria, arterial  thromboembolism  (ATE),  venous  thromboembolism  (VTE),  hemorrhages,  congestive  heart failure (CHF), and ovarian failure/fertility were considered AESIs in study CT-P16 3.1.

## Hypersensitivity/Infusion-related reactions

Altogether 11 (3.2%) patients in the CT-P16 treatment group and 16 (4.7%) patients in the EU-Avastin treatment group were reported with at least 1 TEAESI due to hypersensitivity/IRRs.

## Other TEAESIs

- 3  (0.9%)  patients  in  the  CT-P16  treatment  group  and  5  (1.5%)  patients  in  the  EU-Avastin treatment group) were reported for gastrointestinal perforations and fistulae.
- 1 patient (0.3%) was reported for wound healing complications in the CT-P16 treatment group.

<div style=\"page-break-after: always\"></div>

- 44 (12.8%) patients in the CT-P16 treatment group and 39 (11.3%) patients in the EU-Avastin treatment group were reported with at least 1 TEAESI due to hypertension. PT hypertension was most frequently reported, in 34 (9.9%) patients in the CT-P16 treatment group and 33 (9.6%) patients in the EU-Avastin treatment group), followed by blood pressure increased in 7 (2.0%) patients in each study groups.
- 1 (0.3%) patient was reported for PRES in the CT-P16 treatment group.
- 42 (12.2%) patients in the CT-P16 treatment group and 38 (11.0%) patients in the EU-Avastin treatment group were reported with at least 1 TEAESI due to proteinuria. PT proteinuria was most frequently reported, in 41 (11.9%) patients in the CT-P16 treatment group and 37 (10.8%) patients in the EU-Avastin treatment group.
- 2 (0.6%) patients in the CT-P16 treatment group and 4 (1.2%) patients in the EU-Avastin treatment group were reported with at least 1 TEAESI due to ATE.
- 10 (2.9%) patients in the CT-P16 treatment group and 5 (1.5%) patients in the EU-Avastin treatment group were reported with at least 1 TEAESI due to VTE. Pulmonary embolism was the most frequently reported, in 8 (2.3%)  patients in the CT-P16 treatment  group and 3 (0.9%) patients  in  the  EU-Avastin  treatment  group),  followed  by  deep  vein  thrombosis  in  2  (0.6%) patients in each study group.
- 40 (11.6%) patients in the CT-P16 treatment group and 37 (10.8%) patients in the EU-Avastin treatment group were reported with at least 1 TEAESI due to haemorrhages. Epistaxis was most frequently reported, in 14 (4.1%) patients in the CT-P16 treatment group and 19 (5.5%) patients in the EU-Avastin treatment group, followed by haematuria in 9 (2.6%) patients in the CT-P16 treatment group and 10 (2.9%) patients in the EU-Avastin treatment group.
- 3 (0.9%) patients in the CT-P16 treatment group and 2 (0.6%) patients in the EU-Avastin treatment group were reported with at least 1 TEAESI due to CHF.
- No cases of TEAESI due to ovarian failure/fertility were reported.

## Study CT-P16 1.1 and 1.2

In Studies CT-P16 1.1 and CT-P16 1.2 conducted in healthy subjects, an AESI was pre-defined as an event of hypersensitivity/IRR.

Study CT-P16 1.1: In the CT-P16 and the EU-Avastin treatment groups, 2 (4.3%) subjects reported an IRR in each group and there were 4 (8.3%) subjects reported in the US-Avastin treatment group. All observed IRRs were related to the study drug and were grade 1 in severity. All subjects recovered from IRR without any medication and no subject discontinued due to the event.

Study CT-P16 1.2: No cases of hypersensitivity/IRR were reported.

## 2.4.8.4. Laboratory findings

## Clinical Laboratory Evaluations

An abnormality of the test result for clinical laboratory parameters, e.g. clinical chemistry, haematology, urinalysis and coagulation, was reported as a TEAE if it was determined to be clinically significant by the investigator or if the investigator reported the result as a TEAE.

<div style=\"page-break-after: always\"></div>

The majority of laboratory parameters in the clinical studies had no CTCAE grade, i.e. the post-baseline laboratory result did not satisfy any CTCAE grade criteria, or were CTCAE grade 1 (mild) or grade 2 (moderate).

## Study CT-P16 3.1

The most frequently reported grade 3 or higher clinical chemistry parameter was hypertriglyceridemia; grade 3 was reported for 17 (4.9%) patients and 20 (5.8%) patients, and grade 4 for 6 (1.7%) and 8 (2.3%) patients in the CT-P16 and the EU-Avastin treatment groups, respectively.

The most frequently reported grade 3 or higher haematology parameter was neutrophil count decreased; grade 3 was reported for 27 (7.8%) and 26 (7.6%) patients, and grade 4 for 12 (3.5%) and 9 (2.6%) patients in the CT-P16 and the EU-Avastin treatment groups, respectively. Most of grade 3 or higher haematology parameters in both treatment groups were reported during the Induction Study Period.

## Study CT-P16 1.1 and 1.2

The laboratory parameters with CTCAE grade 3 or 4 are shown in Table 34 and Table 35.

Table 34. Summary of Subjects with CTCAE Grade ≥ 3 in Study CT-P16 1.1. (Safety Population)

| Laboratory Category CTCAE Term CTCAE Grade, n (%)     | CT-P16 N=46   | EU-approved Avastin N=47   | US-licensed Avastin N=48   | Total N =141   |
|-------------------------------------------------------|---------------|----------------------------|----------------------------|----------------|
| Hematology                                            |               |                            |                            |                |
| Lymphocyte count decreased Grade 3 (Severe)           | 0             | 0                          | 1 (2.1)                    | 1 (0.7)        |
| Clinical Chemistry                                    |               |                            |                            |                |
| Aspartate aminotransferase increased Grade 3 (Severe) | 0             | 2 (4.3)                    | 0                          | 2 (1.4)        |
| CPK increased                                         |               |                            |                            |                |
| Grade 3 (Severe)                                      | 1 (2.2)       | 2 (4.3)                    | 1 (2.1)                    | 4 (2.8)        |
| Grade 4 (Life-threatening)                            | 2 (4.3)       | 2 (4.3)                    | 0                          | 4 (2.8)        |
| Hyperuricemia                                         |               |                            |                            |                |
| Grade 4 (Life-threatening)                            | 0             | 1 (2.1)                    | 0                          | 1 (0.7)        |

Abbreviations: CPK = creatine phosphokinase; CTCAE = Common Terminology Criteria for Adverse Events; EU = European Union; US = United States.

Note: The overall summary included only the worst case during unscheduled and scheduled visits.

<div style=\"page-break-after: always\"></div>

Table 35. Summary of Subjects with CTCAE Grade 3 or Higher in Study CT-P16 1.2 (Safety Population)

| CTCAE? Term Grade, n (%)   | CT-P16 (N=22)         | EU-approved Avastin (N=24)   | Overall (N=46)        |
|----------------------------|-----------------------|------------------------------|-----------------------|
|                            | Number (%)of Subjects | Number (%)of Subjects        | Number (%)of Subjects |
| Chemistry                  |                       |                              |                       |
| ASTincreased               |                       |                              |                       |
| Grade 3 (Severe)           | 0                     | 1 (4.2)                      | 1 (2.2)               |
| CPK increased              |                       |                              |                       |
| Grade 3 (Severe)           | 1 (4.5)               | 1 (4.2)                      | 2 (4.3)               |
| Grade 4 (Life-threatening) | 0                     | 2 (8.3)                      | 2 (4.3)               |
| Hypertriglyceridemia       |                       |                              |                       |
| Grade 3 (Severe)           | 4 (18.2)              | 1 (4.2)                      | 5 (10.9)              |

Abbreviations: AST, aspartate aminotransferase; CPK, creatinine phosphokinase; CTCAE, Common

Terminology Criteria for Adverse Events.

The summary includes only the worst case during post-baseline unscheduled and scheduled visits.

(a) CTCAE v5.0.

## Vital signs, Physical Examination, ECG and Other Observations Related to Safety

## Study CT-P16 3.1

Mean changes from baseline in vital sign (systolic and diastolic blood pressure, heart rate, respiratory rate,  body  temperature)  and  body  weight  measurements  were  small,  and  there  were  no  notable differences between the CT-P16 and EU-Avastin treatment groups.

The  majority  of  patients  had  normal  baseline  physical  examination  results  that  remained  normal throughout  the  study  periods.  The  most  commonly  reported  abnormalities  at  baseline  were  in  the respiratory system (148 [42.9%] patients in the CT-P16 and 162 [47.1%] patients in the EU-Avastin treatment group), which were mostly related to lung cancer. There were notable shifts from baseline from normal to abnormal in the head, ears, eyes, nose, throat system and the neurological system, mostly  related  to  alopecia  and  numbness  or  neuropathy,  respectively,  with  no  notable  differences between the 2 treatment groups.

The majority of patients had normal ECG findings. Minor changes from baseline, regarded as clinically non-significant, were observed in both groups. Altogether, 2 (0.6%) patients in the CT-P16 group and 1 (0.3%) patient in the EU-Avastin group was reported for clinically significant abnormal ECG results at any time point after study drug administration with normal ECG recording at baseline.

From hypersensitivity monitoring, the most commonly reported clinically notable vital sign result was high respiratory rate ( ≥ 20 breaths per minute). It was reported for a marked proportion at several time points throughout the hypersensitivity monitoring, with no notable differences between the CT-P16 and the EU-Avastin treatment groups.

## Studies CT-P16 1.1 and 1.2

No notable differences across the treatment groups were seen in vital sign results, physical examinations and ECGs.

## 2.4.8.5. In vitro biomarker test for patient selection for safety

N/A

<div style=\"page-break-after: always\"></div>

## 2.4.8.6. Safety in special populations

N/A

## 2.4.8.7. Immunological events

The  applicant  followed  the  EMA  guideline  'Guideline  on  immunogenicity  assessment  of  therapeutic proteins (EMEA/CHMP/BMWP/14327/2006 Rev 1)' and the immunogenicity of CT-P16 was assessed in 1 primary PK similarity study conducted in healthy male subjects (Study CT-P16 1.1), in 1 supportive Japanese PK similarity study (Study CT-P16 1.2) and in 1 Phase 3 therapeutic similarity study conducted in patients with metastatic or recurrent nsNSCLC (Study CT-P16 3.1).

The drug tolerance of both ADA assays was sufficient to detect 50.0 ng/mL of ADA in most patients in study CT-P16 3.1 and in all patients after D15 in study CT-P16 1.1.

In Study CTP16 3.1 most ADA positive subjects had drug concentrations &gt; 25.0 μg/mL and NAb levels lower than 2000 ng/mL could not have been detected without interference of drug in any patient in Study CT-P16 3.1.

## Frequencies and titres of ADA and NAb

## Healthy subjects

In Study CT-P16 1.1 overall 7 subjects (5.0%) reported at least 1 positive ADA at any time point post dose; 2 subjects (4.3%), 2 subjects (4.3%) and 3 subjects (6.3%) in the CT-P16, EU-Avastin, and US-Avastin treatment groups, respectively. NAb results were negative for all these subjects.

No subject in study CT-P16 1.2 had a positive ADA test result on any day in either treatment group.

## Study CT-P16 3.1

ADA and NAb frequencies in patients with nsNSCLC are summarised in Table 36. Post-treatment incidence of  ADA  formation  was 74  (21.4%)  and  80  (23.3%) in  the  CT-P16  and  EU-Avastin  treatment  groups, respectively.

<div style=\"page-break-after: always\"></div>

Table 36. Summary of Immunogenicity Results in Study CT-P16 3.1 (Safety Population)

| Timepoint/Visit ADA Result                                            | CT-P16 (N=345)         | EU-approved Avastin (N=344)   | Total (N=689)          |
|-----------------------------------------------------------------------|------------------------|-------------------------------|------------------------|
| NAb Result                                                            | Number (%) of patients | Number (%) of patients        | Number (%) of patients |
| Subject with at least 1 result at anytime during theWhole StudyPeriod | 345 (100.0)            | 343 (99.7)                    | 688 (99.9)             |
| Positive                                                              | 78 (22.6)              | 83 (24.1)                     | 161 (23.4)             |
| Positive                                                              | 8 (2.3)                | 8 (2.3)                       | 16 (2.3)               |
| Subject with a result at baseline visit                               | 341 (98.8)             | 340 (98.8)                    | 681 (98.8)             |
| Positive                                                              | 5 (1.4)                | 7 (2.0)                       | 12 (1.7)               |
| Posilive                                                              | 1 (0.3)                | 0                             | 1 (0.1)                |
| Subject with at least 1 result after the first infusion               | 323 (93.6)             | 304 (88.4)                    | 627 (91.0)             |
| Positive                                                              | 74 (21.4)              | 80 (23.3)                     | 154 (22.4)             |
| Positive                                                              | 7 (2.0)                | 8 (2.3)                       | 15 (2.2)               |

Abbreviations: ADA, anti-drug antibodies: NAb, neutralizing antibodies.

Note: The ADA test involves both screening and confirmatory assay to confirm positive results. Samples that are Potential Positivein the screening assay would undergo fiurther testing in the confirmatory assay to determmine if patients are a true positive labeled *Positive'. Only patients with a positive ADA result are included in the NAb summary.

The  ADA  titre  results  up  to  Induction  Cycle  6  were  presented  in  the  Integrated  Summary  of Immunogenicity (Module 2.7). The mean and the median values of ADA titre were similar between the two treatment groups at each timepoint. The titres of ADA were generally low and the ADA titre kinetics were similar between the two treatment groups. Neither ADA progression over time nor transiency of ADA was seen in any of the treatment arms. A majority of subjects who were ADA positive on more than one occasion (n=63) were also ADA positive at the EOT visit if ADA was assessed (4/7 and 10/14 for CT-P16 and EU-Avastin, respectively).

## Impact of ADA on clinical outcome

## Impact of ADA on PK

In the subjects with negative ADA status, the mean serum concentrations are slightly higher in the EU-Avastin group at induction cycles 2 and 4 than in the CT-P16 group and at induction cycles 1 and 6 the mean serum concentration is slightly higher in the CT-P16 group than in the EU-Avastin group. In the subjects with positive ADA status, the trend in mean serum concentrations is similar as in the subjects with negative ADA status. The number of subjects with positive ADA status can be considered small (n = 3-10 per group depending on the cycle) and to draw conclusions of impact of ADAs on PK is not possible.

The applicant was asked to provide a figure, in which the mean serum concentrations (µg/L) at different cycles are shown by the visit-based ADA status of patients. The applicant provided in the response to the D120 questions, acceptable figures in relation to the mean serum concentrations by ADA status. Additionally, descriptive statistics of serum concentration in the maintenance study period by visit-based ADA status were presented. The number of ADA-positive patients was small in the study and it can be

<div style=\"page-break-after: always\"></div>

agreed with the applicant that a definite conclusion could not be drawn on the impact of ADA on PK of bevacizumab.

## Impact of ADA on efficacy

The objective response rate (ORR) during Induction Study Period by ADA status up to Induction Cycle 6 is presented in Table 37.

Table 37. ORR Result during Induction Study Period by ADA Status up to Induction Cycle 6 (PP Population)

|                                      | ADA-Positive   | ADA-Positive      | ADA-Negative   | ADA-Negative       |
|--------------------------------------|----------------|-------------------|----------------|--------------------|
| ADA Status                           | CT-P16 (N=16)  | EU-Avastin (N=14) | CT-P16 (N=301) | EU-Avastin (N=289) |
| Number of Responders (%)             | 5 (31.3)       | 7 (50.0)          | 139 (46.2)     | 136 (47.1)         |
| CR                                   | 1 (6.3)        | 0                 | 1 (0.3)        | 3 (1.0)            |
| PR                                   | 4 (25.0)       | 7 (50.0)          | 138 (45.8)     | 133 (46.0)         |
| Number of Non- Responders (%)        | 11 (68.8)      | 7 (50.0)          | 162 (53.8)     | 153 (52.9)         |
| Objective Response Rate (%) (95% CI) | 31.25          | 50.00 -           | 46.18 -        | 47.06              |
|                                      | (8.54 - 53.96) | (23.81 76.19)     | (40.55 51.81)  | (41.30 - 52.81)    |

Objective  response  rate  was  defined  as  the  proportion  of  patients  whose  best  overall  response  was  CR  or  PR (considered as the 'Responder'). All other patients except responders were considered as non-responder including patients without postbaseline disease assessment.

Abbreviation: ADA, anti-drug antibody; CI, confidence interval; CR, complete response; ORR, objective response rate; PR, partial response

In the CT-P16 treatment group, the difference in ORR was observed for ADA-positive subgroup (31.25%) and ADA-negative subgroup (46.18%) with ORR appearing to decrease for the ADA-positive subgroup. In the EU-Avastin treatment group, ORR was similar regardless of ADA status as ORR was 50.00% for the  ADA-positive  subgroup  and  47.06%  for  the  ADA-negative  subgroup.  Although  a  difference  was observed between the 2 treatment groups the results should be considered in context of the small and fragmented dataset. The trends in DOR and PFS by ADA status was the opposite of the observed trend in ORR during the Induction Study Period; thus, the comparison of Duration of Response (DOR) and Progression-Free  Survival  (PFS)  showed  no  relevant  effect  of  ADA  on  the  efficacy  endpoints  in  any treatment group.

## Impact of ADA on safety

Within each treatment arm the incidence of serious treatment emergent adverse events is slightly lower among patients with positive ADA results than in those with negative results. The incidence of AEs seems comparable between treatment arms among both ADA positive and ADA negative subjects. ADA positivity does not seem to correlate with development of IRR.

## 2.4.8.8. Safety related to drug-drug interactions and other interactions

N/A

## 2.4.8.9. Discontinuation due to adverse events

## Study CT-P16 3.1

<div style=\"page-break-after: always\"></div>

Altogether 55 (15.9%) patients from the CT-P16 treatment group and 55 (16.0%) patients from the EU-Avastin treatment group experienced at least 1 TEAE leading to study drug discontinuation. The most frequently reported TEAE leading to study drug discontinuation was pulmonary embolism in 8 (2.3%) patients in the CT-P16 group and proteinuria in 5 (1.5%) patients in the EU-Avastin group (Table 38).

Table 38. Summary of TEAEs Leading to Study Drug Discontinuation (Reported for at Least 1% of Patients by PT in Either Treatment Group) by SOC and PT in Study CT-P16 3.1 (Safety Population)

| Period                                                                     | Induction Study Period   | Induction Study Period   | Maintenance Study Period   | Maintenance Study Period   | Whole Study Period   | Whole Study Period   |
|----------------------------------------------------------------------------|--------------------------|--------------------------|----------------------------|----------------------------|----------------------|----------------------|
| SOC PT                                                                     | CT-P16 (N=345)           | EU- Avastin (N=344)      | CT-P16 (N=345)             | EU- Avastin (N=344)        | CT-P16 (N=345)       | EU- Avastin (N=344)  |
| Number (%o) of patients with≥ 1 TEAE leading to study drug discontinuation | 34 (9.9)                 | 35 (10.2)                | 21 (6.1)                   | 19 (5.5)                   | 55 (15.9)            | 55 (16.0)            |
| Related                                                                    | 12 (3.5)                 | 15 (4.4)                 | 10 (2.9)                   | 6 (1.7)                    | 22 (6.4)             | 21 (6.1)             |
| Unrelated                                                                  | 22 (6.4)                 | 20 (5.8)                 | 11 (3.2)                   | 13 (3.8)                   | 33 (9.6)             | 34 (9.9)             |
| Blood and lymphatic system disorders                                       | 3 (0.9)                  | 3 (0.9)                  | 1 (0.3)                    | 1 (0.3)                    | 4 (1.2)              | 5 (1.5)              |
| Thrombocytopenia                                                           | 1 (0.3)                  | 2 (0.6)                  | 1 (0.3)                    | 1 (0.3)                    | 2 (0.6)              | 4 (1.2)              |
| Related                                                                    | 0                        | 0                        | 1 (0.3)                    | 1 (0.3)                    | 1 (0.3)              | 1 (0.3)              |
| Unrelated                                                                  | 1 (0.3)                  | 2 (0.6)                  | 0                          | 0                          | 1 (0.3)              | 3 (0.9)              |
| Renal and urinary disorders                                                | 1 (0.3)                  | 0                        | 4 (1.2)                    | 5 (1.5)                    | 5 (1.4)              | 5 (1.5)              |
| Proteinuria                                                                | 0                        | 0                        | 3 (0.9)                    | 5 (1.5)                    | 3 (0.9)              | 5 (1.5)              |
| Related                                                                    | 0                        | 0                        | 3 (0.9)                    | 4 (1.2)                    | 3 (0.9)              | 4 (1.2)              |
| Unrelated                                                                  | 0                        | 0                        | 0                          | 1 (0.3)                    | 0                    | 1 (0.3)              |
| Respiratory,thoracic and mediastinal disorders                             | 10 (2.9)                 | 8 (2.3)                  | 5 (1.4)                    | 0                          | 15 (4.3)             | 8 (2.3)              |
| Pulmonary embolism                                                         | 5 (1.4)                  | 2 (0.6)                  | 3 (0.9)                    | 0                          | 8 (2.3)              | 2 (0.6)              |
| Related                                                                    | 5 (1.4)                  | 2 (0.6)                  | 1 (0.3)                    | 0                          | 6 (1.7)              | 2 (0.6)              |
| Unrelated                                                                  | 0                        | 0                        | 2 (0.6)                    | 0                          | 2 (0.6)              | 0                    |

Note: At each level of summarization. patients are counted once if they reported one or more events and the most severe event is counted.

1 Whole Study Period includes data from Follow-up Period in addition to Induction Study Period and Maintenance Study Period

Abbreviations: PT. preferred term: SOC. system organ class: TEAE. treatment-emergent adverse event

## Study CT-P16 1.1 and 1.2

In the healthy subjects of Studies CT-P16 1.1 and CT-P16 1.2, no subjects experienced a TEAE leading to treatment discontinuation.

## 2.4.8.10. Post marketing experience

N/A

<div style=\"page-break-after: always\"></div>

## 2.4.9. Discussion on clinical safety

The applicant has provided safety data from three clinical studies; a pivotal Phase 3 study CT-P16 3.1 in patients with metastatic or recurrent nsNSCLC, Phase 1 PK study CT-P16 1.1 in healthy male subjects and a supportive PK study CT-P16 1.2 in healthy Japanese subjects.

The development of CT-P16 was discussed with DKMA and MPA in February 2016 and EMA Scientific Advice was received in July 2016 (EMA/CHMP/SAWP/476333/2016). Further, the global development of CT-P16 has been discussed with the FDA.

From the safety perspective, the design of the conducted Phase 3 study as well as the safety assessments included in the clinical studies are considered to be sufficiently aligned with the EMA Scientific Advice (EMA/CHMP/SAWP/476333/2016) and adequate. The Phase 3 study (CT-P16 3.1) is ongoing and has been  completed  up  to  1  year  from  the  last  enrolled  patient.  Clinical  data  up  to  the  cut-off  date (21 September 2021) has been provided by the applicant that includes complete data for all patients through Induction Study Period and data for a total of 148 (21.5%) patients who have completed 1 year of treatment ( ≥ Maintenance Cycle 12).

The safety evaluations were planned according to the known safety profile of Avastin, considering the adverse reactions presented in the SmPC and AESIs identified for Avastin e.g. in the RMP for Avastin. The safety analyses were conducted on safety population, consisting of all subjects receiving at least 1 dose of either CT-P16 or Avastin. The safety data for the Phase 3 study CT-P16 is presented separately for the induction study period (combination with paclitaxel and carboplatin), maintenance study period (monotherapy), follow-up  period  and  whole  study  period.  In  general,  the  safety  data  has  not  been pooled, but presented separately for the 3 clinical studies, which is acceptable.

In the Phase 3 study CT-P16 3.1, a total of 689 patients with nsNSCLC received at least one dose of the study drug, 345 patients in the CT-P16 treatment group and 344 patients in the EU-Avastin treatment group. In addition, 141 healthy subjects received a single dose of CT-P16 (n=46), EU-Avastin (n=47) or US-Avastin (n=48) in the pivotal PK study CT-P16 1.1 and 46 healthy subjects received a single dose of CT-P16 (n=22) or EU-Avastin (n=24) in the supportive PK study CT-P16 1.2.

In terms of drug exposure, some imbalances between the treatment groups were observed in number of patients that received the study drug after the first induction cycle. At cycle 1: 100% and 100%; at cycle 2: 95.7% and 92.2%; at cycle 3: 89.6% and 80.5%, and at the last induction cycle 6: 76.2% and 69.8% of the patients in CT-P16 and EU-Avastin treatment groups, respectively, received the study drug. This was also reflected in higher number of patients receiving concomitant paclitaxel and carboplatin in the CT-P16 group. Consequently, more patients in the CT-P16 than in the EU-Avastin group continued to receive the study drug during the maintenance period. The administered dose intensities were similar in both study groups, including chemotherapy during the induction period. In the PK studies CT-P16 1.1 and CT-P16 1.2, all subjects received full dose of the study drug.

Overall, the size of the safety population included in the clinical studies can be considered sufficient to allow a meaningful comparison of safety and immunogenicity between CT-P16 and EU-Avastin in the context of a biosimilar MAA.

In the Phase 3 study CT-P16 3.1, the patient demographics were comparable between the study groups (CT-P16 and EU-Avastin) in terms of mean age (61.3 and 61.5 years, respectively), gender (65.2% and 64.0% males), race (77.2% and 76.1% white) and other characteristics. The majority of patients had a metastatic disease (92.7% and 90.5%) and ECOG Grade 1 performance status (69.3% and 68.3%). The pathological diagnosis was adenocarcinoma in almost all cases (98.2% and 98.0%, respectively) and clinical stage in most cases either stage IVA (43.0% and 47.3%, respectively) or Stage IVB (49.7% and 42.9%, respectively). In general, the study groups were comparable in terms of medical history and

<div style=\"page-break-after: always\"></div>

previous treatments, but some minor differences were observed between study groups (CT-P16 and EU-Avastin) e.g. in number of patients with previous lung lobectomy (5.8% and 9.2%) and previous cytotoxic chemotherapy (1.8% and 2.9%). Overall, the demographics and baseline characteristics were sufficiently balanced between the treatment groups in all three clinical studies.

## Adverse events in the Phase 3 study CT-P16 3.1:

At least 1 TEAE was reported for 96.2% and 93.0% and treatment related TEAEs for 51.6% and 50.6% of patients in the CT-P16 and EU-Avastin groups, respectively.

In terms of common TEAEs by SOC, skin and subcutaneous tissue disorders were reported for 67.0% and 65.4%, nervous system disorders for 52.5% and 47.4%, blood and lymphatic system disorders for 50.4%  and  42.2%,  gastrointestinal  disorders  for  44.9%  and  40.7%,  and  general  disorders  and administration site conditions for 41.2% and 34.9% of patients in the CT-P16 and EU-Avastin groups, respectively.

In terms of common TEAEs by PT, alopecia was reported for 63.8% and 63.4%, anaemia for 31.6% and 27.0%, neutropenia for  21.7%  and  16.0%,  nausea  for  21.4%  and  18.9%,  asthenia  for  18.3%  and 15.7%,  thrombocytopenia  for  18.3%  and  13.7%  of  patients  in  the  CT-P16  and  EU-Avastin  groups, respectively. A vast majority of these TEAEs were reported during the induction period.

Of the common related TEAEs by PT, proteinuria was reported for 10.4% and 9.3%, anaemia for 7.2% and 8.4%, hypertension for 7.2% and 7.3%, alopecia for 6.7% and 6.1%, thrombocytopenia for 6.4% and  2.6%,  and  neutropenia  for  3.8%  and  5.2%  of  patients  in  the  CT-P16  and  EU-Avastin  groups, respectively. The frequency of related TEAEs were comparable between the study groups, i.e. at least 1 related TEAE was reported for 51.6% and 50.6% of patients in the CT-P16 and the EU-Avastin treatment groups, respectively.

Overall,  the  frequency  of  common  TEAEs  was  somewhat  higher  in  the  CT-P16  group  compared  to EU-Avastin group both during the induction (95.1% vs 91.6%) and maintenance periods (50.7% vs 45.1%). At least 5% difference was reported for CT-P16 vs. EU-Avastin in SOCs blood and lymphatic system disorders, general disorders and administration site conditions and nervous system disorders. TEAEs from these SOCs were analysed further by the applicant and it can be concluded that the higher frequency of TEAEs in the CT-P16 vs. EU-Avastin group was mainly driven by chemotherapy-related TEAEs during the induction period. As discussed above, more patients in the CT-P16 group than in the EU-Avastin groups received the study drug and chemotherapy after the first cycle during the induction period. Consequently, more patients in the CT-P16 group continued to receive the study drug during the maintenance period. Given that the frequencies (%) for the TEAEs were calculated from the total safety population (i.e. all subjects who received at least 1 dose of study drug), it is likely that the imbalance in drug exposure contributed to the observed numerical difference in the TEAEs between the study groups. Importantly, no major differences in the frequency of study drug-related TEAEs were observed during the induction or maintenance periods in the three SOCs analysed.

At least 1 ≥ Grade 3 TEAE was reported for 43.8% and 41.9% of patients in the CT-P16 and EU-Avastin groups, respectively. The most common ≥ Grade 3 TEAE was neutropenia, reported for 10.4% and 7.3% of patients in the CT-P16 and EU-Avastin groups, respectively. Dyspnoea was reported for 7 vs 0 patients (6 vs 0 during maintenance period) and pulmonary embolism for 6 vs 3 of patients (2 vs 0 during maintenance period) in the CT-P16 and EU-Avastin groups, respectively. When examining the risk factors for the patients that experienced dyspnoea during the maintenance period, most notably, 12 (75%) vs. 4 (40%) of the patients in CT-P16 and EU-Avastin treatment groups, respectively, reported dyspnoea already  at  screening.  Some  further  imbalances  in  the  risk  factors  were  also  observed,  e.g.  more unfavourable smoking history in CT-P16 group, and altogether these imbalances can be considered a plausible  reason  for  the  observed  difference  in  the  grade  ≥  3  cases  between  the  s tudy  groups.

<div style=\"page-break-after: always\"></div>

Importantly, all grade ≥ 3 events of dyspnoea were considered unrelated to the study drug by the investigator.

TEAEs leading to study drug discontinuation was reported for 15.9% and 16.0% of the patients in the CT-P16  and  EU-Avastin  groups,  respectively.  The  most  common  reason  for  discontinuation  was pulmonary  embolism,  in  8  (2.3%)  and  2  (0.6%),  proteinuria  in  3  (0.9%)  and  5  (1.5%),  and thrombocytopenia in 2 (0.6%) and 4 (1.2%) patients in the CT-P16 and EU-Avastin groups, respectively. All other TEAEs that led to discontinuation, were reported for less than 1% of subjects in each group. Except for the numerical difference in the pulmonary embolism cases, the safety profile based on TEAEs that led to discontinuation was similar between the CT-P16 and EU-Avastin group.

In the Phase 3 study CT-P16 3.1, the number of patients that died was 23 (6.7%) and 24 (7.0%) in CT-P16 and EU-Avastin treatment groups, respectively. Number of patients with drug-related TESAE leading to death was higher in the EU-Avastin group, i.e. 3 (0.9%) and 7 (2.0%) of the cases were regarded as study drug-related in the CT-P16 and EU-Avastin groups, respectively. All, except one studydrug related death occurred during the induction study period.

TESAEs were reported in 20.0% and 21.2% and related TESAEs in 5.2% and 6.7% of patients in the CT-P16 and EU-Avastin treatment groups, respectively. The most common TESAEs were pneumonia in 2.3% and 2.9%, febrile  neutropenia  in  1.7%  and  0.6%,  COVID-19  pneumonia  in  1.4%  and  1.2%, neutropenia in 1.4% and 0.3% and pulmonary embolism in 1.4% and 0.3% of patients in the CT-P16 and EU-Avastin treatment groups, respectively.

Overall, the number of deaths, other TESAEs and related TESAEs were comparable between CT-P16 and EU-Avastin treatment groups in the Phase 3 study CT-P16 3.1. No deaths or other TESAEs were reported in the PK studies CT-P16 1.1 and 1.2. The applicant has provided full narratives of TESAEs and deaths, where the cases are adequately described.

The AESIs were adequately pre-defined based on known safety profile of Avastin as described in the SmPC of Avastin, as well as important identified and potential risks in the RMP of Avastin. In the Phase 3 study CT-P16 3.1, the following AESIs were included: hypersensitivity/infusion-related reactions (IRR), gastrointestinal perforations and  fistulae, wound  healing  complications, hypertension, posterior reversible  encephalopathy  syndrome  (PRES),  proteinuria,  arterial  thromboembolism  (ATE),  venous thromboembolism  (VTE),  hemorrhages,  congestive  heart  failure  (CHF),  and  ovarian  failure/fertility. Overall, apart from the numerical differences in pulmonary embolism discussed above, the frequency of most AESIs was similar between the CT-P16 and EU-Avastin treatment groups.

In general, no major differences were observed in the clinical laboratory evaluations between the study groups. The mean values over time in haematology laboratory parameters followed a similar pattern in both  groups,  with  no  major  differences  between  the  CT-P16  and  EU-Avastin.  By  CTCAE  grading, numerically  slightly  more  (mainly  grades  1-2)  anaemia,  neutrophil  count  decreased,  platelet  count decreased and white blood cell decreased was reported in CT-P16 vs. EU-Avastin group, which is in line with the observations related to the TEAEs under SOC Blood and Lymphatic System Disorders.

Data on vital signs, physical examination and ECG did not reveal any notable differences between the study groups.

In summary, the safety of CT-P16 was consistent with the known safety profile of Avastin with or without chemotherapy that was used during the induction phase in the Phase 3 study CT-P16 3.1. As discussed above,  some  numerical  differences  were  observed  in  the  TEAEs  between  the  study  groups,  but considering the safety data as a whole, CT-P16 and EU-Avastin can be concluded to be biosimilar in terms of safety.

<div style=\"page-break-after: always\"></div>

## Adverse events in the PK Phase 1 studies CT-P16 1.1 and 1.2:

Of the 141 healthy subjects included in the safety population in Study CT-P16 1.1, at least 1 TEAE was reported for 50.0%, 72.3% and 54.2% of subjects, treatment related TEAEs for 19.6%, 42.6% and 33.3%  and  ≥  Grade  3  TEAEs  for  4.3%,  4.3%  and  0%  of  subjects  in  the  CT -P16,  EU-Avastin  and US-Avastin groups, respectively.

In terms of common TEAEs by PT in Study CT-P16 1.1, diarrhoea was reported for 6.5%, 12.8% and 8.3%, blood CPK increased for 6.5%, 10.6% and 8.3%, CRP increased for 4.3%, 10.6% and 8.3%, nasopharyngitis for 8.7%, 2.1% and 12.5%, and IRR for 4.3%, 4.3% and 8.3% of subjects in the CT-P16, EU-Avastin and USAvastin groups, respectively. All other TEAEs were reported for ≤3 subjects in each group.  Of the common related TEAEs by PT, diarrhoea was reported for 6.5%, 12.8% and 4.2%, and CRP increased for 2.2%, 8.5% and 8.3% of subjects in the CT-P16, EU-Avastin and US-Avastin groups, respectively. TEAEs of ≥ Grade 3 was observed in 2 subjects (4.3%) in CT-P16 and EU-Avastin groups.

Of the 46 healthy subjects included in the safety population in study CT-P16 1.2, TEAEs were reported for 2 subjects (9.1%) in the CT-P16 groups and 3 subjects (12.5%) in the EU-Avastin group. Related TEAEs were reported for 1 subject in the CT-P16 group (drug eruption) and 1 subject in the EU-Avastin group (nausea and dizziness). Two TEAEs of ≥ Grade 3 were reported for 1 subject in the EU-Avastin group (AST increased and blood CPK increased).

In the PK studies CT-P16 1.1 and 1.2, no TEAEs leading to study drug discontinuation, deaths or other TESAEs  were  reported.  Only  individual  grade  ≥  3  laboratory  findings  were  seen,  with  no relevant differences between the study groups.

Overall,  although  some numerical differences  in  the  TEAEs  were  seen  in  the  single  dose  PK  studies between study groups, there were no findings that were considered relevant in the context of similarity assessment of safety.

## Immunological events:

The proportion of healthy subjects who had post-dose ADA positive results was 4.3% in both CT-P16 and EU-Avastin treated subjects in study 1.1. The low proportion of ADA positive subjects in this study is in line with historical studies with bevacizumab. NAb results were negative for all healthy subjects. Of note, due to weak drug tolerance of the NAb assay, no meaningful NAb detection was possible at Day 15 and Day 43 in these two studies.

In study CT-P16 1.2 no subject had a positive ADA test result on any day in either treatment group. The applicant pointed out that the lack of ADA detection in Study CT-P16 1.2 was probably due to the low sample  size  and  the  generally  low  incidence  of  anti-bevacizumab  antibodies.  The  applicant  further provided literature data from other phase 1 studies with similar results.

In the phase III study 3.1 no meaningful difference in post-treatment ADA or NAb incidence was observed between the two treatment groups. The prevalence of ADA positive patients at each time point was low (&lt; 5%) and in line with historical studies. The overall ADA incidence was 78 (22.6%) and 83 (24.1%) for the CT-P16 and EU-Avastin treatment groups, respectively. The titres of ADA were generally low and the ADA titre kinetics were similar between the two treatment groups. Neither ADA progression over time nor transiency of ADA was seen in any of the treatment arms. As the number of ADA positive subjects in each treatment arm can be considered small (n = 1-17 depending on the cycle), it is not possible to draw conclusions on the impact of ADAs on PK.  No relevant effect of ADA on the efficacy or safety endpoints could be determined in any treatment group.

<div style=\"page-break-after: always\"></div>

## 2.4.10. Conclusions on the clinical safety

In summary, the safety and immunogenicity of CT-P16 was consistent with the known safety profile of Avastin with or without chemotherapy that was used during the induction phase in the Phase 3 study CT-P16 3.1. Considering the safety data as a whole, CT-P16 and EU-Avastin can be concluded to be biosimilar in terms of safety and immunogenicity.

## 2.5. Risk Management Plan

## 2.5.1. Safety concerns

The applicant identified the following safety concerns in the RMP version 0.2:

Table 39. Summary of safety concerns

| Summary of safety concerns   | Summary of safety concerns   |
|------------------------------|------------------------------|
| Important identified risks   | None                         |
| Important potential risks    | None                         |
| Missing information          | None                         |

## 2.5.2. Pharmacovigilance plan

There are no additional pharmacovigilance activities conducted or planned.

## 2.5.3. Risk minimisation measures

Since there are no safety concerns identified for the medicinal product, neither routine nor additional risk minimisation measures are considered applicable.

## 2.5.4. Conclusion

The CHMP considers that the risk management plan version 0.2 is acceptable.

## 2.6. Pharmacovigilance

## 2.6.1. Pharmacovigilance system

The CHMP considered that the pharmacovigilance system summary submitted by the applicant fulfils the requirements of Article 8(3) of Directive 2001/83/EC.

## 2.6.2. Periodic Safety Update Reports submission requirements

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

<div style=\"page-break-after: always\"></div>

## 2.7. Product information

## 2.7.1. User consultation

No full user consultation with target patient groups on the package leaflet has been performed on the basis of a bridging report making reference to Abevmy and Herzuma.  The bridging report submitted by the applicant has been found acceptable.

## 2.7.2. Additional monitoring

Pursuant to Article 23(1) of Regulation No (EU) 726/2004, Vegzelma (bevacizumab) is included in the additional monitoring list as it is a biological product authorised after 1 January 2011.

Therefore the summary of product characteristics and the package leaflet includes a statement that this medicinal product is subject to additional monitoring and that this will allow quick identification of new safety information. The statement is preceded by an inverted equilateral black triangle.

## 3. Biosimilarity assessment

## 3.1. Comparability exercise and indications claimed

Vegzelma has been developed as a proposed biosimilar to the reference product Avastin (bevacizumab). The applicant is claiming all of the approved indications for Avastin.

The proposed indications are:

VEGZELMA in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum.

VEGZELMA in combination with paclitaxel is indicated for first-line treatment of adult patients with metastatic breast cancer. For further information as to human epidermal growth factor receptor 2 (HER2) status, please refer to section 5.1.

VEGZELMA in combination with capecitabine is indicated for first-line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. Patients who have received taxane and anthracycline-containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with VEGZELMA in combination with capecitabine. For further information as to HER2 status, please refer to section 5.1.

VEGZELMA, in addition to platinum-based chemotherapy, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer (NSCLC) other than predominantly squamous cell histology.

VEGZELMA, in combination with erlotinib, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent NSCLC with Epidermal Growth Factor Receptor (EGFR) activating mutations (see section 5.1).

VEGZELMA, in combination with interferon alfa-2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer.

VEGZELMA, in combination with carboplatin and paclitaxel is indicated for the front-line treatment of

<div style=\"page-break-after: always\"></div>

adult patients with advanced (International Federation of Gynecology and Obstetrics (FIGO) stages III B, III C and IV) epithelial ovarian, fallopian tube, or primary peritoneal cancer (see section 5.1).

VEGZELMA, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vascular endothelial growth factor (VEGF) inhibitors or VEGF receptor-targeted agents.

VEGZELMA in combination with paclitaxel, topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor-targeted agents (see section 5.1).

VEGZELMA, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix (see section 5.1).

## Summary of quality comparability data

A comprehensive similarity exercise following the general principles outlined in the guideline on similar biological  medicinal  products  containing  biotechnology-derived  proteins  as  active  substance;  Quality issues  (EMA/CHMP/BWP/247713/2012)  has  been  performed.  Ten  independent  CT-P16  DP  batches representative  of  the  commercial  scale  and  10  EU-approved  Avastin  batches  were  included  in  the similarity study. The batches reflected a range of expiration dates and product ages. The DP material used in the analytical biosimilarity studies is considered representative of the material used in clinical trials. The similarity analyses were performed side-by-side using qualified in-house reference standard (P2-RF-JPP01). A ±3*SD quality range was set by analysis of 10 batches of EU-approved Avastin for key biological  quality  attributes.  Results  of  physicochemical  analyses  were  presented  without  statistical analysis; instead the mean and SD as well as the spread of the underlying distribution from quantitative analyses have been compared and differences have been highlighted and discussed. In addition, raw data has been provided to allow assessment of biosimilarity independently of statistical approach chosen.

Analytical  comparability  studies  included  primary  and  higher  order  structures,  post-translational modifications,  glycation  and  glycosylation,  charge  heterogeneity,  purity/impurity,  content,  biological activity of Fab and Fc related functions, and comparative forced degradation studies.

## Summary of nonclinical comparability data

A comprehensive in vitro similarity exercise included biological activity of Fab and Fc -related functions of bevacizumab presented and described under quality comparability data. A supportive four weeks of duration repeated toxicology study with toxicokinetic analysis in cynomolgus monkeys comparing CT-P16 to EU-Avastin of was conducted.

## Summary of clinical comparability data

One pivotal PK study (i.e. CT-P16 1.1) was conducted: a single-dose (i.e. 5 mg /kg IV infusion for 90 min) randomised, double-blind, 3-arm, parallel study in healthy subjects comparing CT-P16, EU-Avastin and US-Avastin (N ~ 46-48 subjects administered/group). Supportive PK data was obtained from a study with healthy Japanese subjects (i.e. study CT-P16 1.2) and with nsNSCLC patients in the clinical efficacy and safety study CT-P16 3.1.

The main efficacy and safety study CT-P16 3.1 is an ongoing double-blind, randomised, active-controlled, parallel group Phase 3 study to compare the efficacy, PK, and overall safety of CT-P16 (15 mg/kg) and

<div style=\"page-break-after: always\"></div>

EU-Avastin (15 mg/kg) when co-administered with paclitaxel and carboplatin as first-line treatment in patients with metastatic or recurrent nsNSCLC.

In general, the clinical programme for Vegzelma is consistent with relevant CHMP Guidance concerning development of biosimilars.

## 3.2. Results supporting biosimilarity

## Quality data

Similarity between CT-P16 and EU-approved Avastin has been demonstrated for the following physicochemical and biological properties:

- -Primary structure
- -Content
- -Charge heterogeneity
- -Glycan profile
- -Size heterogeneity and purity/impurity profile
- -Antiproliferation activity, and binding to VEGF-A165 and VEGF-A121
- -Binding to FcγRIIIa (F-type, Vtype), FcγRIIa, FcγRIIb, FcγRI, FcRn, C1q
- -ADCC and CDC activity
- -Inhibition of VEGFR2 RTK autophosphorylation
- -Binding to VEGF-A isoforms (VEGF-A145, VEGF-A189, VEGF-A206) and VEGF family (VEGF-B, -C, -D, and -E; PlGF-1 and -2)
- -Stability under forced degradation

Minor differences in the levels of post-translational modifications (deamidation, oxidation, N-terminal pyroglutamic acid, C-terminal lysine, proline amidation), free thiol groups, relative proportion of the charge variants, individual fucosylated glycan species, levels of glycation, and levels of monomer, HMW, LMW, HC+LC and NGHC were sufficiently justified to have no clinical impact.

## Nonclinical data

Similarity between CT-P16 and EU-approved Avastin was demonstrated for the functional properties as described above under Quality data (antiproliferation activity, binding to VEGF-A165 and VEGF-A121, binding to FcγR subtypes, FcRn, C1q, ADCC  and CDC  activity, Inhibition of VEGFR2  RTK autophosphorylation and binding to other VEGF-A isoforms and VEGF family members). CT-P16 and EU-Avastin did not differ in cynomolgus monkeys on their toxicological and toxicokinetic characteristics.

## Clinical data

## Pharmacokinetics

In the comparison of PK data (pivotal PK study CT-P16 1.1) for the CT-P16 group with the EU-Avastin and US-Avastin treatment groups, the 90% CIs of the geometric LS mean ratios for the three primary PK parameters (i.e. Cmax, AUC0-last and AUC0-inf) were all within 80% and 125% (including 100.00). In the  comparison  of  the  AUCs  between  EU-Avastin  and  US-Avastin,  the  90%  CIs  were  between  the range 80% - 125% but the range did not include 100.00%. This is, however, not any concern. The sensitivity analysis supported the PK similarity between CT-P16 and EU-Avastin.

<div style=\"page-break-after: always\"></div>

In the supportive PK study in Japanese subjects the 90% CIs of ratios of geometric LS means of Cmax, AUC0-last, and AUC0-inf were entirely contained within the predefined equivalence margin of 80% to 125% which indicated that bevacizumab exposures from CT-P16 were similar to those from EU-Avastin.

The mean trough concentrations were comparable between CT-P16 group and EU-Avastin group (PK data up to induction  cycle 6) in nsNSCLC patients in the study CT-P16 3.1.

## Efficacy

In the clinical efficacy study CT-P16 3.1, CT-P16 and EU-Avastin were compared in a Phase III study in nsNSCLC patients. The design and other general characteristics of the study are considered fit for the purpose of demonstrating biosimilarity. The primary endpoint was ORR (based on BOR as per central review) during the Induction Study Period. For the ITT and the PP populations, the reported CT-P16 EU-Avastin risk differences of 0.40 (95% CI -7.02, 7.83) and -1.90 (95% CI -9.80, 6.00), respectively, were entirely contained within the pre-specified equivalence margin of -12.5 to 12.5. Also based on the local investigators' response evaluation, the 95% CI for difference between CT-P16 and EU-Avastin in ORR during the Induction Study Period was within the equivalence margin of -12.5 to 12.5 (ITT: 4.87% [95 %CI: -2.53 to 12.26]; PP: 2.90% [95 % CI: -4.99 to 10.79]).

The post-hoc analysis of ORR by treatment cycle showed similar response rates between the treatment groups; at Induction Cycle 6, the reported ORR was 42.69% (95% CI 37.45, 47.93) for CT-P16 and 43.52% (95% CI 38.30, 48.73) for EU-Avastin in the ITT population, and 44.97% (95% CI 39.50, 50.44) for CT-P16 and 48.84% (95% CI 43.22, 54.47) for EU-Avastin in the PP population. Also in this analysis, the  reported  CT-P16  -  EU-Avastin  risk  differences  of  -0.77  (95%  CI  -8.21,  6.68)  and  -3.79 (95% CI -11.69, 4.11), for the ITT and the PP populations respectively.

Data on time-dependent endpoints is also supportive of biosimilarity.

In the ITT population, median PFS was 7.9 [95% CI: 6.9 - 8.3] months and 7.2 [95% CI: 6.5 - 8.3] months  for  the  CT-P16  and  EU-Avastin  treatment  groups,  respectively,  with  a  hazard  ratio  of 0.92 (95% CI: 0.77 - 1.10). In the PP population, median PFS was 8.3 [95% CI: 7.2 - 8.5] months and 8.1 [95% CI: 6.8 - 8.6] months for the CT-P16 and EU-Avastin treatment groups, respectively, with a hazard  ratio  of  0.93  (95%  CI:  0.76  -  1.12).  With  respect  to  the  comparison  between  CT-P16  and EU-Avastin,  similar  results  were  observed  in  additional  PFS  analyses  performed  by  the  applicant  in response to D180 LoQ.

In the ITT population, median OS was 17.1 [95% CI: 14.6 -18.7] months and 15.6 [95% CI: 13.4 - 18.0] months for the CT-P16 and EU-Avastin treatment groups, respectively, with a hazard ratio of 0.95 (95% CI: 0.77 -1.19). In the PP population, median OS was 17.5 [95% CI: 15.5  -  19.2]  months  and  17.0  [95%  CI:  14.6  -  20.5]  months  for  the  CT-P16  and EU-Avastin treatment groups, respectively, with a hazard ratio of 0.96 (95% CI: 0.76 - 1.22).

## Safety

The clinical Safety Population includes data from 689 nsNSCLC patients in Study CT-P16 3.1 that received CT-P16  (n=345)  or  EU-Avastin  (n=344).  In  addition,  187  healthy  subjects  received  a  single  dose (5 mg/kg) of CT-P16, EU-Avastin or US-Avastin in studies CT-P16 1.1 and 1.2.

The design of the clinical studies and the safety assessments were adequate, including AESIs, that were identified based on the known safety profile of Avastin. The safety data for the Phase 3 study CT-P16 3.1  was  presented  separately  for  the  induction  study  period  (combination  with  paclitaxel  and carboplatin), maintenance study period (monotherapy), follow-up period and whole study period. The safety data was not pooled, but presented separately for the three clinical studies. Overall, the size of the  safety  population  included  in  the  clinical  studies  can  be  considered  sufficient  and  the  groups

<div style=\"page-break-after: always\"></div>

comparable in terms of demographics and baseline characteristics to allow a meaningful comparison of safety between CT-P16 and EU-Avastin in the context of a biosimilar MAA.

In the Phase 3 study CT-P16 3.1, at least 1 TEAE was reported for 96.2% and 93.0%, treatment related TEAEs for 51.6% and 50.6% and ≥ Grade 3 TEAEs for 43.8% and 41.9% of patients in the CT -P16 and EU-Avastin groups, respectively. In terms of common TEAEs by SOC, similar frequencies were reported in several SOCs, e.g. skin and subcutaneous tissue disorders were reported for 67.0% and 65.4% and gastrointestinal  disorders  for  44.9%  and  40.7%  of  patients  in  the  CT-P16  and  EU-Avastin  groups, respectively. In terms of most common TEAEs by PT, alopecia was reported for 63.8% and 63.4% of patients in the CT-P16 and EU-Avastin groups, respectively. TEAEs leading to study drug discontinuation was reported for 15.9% and 16.0% of the patients in the CT-P16 and EU-Avastin groups, respectively. The number of deaths (6.7% vs 7.0%), other TESAEs (20.0% vs 21.2%) and related TESAEs (5.2% vs 6.7%), as well as AESIs were generally comparable between CT-P16 and EU-Avastin treatment groups.

Overall,  although  some numerical differences  in  the  TEAEs  were  seen  in  the  single  dose  PK  studies (CT-P16 1.1 and 1.2) between study groups, there were no findings that were considered relevant in the context of similarity assessment of safety.

## Immunogenicity

The proportion of healthy subjects who had post-dose ADA positive results was 4.3% in both CT-P16 and EU-Avastin treated subjects in study 1.1. In study CT-P16 1.2 no subject were ADA positive.

In the phase III study 3.1 the prevalence of ADA positive patients at each time point was low (&lt; 5%) and in line with historical studies. The overall ADA incidence was 78 [22.6%] and 83 [24.1%] for the CT-P16 and EU- Avastin treatment groups, respectively.

## 3.3. Uncertainties and limitations about biosimilarity

## Safety

- -Overall, the frequency of common TEAEs was somewhat higher in the CT-P16 group compared to EU-Avastin group in the Phase 3 study CT-P16 3.1. At least 5% difference in the number of patients with TEAEs was reported in the CT-P16 vs. EU-Avastin group in SOCs blood and lymphatic system disorders (including neutropenia), general disorders and administration site conditions  and nervous system disorders. However, more patients were exposed to the CT-16 + chemotherapy vs EU-Avastin +  chemotherapy  after  the  first  treatment  cycle  during  the  induction  phase  and  the  numerical differences  were  largely  driven  by  the  chemotherapy-related  TEAEs  during  the  induction  period. Importantly, no major differences in the frequency of study drug-related TEAEs were observed in the three SOCs analysed.
- -The most notable difference between study groups were observed in the number of patients with ≥ Grade 3 dyspnoea which was reported for 7 vs 0 patients in the CT-P16 and EU-Avastin groups, respectively. Six (6) out of the 7 cases in the CT-P16 group occurred during the maintenance period. In a more thorough analysis of these cases, some imbalances in the baseline factors (e.g. presence of dyspnoea already at screening and smoking history) were identified that potentially could explain the d ifferences. Further, pulmonary embolism was reported for 8 (2.3%) vs 3 (0.9%), and ≥ Grade 3 pulmonary embolism for 6 (1.7%) vs 3 (0.9%) patients in the CT-P16 and EU-Avastin groups, respectively, which could not be explained by imbalance of risk factors at baseline. On the other hand, e.g. drug related TESAEs leading to death was reported in 7 (2.0%) patients in EU-Avastin group  and in  3  (0.9%)  patients  in  CT-P16  group.  Therefore,  the  numerical  imbalances  in  these individual TEAEs were likely a chance finding.

<div style=\"page-break-after: always\"></div>

- -None of the findings described above are considered to be uncertainties that would have an impact on the conclusion of biosimilarity.

## 3.4. Discussion on biosimilarity

## Quality

A comprehensive similarity exercise following the general principles outlined in the guideline on similar biological  medicinal  products  containing  biotechnology-derived  proteins  as  active  substance;  Quality issues  (EMA/CHMP/BWP/247713/2012)  has  been  performed.  The  comparability  studies  have  been conducted by analysing CT-P16 DP and EU-approved Avastin side-by-side (as possible) with qualified state of-the-art physicochemical and biological methods.

For most physicochemical and biological quality attributes high similarity has been demonstrated. Minor difference were observed mainly in post-translational modifications, charge variants, glycation levels, and levels of monomer and aggregates, and were without implications to Fab and Fc -related functions. The differences were sufficiently justified to have no clinical impact.

## Nonclinical

Comprehensive similarity exercise following the principles laid down in the guideline on similar biological medicinal products containing monoclonal antibodies -nonclinical and clinical issues (EMA/CHMP/BMWP/403543/2010) and containing biotechnology derived medicinal products as active substances:  non-clinical  and  clinical  issues  (EMEA/CHMP/42832/2005  Rev  1)  was  performed.  The functional comparability data was identical to in vitro comparative data presented under Quality section and was, in order to avoid repeating the data, assessed under Quality. This data demonstrated high similarity  of  CT-P16  and  EU-Avastin  in  their  functional  characteristics.  Toxicology  and  toxicokinetic analysis in cynomolgus monkeys did not reveal differences between CT-P16 and EU-Avastin, and can be considered as supportive data for the similarity.

## Clinical

Biosimilarity in the pivotal PK study CT-P16 1.1 using healthy subjects has been formally demonstrated between CT-P16 and EU-Avastin and US-Avastin as in the primary PK parameters Cmax, AUC0-last and AUC0-inf, the 90% CI for the ratio of test-to-reference/comparator fell within the acceptance range of 80.00-125.00%. Also, in the supportive PK study in Japanese subjects in the primary PK parameters (i.e. Cmax, AUC0- last and AUC0-inf), the 90% CI for the ratio of test-to-reference fell within the acceptance range  of  80.00-125.00%.  The  sensitivity  analyses  support  the  biosimilarity.  Additional  support  for similarity between CT-P16 and EU-Avastin was obtained in the study in nsNSCLC patients (clinical study CT-P16 3.1). The mean Ctrough concentrations were comparable between CT-P16 and EU-Avastin.

As indicated above, efficacy data from the nsNSCLC study CT-P16 3.1 can be considered to support biosimilarity. The primary endpoint was met, with the risk difference contained within the pre-specified equivalence margin, and available sensitivity analyses support this view. This position is supported by the analyses for relevant time-dependent endpoints (PFS, OS).

The  safety  of  CT-P16  was  consistent  with  the  known  safety  profile  of  Avastin  with  or  without chemotherapy  that  was  used  during  the  induction  phase  in  the  Phase  3  study  CT-P16  3.1.  Some numerical differences were observed in the TEAEs between the study groups, but considering the safety data  as  a  whole,  CT-P16  and  EU-Avastin  can  be  concluded  to  be  biosimilar  in  terms  of  safety  and immunogenicity.

<div style=\"page-break-after: always\"></div>

## 3.5. Extrapolation of safety and efficacy

The applicant is claiming all indications approved for the reference product Avastin. In principle, it is agreed  that  the  MoA  of  bevacizumab  across  its  approved  indications  is  to  inhibit  VEGF-induced angiogenesis and vascular permeability, and there is no evidence to support claims of a unique MoA in any  specific  indication.  It  is  thus  agreed  that  extrapolation  to  other  indications  is  appropriate  and authorisation can be granted for all indications approved for Avastin. This approach is also consistent with regulatory precedence for other previously authorised bevacizumab biosimilars.

## 3.6. Additional considerations

Not applicable.

## 3.7. Conclusions on biosimilarity and benefit risk balance

Based on the review of the submitted data, Vegzelma is considered biosimilar to the reference product Avastin. Therefore, a benefit/risk balance comparable to the reference product can be concluded.

## 4. Recommendations

## Similarity with authorised orphan medicinal products

The CHMP by consensus is of the opinion that Vegzelma is not similar to Zejula within the meaning of Article 3 of Commission Regulation (EC) No. 847/2000.

## Outcome

Based on the CHMP review of data on quality, safety and efficacy, the CHMP considers by consensus that the benefit-risk balance of Vegzelma is favourable in the following indications:

Vegzelma in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum.

Vegzelma in combination with paclitaxel is indicated for first-line treatment of adult patients with metastatic breast cancer. For further information as to human epidermal growth factor receptor 2 (HER2) status, please refer to section 5.1.

Vegzelma in combination with capecitabine is indicated for first-line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. Patients who have received taxane and anthracycline-containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with Vegzelma in combination with capecitabine. For further information as to HER2 status, please refer to section 5.1.

Vegzelma, in addition to platinum-based chemotherapy, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer (NSCLC) other than predominantly squamous cell histology.

Vegzelma, in combination with erlotinib, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent NSCLC with Epidermal Growth Factor Receptor (EGFR) activating mutations (see section 5.1).

Vegzelma, in combination with interferon alfa-2a is indicated for first line treatment of adult patients

<div style=\"page-break-after: always\"></div>

with advanced and/or metastatic renal cell cancer.

Vegzelma, in combination with carboplatin and paclitaxel is indicated for the front-line treatment of adult patients with advanced (International Federation of Gynecology and Obstetrics (FIGO) stages III B, III C and IV) epithelial ovarian, fallopian tube, or primary peritoneal cancer (see section 5.1).

Vegzelma, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vascular endothelial growth factor (VEGF) inhibitors or VEGF receptor-targeted agents.

Vegzelma in combination with paclitaxel, topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor-targeted agents (see section 5.1).

Vegzelma, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix (see section 5.1).

The CHMP therefore recommends the granting of the marketing authorisation subject to the following conditions:

## Conditions or restrictions regarding supply and use

Medicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2).

## Other conditions and requirements of the marketing authorisation

## · Periodic Safety Update Reports

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

## Conditions or restrictions with regard to the safe and effective use of the medicinal product

## · Risk Management Plan (RMP)

The marketing authorisation holder (MAH) shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the marketing authorisation and any agreed subsequent updates of the RMP.

An updated RMP should be submitted:

- At the request of the European Medicines Agency;
- Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.

## Conditions or restrictions with regard to the safe and effective use of the medicinal product to be implemented by the Member States

Not applicable.